KNOWN AND SUSPECTED HUMAN CARCINOGENS
Carcinogens Reference List

SOURCE AGENCY CARCINOGEN CLASSIFICATIONS:

OSHA (**O**)	Occupational Safety and Health Administration
ACGIH (**G**)	American Conference of Governmental Industrial Hygienists
A1	Confirmed human carcinogen.
A2	Suspected human carcinogen.
A3	Animal carcinogen. "Available evidence suggests that the agent is not likely to cause cancer in humans except under uncommon or unlikely routes or levels of exposure."
A4	Not classifiable as a human carcinogen. "There are inadequate data on which to classify the agent in terms of its carcinogenicity in humans and/or animals."
A5	Not suspected as a human carcinogen.
IARC (**I**)	International Agency for Research on Cancer (World Health Organization)
1	The agent (mixture) is carcinogenic to humans.
2A	The agent (mixture) is probably carcinogenic to humans; there is limited evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals.
2B	The agent (mixture) is possibly carcinogenic to humans; there is limited evidence of carcinogenicity in humans in the absence of sufficient evidence of carcinogenicity in experimental animals.
3	The agent (mixture, exposure circumstance) is not classifiable as to its carcinogenicity to humans.
4	The agent (mixture, exposure circumstance) is probably not carcinogenic to humans.
NTP (**N**)	National Toxicology Program (Health and Human Services Dept., Public Health Service, NIH/NIEHS)
1	Known to be carcinogens.
2	Reasonably anticipated to be carcinogens.
CP65	California Proposition 65, "Chemicals Known to the State to Cause Cancer."

Abbreviation:

n.o.s.	Not otherwise specified; i.e., there is no PEL or TLV.

Note: CASRNs fitting the pattern 0-##-0 or 1-##-0 are generated for electronic database purposes only.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1	26148-68-5	?	A-*alpha*-C		n.o.s.	I-2B, CP65	
2	75-07-0	?	Acetaldehyde		C 25 ppm TLV {C 45 mg/m^3}	G-A3, I-2B, N-2, CP65	
3	16568-02-8		Acetaldehyde Methylformylhydrazone		n.o.s.	CP65	
4	60-35-5	?	Acetamide		n.o.s.	I-2B, CP65	
5	34256-82-1		Acetochlor		n.o.s.	CP65	
6	53-96-3	✓	2-Acetylaminofluorene	IS	[1910.1003]	O, N-2, CP65	
7	62476-59-9		Acifluorfen		n.o.s.	CP65	
8	79-06-1	?	Acrylamide	IS	0.03 mg/m^3 TLV	G-A3, I-2A, N-2, CP65	
9	107-13-1	✓	Acrylonitrile [1910.1045]	IS	2 ppm PEL {4.3 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
10	77536-66-4	✓	Actinolite [asbestiform]	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
11	50-76-0		Actinomycin D		n.o.s.	CP65	
12	23214-92-8	?	Adriamycin®		n.o.s.	I-2A, N-2, CP65	
13	25316-40-9	?	Adriamycin®		n.o.s.	I-2A, N-2, CP65	
14	3688-53-7	?	AF-2		n.o.s.	I-2B, CP65	
15	6795-23-9	?	Aflatoxin M1		n.o.s.	I-2B, CP65	
16	1402-68-2	✓	Aflatoxins	IG	n.o.s.	I-1, N-1, CP65	
17	15972-60-8		Alachlor		1 mg/m^3 TLV {Sensitizer}	G-A3, CP65	
18	0-01-0	✓	Alcoholic Beverages (CP65: assoc. w/alcohol abuse)	G	n.o.s.	I-1, N-1, CP65	
19	309-00-2		Aldrin	S	0.05 mg/m^3 TLV	G-A3, CP65	
20	0-83-0	✓	Aluminum (production)	I	n.o.s.	I-1	
21	61-82-5	?	3-Amino-1,2,4-triazole		0.2 mg/m^3 PEL	G-A3, N-2, CP65	
22	62450-06-0	?	3-Amino-1,4-dimethyl-5H-pyrido[4,3-*b*]indole		n.o.s.	I-2B, CP65	
23	62450-07-1	?	3-Amino-1-methyl-5H-pyrido[4,3-*b*]indole		n.o.s.	I-2B, CP65	
24	105650-23-5	?	2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine		n.o.s.	I-2B, N-2, CP65	
25	81-49-2	?	1-Amino-2,4-dibromoanthraquinone		n.o.s.	N-2, CP65	
26	82-28-0	?	1-Amino-2-methylanthraquinone	I	n.o.s.	N-2, CP65	
27	119-34-6		4-Amino-2-nitrophenol		n.o.s.	CP65	
28	77094-11-2	?	2-Amino-3,4-dimethylimidazo[4,5-*f*]quinoline		n.o.s.	I-2B, N-2, CP65	
29	77500-04-0	?	2-Amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline		n.o.s.	I-2B, N-2, CP65	
30	68006-83-7	?	2-Amino-3-methyl-9H-pyrido[2,3-*b*]indole		n.o.s.	I-2B, CP65	
31	76180-96-6	?	2-Amino-3-methylimidazo[4,5-*f*]quinoline		n.o.s.	I-2A, N-2, CP65	
32	712-68-5	?	2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole		n.o.s.	I-2B, CP65	
33	67730-11-4	?	2-Amino-6-methyldipyrido[1,2-*a*:3',2'-*d*]imidazole		n.o.s.	I-2B, CP65	
34	6109-97-3		3-Amino-9-ethylcarbazole Hydrochloride		n.o.s.	CP65	
35	26148-68-5	?	2-Amino-9H-pyrido[2,3-*b*]indole		n.o.s.	I-2B, CP65	
36	117-79-3	?	2-Aminoanthraquinone		n.o.s.	N-2, CP65	
37	60-09-3	?	*p*-Aminoazobenzene		n.o.s.	I-2B, CP65	
38	97-56-3	?	*o*-Aminoazotoluene		n.o.s.	I-2B, N-2, CP65	
39	92-67-1	✓	4-Aminobiphenyl	IS	[1910.1003]	O, G-A1, I-1, N-1, CP65	
40	92-67-1	✓	4-Aminodiphenyl	IS	[1910.1003]	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
41	67730-10-3	?	2-Aminodipyrido[1,2-*a*:3',2'-*d*]imidazole		n.o.s.	I-2B, CP65	
42	153-78-6		2-Aminofluorene		n.o.s.	CP65	
43	91-59-8	✓	2-Aminonaphthalene		[1910.1003]	O, G-A1, I-1, N-1, CP65	
44	61-82-5	?	Amitrole		0.2 mg/m^3 PEL	G-A3, N-2, CP65	
45	7788-98-9	✓	Ammonium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
46	7789-09-5	✓	Ammonium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
47	12172-73-5	✓	Amosite	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
48	51264-14-3	?	Amsacrine		n.o.s.	I-2B	
49	0-44-0	✓	Analgesic mixtures containing phenacetin		n.o.s.	I-1, N-1, CP65	
50	0-33-0	?	Androgenic (anabolic) steroids		n.o.s.	I-2A	
51	62-53-3		Aniline	S	2 ppm TLV {7.6 mg/m^3}	G-A3, CP65	
52	142-04-1		Aniline Hydrochloride		n.o.s.	CP65	
53	90-04-0	?	*o*-Anisidine	S	0.5 mg/m^3 PEL {0.1 ppm}	G-A3, I-2B, CP65	
54	29191-52-4	?	*o*-Anisidine	S	0.5 mg/m^3 PEL {0.1 ppm}	G-A3, I-2B	
55	134-29-2	?	*o*-Anisidine Hydrochloride		n.o.s.	N-2, CP65	
56	77536-67-5	✓	Anthophyllite [asbestiform]	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
57	84-65-1		Anthraquinone		n.o.s.	CP65	
58	1309-64-4	?	Antimony Trioxide (ACGIH®: production)	I	0.5 mg/m^3 PEL	G-A2, I-2B, CP65	
59	140-57-8	?	Aramite®		n.o.s.	I-2B, CP65	
60	0-02-0	✓	Areca Nut		n.o.s.	I-1, CP65	
61	0-03-0	✓	Aristolochic Acids (naturally occurring mixtures)		n.o.s.	I-1, CP65	
62	11097-69-1	?	Aroclor® 1254 {PCBs}	S	0.5 mg/m^3 PEL	G-A3, I-2A, N-2, CP65	
63	11096-82-5	?	Aroclor® 1260 {PCBs}	S	n.o.s.	N-2, CP65	
64	7440-38-2	✓	Arsenic in Drinking Water	IG	n.o.s.	I-1	
65	10102-53-1	✓	*m*-Arsenic Acid	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
66	7778-39-4	✓	*o*-Arsenic Acid	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
67	7774-41-6	✓	Arsenic Acid Hemihydrate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
68	1303-32-8	✓	Arsenic Disulfide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
69	1303-28-2	✓	Arsenic Pentoxide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
70	7784-33-0	✓	Arsenic Tribromide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
71	7784-34-1	✓	Arsenic Trichloride	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
72	7784-35-2	✓	Arsenic Trifluoride	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
73	7784-45-4	✓	Arsenic Triiodide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
74	1327-53-3	✓	Arsenic Trioxide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
75	1303-36-2	✓	Arsenic Triselenide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
76	1303-33-9	✓	Arsenic Trisulfide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
77	7440-38-2	✓	Arsenic, Inorganic [1910.1018] - [see specific compound]	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
78	8024-75-9	✓	Arsenical Dip	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
79	14060-38-9	✓	Arsenious Acid	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
80	0-92-0	?	Art Glass, Glass Containers, and Pressed Ware (manufacture of)	I	n.o.s.	I-2A	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
81	1332-21-4	✓	Asbestos	I	0.1 f/cc PEL	O, G-A1, I-1, N-1, CP65	
82	8052-42-4	?	Asphalt (Petroleum) Fumes	I	0.5 mg/m^3 TLV	I-2B, CP65	
83	12174-11-7	?	Attapulgite (long fibers, > 5 µm)	I	n.o.s.	I-2B, CP65	
84	0-84-0	✓	Auramine (production)		n.o.s.	I-1	
85	492-80-8	?	Auramine (technical grade)		n.o.s.	I-2B, CP65	
86	320-67-2	?	5-AzaC		n.o.s.	I-2A, N-2, CP65	
87	320-67-2	?	Azacitidine		n.o.s.	I-2A, N-2, CP65	
88	320-67-2	?	5-Azacytidine®		n.o.s.	I-2A, N-2, CP65	
89	115-02-6	?	Azaserine		n.o.s.	I-2B, CP65	
90	446-86-6	✓	Azathioprine	J	n.o.s.	I-1, N-1, CP65	
91	151-56-4	✓	Aziridine	IS	[1910.1003] {0.05 ppm TLV, 0.088 mg/m^3}	O, G-A3, I-2B, CP65	
92	52-24-4	✓	*tris*(1-Aziridinyl)phosphine Sulfide		n.o.s.	I-1, N-1, CP65	
93	103-33-3		Azobenzene		n.o.s.	CP65	
94	30516-87-1	?	AZT		n.o.s.	I-2B	
95	10294-40-3	✓	Barium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
96	12000-34-9	✓	Barium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
97	12231-18-4	✓	Barium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
98	37235-82-8	✓	Basic Bismuth Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
99	1308-09-4	✓	Basic Copper (II) Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
100	1319-48-8	?	Basic Lead Carbonate Sulfate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
101	1344-38-3	✓	Basic Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
102	18454-12-1	✓	Basic Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
103	54692-53-4	✓	Basic Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
104	3296-90-0	?	BBMP		n.o.s.	I-2B, N-2, CP65	
105	154-93-8	?	BCNU		n.o.s.	I-2A, N-2, CP65	
106	177406-68-7		Benthiavalicarb-isopropyl		n.o.s.	CP65	
107	56-55-3	?	Benz[*a*]anthracene {PAH}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
108	202-33-5	?	Benz[*j*]aceanthrylene {PAH}	I	0.2 mg/m^3 PEL	I-2B	
109	98-87-3	?	Benzal Chloride (and Benzoyl Chloride [combined exposure])		n.o.s.	I-2A	
110	71-43-2	✓	Benzene [1910.1028]	IS	0.5 ppm TLV {1.6 mg/m^3}	O, G-A1, I-1, N-1, CP65	
111	1684-47-5	✓	Benzene-1,3,5-d_3 {$C_6H_3D_3$}	IS	0.5 ppm TLV {1.6 mg/m^3}	O, G-A1, I-1, N-1, CP65	
112	1120-89-4	✓	Benzene-d {$C_6H_5D_1$}	IS	0.5 ppm TLV {1.6 mg/m^3}	O, G-A1, I-1, N-1, CP65	
113	1076-43-3	✓	Benzene-d6 {C_6D_6}	IS	0.5 ppm TLV {1.6 mg/m^3}	O, G-A1, I-1, N-1, CP65	
114	92-87-5	✓	Benzidine	IS	[1910.1003]	O, G-A1, I-1, N-1, CP65	
115	0-29-0	✓	Benzidine-based Dyes		n.o.s.	I-1, CP65	
116	50-32-8	✓	Benzo[*a*]pyrene {PAH}		0.2 mg/m^3 PEL	G-A2, I-1, N-2, CP65	
117	205-99-2	?	Benzo[*b*]fluoranthene {PAH}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
118	195-19-7	?	Benzo[*c*]phenanthrene {PAH}	I	0.2 mg/m^3 PEL	I-2B	
119	205-82-3	?	Benzo[*j*]fluoranthene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
120	207-08-9	?	Benzo[*k*]fluoranthene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
121	271-89-6	?	Benzofuran		n.o.s.	I-2B, CP65	
122	98-07-7	?	Benzotrichloride	S	C 0.1 ppm TLV {C 0.8 mg/m^3}	G-A2, I-2A, N-2, CP65	
123	98-88-4	?	Benzoyl Chloride (and *alpha*-Chlorinated Toluenes [combined exposure])		C 0.5 ppm TLV	I-2A	
124	100-44-7	?	Benzyl Chloride		1 ppm PEL {5 mg/m^3}	G-A3, I-2A, CP65	
125	1694-09-3	?	Benzyl Violet 4B		n.o.s.	I-2B, CP65	
126	12161-82-9	✓	Bertrandite	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
127	1302-52-9	✓	Beryl Ore	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
128	7440-41-7	✓	Beryllium & compounds, as Be - [see specific compound]	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
129	543-81-7	✓	Beryllium Acetate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
130	1332-52-1	✓	Beryllium Acetate, Basic	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
131	19049-40-2	✓	Beryllium Acetate, Basic	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
132	10210-64-7	✓	Beryllium Acetylacetonate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
133	1302-52-9	✓	Beryllium Aluminum Silicate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
134	17440-85-6	✓	Beryllium Borohydride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
135	7787-46-4	✓	Beryllium Bromide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
136	506-66-1	✓	Beryllium Carbide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
137	13106-47-3	✓	Beryllium Carbonate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
138	66104-24-3	✓	Beryllium Carbonate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
139	1319-43-3	✓	Beryllium Carbonate Basic	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
140	7787-47-5	✓	Beryllium Chloride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
141	7787-49-7	✓	Beryllium Fluoride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
142	1111-71-3	✓	Beryllium Formate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
143	7787-52-2	✓	Beryllium Hydride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
144	13327-32-7	✓	Beryllium Hydroxide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
145	7787-53-3	✓	Beryllium Iodide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
146	13597-99-4	✓	Beryllium Nitrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
147	13510-48-0	✓	Beryllium Nitrate Tetrahydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
148	7787-55-5	✓	Beryllium Nitrate Trihydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
149	1304-54-7	✓	Beryllium Nitride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
150	1304-56-9	✓	Beryllium Oxide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
151	13597-95-0	✓	Beryllium Perchlorate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
152	13598-15-7	✓	Beryllium Phosphate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
153	13598-26-0	✓	Beryllium Phosphate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
154	35089-00-0	✓	Beryllium Phosphate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
155	7787-50-0	✓	Beryllium Potassium Fluoride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
156	53684-48-3	✓	Beryllium Potassium Sulfate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
157	10039-31-3	✓	Beryllium Selenate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
158	13598-00-0	✓	Beryllium Silicate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
159	15191-85-2	✓	Beryllium Silicate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
160	58500-38-2	✓	Beryllium Silicate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
161	12161-82-9	✓	Beryllium Silicate Hydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
162	13871-27-7	✓	Beryllium Sodium Fluoride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
163	13510-49-1	✓	Beryllium Sulfate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
164	7787-56-6	✓	Beryllium Sulfate Tetrahydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
165	39413-47-3	✓	Beryllium Zinc Silicate, as Be	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
166	12770-50-2	✓	Beryllium-Aluminum Alloy, as Be fume or dust	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
167	11133-98-5	✓	Beryllium-Copper Alloy, as Be fume or dust	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
168	55158-44-6	✓	Beryllium-Copper-Cobalt Alloy, as Be fume or dust	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
169	37227-61-5	✓	Beryllium-Nickel Alloy, as Be fume or dust [also see Ni]	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
170	0-06-0	✓	Betel quid with or without tobacco		n.o.s.	I-1, CP65	
171	25013-16-5	?	BHA		n.o.s.	I-2B, N-2, CP65	
172	8052-42-4	?	Bitumen (extracts of steam-refined and air-refined)	I	0.5 mg/m^3 TLV	I-2B, CP65	
173	11056-06-7	?	Bleomycins		n.o.s.	I-2B	
174	0-93-0	✓	Boot and Shoe Manufacture and Repair		n.o.s.	I-1	
175	0-07-0	?	Bracken Fern		n.o.s.	I-2B, CP65	
176	0-71-0	✓	Broad Spectrum Ultraviolet Radiation	S	n.o.s.	N-1	
177	15541-45-4		Bromate		n.o.s.	CP65	
178	75-27-4	?	Bromodichloromethane		n.o.s.	I-2B, N-2, CP65	
179	74-96-4		Bromoethane	S	5 ppm TLV {23 mg/m^3}	G-A3, CP65	
180	75-25-2		Bromoform	S	0.5 ppm PEL {5 mg/m^3}	G-A3, CP65	
181	3296-90-0	?	2,2-*bis*(Bromomethyl)-1,3-propandiol		n.o.s.	I-2B, N-2, CP65	
182	3296-90-0	?	2,2-*bis*(Bromomethyl)propane-1,3-diol		n.o.s.	I-2B, N-2, CP65	
183	55-98-1	✓	Busulfan	G	n.o.s.	I-1, N-1, CP65	
184	106-99-0	✓	1,3-Butadiene [1910.1051]	I	1 ppm PEL {2.2 mg/m^3}	O, G-A2, I-1, N-1, CP65	
185	55-98-1	✓	1,4-Butanediol Dimethylsulfonate	G	n.o.s.	I-1, N-1, CP65	
186	1189-85-1	✓	*tert*-Butyl Chromate, as Cr^{6+}	S	5 µg/m^3 PEL	O, I-1, N-1, CP65	
187	25013-16-5	?	Butylated Hydroxyanisole		n.o.s.	I-2B, N-2, CP65	
188	140-57-8	?	Butylphenoxyisopropyl Chloroethyl Sulfite		n.o.s.	I-2B, CP65	
189	3068-88-0	?	*beta*-Butyrolactone		n.o.s.	I-2B, CP65	
190	6459-94-5	?	C.I. Acid Red 114	I	n.o.s.	I-2B, CP65	
191	569-61-9	?	C.I. Basic Red 9 Monohydrochloride	IS	n.o.s.	I-2B, N-2, CP65	
192	72-57-1	?	C.I. Direct Blue 14	I	n.o.s.	I-2B, CP65	
193	2429-74-5	?	C.I. Direct Blue 15	I	n.o.s.	I-2B, CP65	
194	28407-37-6		C.I. Direct Blue 218		n.o.s.	CP65	
195	82-28-0	?	C.I. Disperse Orange 11	I	n.o.s.	N-2, CP65	
196	1307-96-6	?	C.I. Pigment Black 13	I	0.02 mg/m^3 TLV	G-A3, I-2B, CP65	
197	1344-38-3	✓	C.I. Pigment Orange 21, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
198	54692-53-4	✓	C.I. Pigment Orange 21, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
199	8005-36-5	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
200	12213-61-5	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
201	12656-85-8	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
202	12709-98-7	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
203	64523-06-4	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
204	7758-97-6	✓	C.I. Pigment Yellow 34, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A2, I-1, N-1, CP65	
205	1308-13-0	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
206	1328-67-2	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
207	13530-65-9	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
208	14675-41-3	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
209	37300-23-5	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
210	57486-12-1	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
211	10294-52-7	✓	C.I. Pigment Yellow 45, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
212	2646-17-5	?	C.I. Solvent Orange 2		n.o.s.	I-2B, CP65	
213	842-07-9		C.I. Solvent Yellow 14		n.o.s.	CP65	
214	75-60-5		Cacodylic Acid		0.5 mg/m³ PEL	CP65	
215	7440-43-9	✓	Cadmium & Cd compounds, as Cd [1910.1027] - [see specific compound]	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
216	543-90-8	✓	Cadmium Acetate	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
217	7789-42-6	✓	Cadmium Bromide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
218	513-78-0	✓	Cadmium Carbonate	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
219	10108-64-2	✓	Cadmium Chloride	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
220	542-83-6	✓	Cadmium Cyanide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
221	14486-19-2	✓	Cadmium Fluoborate		5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
222	7790-79-6	✓	Cadmium Fluoride	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
223	21041-95-2	✓	Cadmium Hydroxide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
224	7790-80-9	✓	Cadmium Iodide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
225	10325-94-7	✓	Cadmium Nitrate	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
226	1306-19-0	✓	Cadmium Oxide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
227	14402-75-6	✓	Cadmium Potassium Cyanide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
228	13814-62-5	✓	Cadmium Selenate	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
229	1306-24-7	✓	Cadmium Selenide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
230	2223-93-0	✓	Cadmium Stearate	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
231	10124-36-4	✓	Cadmium Sulfate	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
232	1306-23-6	✓	Cadmium Sulfide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
233	1306-25-8	✓	Cadmium Telluride	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
234	7790-85-4	✓	Cadmium Tungstate (VI)	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
235	12685-29-9	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
236	37364-06-0	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
237	132295-56-8	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
238	132295-57-9	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
239	331-39-5	?	Caffeic Acid		n.o.s.	I-2B, CP65	
240	7778-44-1	✓	Calcium Arsenate	IG	10 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
241	10103-62-5	✓	Calcium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
242	52740-16-6	✓	Calcium Arsenite, 1:1	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
243	15194-98-6	✓	Calcium Arsenite, 2:1	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
244	27152-57-4	✓	Calcium Arsenite, 2:3	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
245	13765-19-0	✓	Calcium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL {1 µg/m^3 TLV}	O, G-A2, I-1, N-1, CP65	
246	2425-06-1	?	Captafol	S	0.1 mg/m^3 PEL	I-2A, CP65	
247	133-06-2		Captan		5 mg/m^3 TLV {Sensitizer}	G-A3, CP65	
248	51-79-6	?	Carbamic Acid, Ethyl Ester		n.o.s.	I-2A, N-2, CP65	
249	86-74-8		Carbazole		n.o.s.	CP65	
250	1333-86-4	?	Carbon Black (CP65: airborne, unbound particles of respirable size)	I	3.5 mg/m^3 PEL	I-2B, CP65	
251	0-54-0	?	Carbon Black extracts (benzene solvent) {PAH}		n.o.s.	I-2B, CP65	
252	0-85-0	?	Carbon electrode manufacture	I	n.o.s.	I-2A	
253	56-23-5	?	Carbon Tetrachloride	IS	5 ppm TLV {31.5 mg/m^3}	G-A2, I-2B, N-2, CP65	
254	60391-92-6		N-Carboxymethyl-N-nitrosourea		n.o.s.	CP65	
255	154-93-8	?	Carmustine		n.o.s.	I-2A, N-2, CP65	
256	0-94-0	?	Carpentry and Joinery	I	n.o.s.	I-2B	
257	9000-07-1	?	Carrageenan, degraded		n.o.s.	I-2B	
258	120-80-9	?	Catechol	S	5 ppm TLV	G-A3, I-2B, CP65	
259	13010-47-4	?	CCNU		n.o.s.	I-2A, N-2, CP65	
260	409-21-2	?	Ceramic Fiber (CP65: airborne particles of respirable size)	I	0.2 f/cc TLV (respirable fibers)	G-A2, I-2B, N-2, CP65	
261	13454-78-9	✓	Cesium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
262	0-95-0	✓	Chimney Sweeping	IS	n.o.s.	I-1	
263	305-03-3	✓	Chlorambucil	G	n.o.s.	I-1, N-1, CP65	
264	56-75-7	?	Chloramphenicol		n.o.s.	I-2A, N-2, CP65	
265	57-74-9	?	Chlordane	S	0.5 mg/m^3 PEL	G-A3, I-2B, CP65	
266	12789-03-6	?	Chlordane (technical grade)	S	0.5 mg/m^3 TLV	G-A3, I-2B	
267	143-50-0	?	Chlordecone		n.o.s.	I-2B, N-2, CP65	
268	6164-98-3		Chlordimeform		n.o.s.	CP65	
269	115-28-6	?	Chlorendic Acid		n.o.s.	I-2B, N-2, CP65	
270	8001-35-2	?	Chlorinated Camphene	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
271	63449-39-8	?	Chlorinated Paraffins (avg. C_{12}, 60% Chlorine)		n.o.s.	I-2B, N-2	
272	108171-26-2	?	Chlorinated Paraffins (avg. C_{12}, 60% Chlorine)		n.o.s.	I-2B, N-2, CP65	
273	0-24-0	?	*alpha*-Chlorinated Toluenes and Benzoyl Chloride (combined exposures)		n.o.s.	I-2A	
274	494-03-1	✓	Chlornaphazine		n.o.s.	I-1, CP65	
275	108-60-1		*bis*(2-Chloro-1-methylethyl) Ether (technical grade)		n.o.s.	CP65	
276	106-89-8	?	1-Chloro-2,3-epoxy-propane	IS	0.5 ppm TLV {1.9 mg/m^3}	G-A3, I-2A, N-2, CP65	
277	95-69-2	?	4-Chloro-2-methylbenzenamine (and its strong acid salts)		n.o.s.	I-2A, N-2, CP65	
278	3165-93-3	?	4-Chloro-2-methylbenzenamine Hydrochloride		n.o.s.	I-2A, N-2, CP65	
279	513-37-1	?	1-Chloro-2-methylpropene		n.o.s.	I-2B, N-2, CP65	
280	563-47-3	?	3-Chloro-2-methylpropene		n.o.s.	N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
281	77439-76-0	?	3-Chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone		n.o.s.	I-2B, CP65	
282	100-00-5		1-Chloro-4-nitrobenzene	S	1 mg/m^3 PEL {0.1 ppm TLV}	G-A3, CP65	
283	106-47-8	?	4-Chloroaniline		n.o.s.	I-2B, CP65	
284	106-47-8	?	*p*-Chloroaniline		n.o.s.	I-2B, CP65	
285	20265-96-7		*p*-Chloroaniline Hydrochloride		n.o.s.	CP65	
286	53469-21-9	?	Chlorodiphenyl (42% chlorine) {PCBs}	S	1 mg/m^3 PEL	I-2A, CP65	
287	11097-69-1	?	Chlorodiphenyl (54% chlorine) {PCBs}	S	0.5 mg/m^3 PEL	G-A3, I-2A, N-2, CP65	
288	75-00-3		Chloroethane	S	100 ppm TLV {264 mg/m^3}	G-A3, CP65	
289	111-44-4		*bis*(2-Chloroethyl) Ether	S	5 ppm TLV {29 mg/m^3}	CP65	
290	154-93-8	?	*bis*(Chloroethyl) Nitrosourea		n.o.s.	I-2A, N-2, CP65	
291	115-96-8		*tris*(2-Chloroethyl) Phosphate		n.o.s.	CP65	
292	494-03-1	✓	N,N-*bis*(2-Chloroethyl)-2-naphthylamine		n.o.s.	I-1, CP65	
293	13909-09-6	✓	1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea		n.o.s.	I-1, N-1, CP65	
294	13010-47-4	?	1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea		n.o.s.	I-2A, N-2, CP65	
295	75-01-4	✓	Chloroethylene [1910.1017]		1 ppm PEL	O, G-A1, I-1, N-1, CP65	
296	67-66-3	?	Chloroform	IA	10 ppm TLV {48.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
297	865-49-6	?	Chloroform-d {$CDCl_3$}	IA	10 ppm TLV {48.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
298	107-30-2	✓	Chloromethyl Methyl Ether	IS	[1910.1003]	O, G-A2, I-1, N-1, CP65	
299	542-88-1	✓	*bis*(Chloromethyl) Ether	I	[1910.1003] {1 ppb TLV, 4.7 µg/m^3}	O, G-A1, I-1, N-1, CP65	
300	95-83-0	?	4-Chloro-*o*-phenylenediamine		n.o.s.	I-2B, N-2, CP65	
301	95-69-2	?	4-Chloro-*o*-toluidine (and its strong acid salts)		n.o.s.	I-2A, N-2, CP65	
302	95-79-4		5-Chloro-*o*-toluidine (and its strong acid salts)		n.o.s.	CP65	
303	95-69-2	?	*p*-Chloro-*o*-toluidine (and its strong acid salts)		n.o.s.	I-2A, N-2, CP65	
304	3165-93-3	?	*p*-Chloro-*o*-toluidine Hydrochloride		n.o.s.	I-2A, N-2, CP65	
305	95-57-8	?	2-Chlorophenol	S	n.o.s.	I-2B	
306	108-43-0	?	3-Chlorophenol	S	n.o.s.	I-2B	
307	106-48-9	?	4-Chlorophenol	S	n.o.s.	I-2B	
308	0-25-0	?	Chlorophenoxy Herbicides	S	10 mg/m^3 PEL	I-2B	
309	126-99-8	?	*beta*-Chloroprene	S	10 ppm TLV	I-2B, N-2, CP65	
310	1897-45-6	?	Chlorothalonil		n.o.s.	I-2B, CP65	
311	569-57-3		Chlorotrianisene		n.o.s.	CP65	
312	54749-90-5	?	Chlorozotocin		n.o.s.	I-2A, N-2, CP65	
313	18454-12-1	✓	Chrome Red, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
314	1066-30-4	✓	Chromic Acetate, as Cr^{6+} [water-soluble]		5 µg/m^3 PEL	O, N-1, CP65	
315	1333-82-0	✓	Chromic Acid, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
316	12324-05-9	✓	Chromic Acid, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
317	12324-08-2	✓	Chromic Acid, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
318	24613-89-6	✓	Chromic Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
319	0-86-0	✓	Chromite Ore Processing, as Cr^{6+}	I	5 µg/m^3 PEL	G-A1	
320	18540-29-9	✓	Chromium (VI) & inorganic Cr^{6+} compounds - [see specific compound]	I	5 µg/m^3 PEL	O, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
321	14986-48-2	✓	Chromium [VI] Chloride	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
322	29689-14-3	✓	Chromium Carbonate, as Cr^{6+} [water-soluble]		5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
323	13007-92-6	✓	Chromium Carbonyl, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
324	13930-94-4	✓	Chromium Carbonyl, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
325	14986-48-2	✓	Chromium Hexachloride, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
326	1333-82-0	✓	Chromium Oxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
327	12324-05-9	✓	Chromium Oxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
328	12324-08-2	✓	Chromium Oxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
329	7789-04-0	✓	Chromium Phosphate, as Cr^{6+} [water-soluble]		5 µg/m^3 PEL	O, N-1, CP65	
330	1333-82-0	✓	Chromium Trioxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
331	12324-05-9	✓	Chromium Trioxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
332	12324-08-2	✓	Chromium Trioxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
333	14977-61-8	✓	Chromyl Chloride, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, I-1, N-1, CP65	
334	117-10-2	?	Chrysazin		n.o.s.	I-2B, N-2, CP65	
335	218-01-9	?	Chrysene	S	0.2 mg/m^3 PEL	G-A3, I-2B, CP65	
336	12001-29-5	✓	Chrysotile	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
337	59865-13-3	✓	Ciclosporin		n.o.s.	N-1, CP65	
338	79217-60-0		Ciclosporin		n.o.s.	CP65	
339	59865-13-3	✓	Ciclosporine		n.o.s.	I-1, N-1, CP65	
340	113852-37-2		Cidofovir		n.o.s.	CP65	
341	87-29-6		Cinnamyl Anthranilate		n.o.s.	CP65	
342	15663-27-1	?	Cisplatin		n.o.s.	I-2A, N-2, CP65	
343	6358-53-8	?	Citrus Red No.2		n.o.s.	I-2B, CP65	
344	637-07-0		Clofibrate		n.o.s.	CP65	
345	0-60-0	✓	Coal Gasification	I	n.o.s.	I-1	
346	65996-93-2	✓	Coal Tar Pitch Volatiles (as benzene solubles)	I	0.2 mg/m^3 PEL	G-A1, I-1, N-1	
347	8007-45-2	✓	Coal Tars	I	n.o.s.	I-1, N-1	
348	65996-89-6	✓	Coal Tars & Extracts, and high-temp. coal tars	I	n.o.s.	I-1, N-1	
349	0-59-0	✓	Coal-tar Distillation	I	n.o.s.	I-1	
350	7440-48-4		Cobalt metal powder	I	0.02 mg/m^3 TLV	G-A3, CP65	
351	0-14-0	?	Cobalt metal with tungsten carbide	I	0.02 mg/m^3 TLV	G-A3, I-2A	
352	71-48-7	?	Cobalt (II) Acetate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
353	6147-53-1	?	Cobalt (II) Acetate Tetrahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
354	7785-24-2	✓	Cobalt (II) Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
355	7789-43-7	?	Cobalt (II) Bromide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
356	513-79-1	?	Cobalt (II) Carbonate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
357	12069-68-0	?	Cobalt (II) Carbonate Hydroxide (1:1)	I	0.02 mg/m^3 TLV	G-A3, I-2B	
358	12602-23-2	?	Cobalt (II) Carbonate Hydroxide (2:3)	I	0.02 mg/m^3 TLV	G-A3, I-2B	
359	51839-24-8	?	Cobalt (II) Carbonate Hydroxide (2:3) Monohydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
360	7646-79-9	?	Cobalt (II) Chloride	I	0.02 mg/m^3 TLV	G-A3, I-2B	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
361	7791-13-1	?	Cobalt (II) Chloride Hexahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
362	13455-25-9	?	Cobalt (II) Chromate (III)	I	0.02 mg/m^3 TLV	G-A3, I-2B	
363	542-84-7	?	Cobalt (II) Cyanide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
364	10026-17-2	?	Cobalt (II) Fluoride	I	0.02 mg/m^3 TLV	G-A3, I-2B	
365	544-18-3	?	Cobalt (II) Formate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
366	21041-93-0	?	Cobalt (II) Hydroxide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
367	15238-00-3	?	Cobalt (II) Iodide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
368	13762-14-6	?	Cobalt (II) Molybdenum (VI) Oxide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
369	61789-51-3	?	Cobalt (II) Naphthenate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
370	10141-05-6	?	Cobalt (II) Nitrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
371	10026-22-9	?	Cobalt (II) Nitrate Hexahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
372	814-89-1	?	Cobalt (II) Oxalate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
373	1307-96-6	?	Cobalt (II) Oxide	I	0.02 mg/m^3 TLV	G-A3, I-2B, CP65	
374	13455-36-2	?	Cobalt (II) Phosphate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
375	13596-22-0	?	Cobalt (II) Potassium Sulfate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
376	10124-43-3	?	Cobalt (II) Sulfate	I	0.02 mg/m^3 TLV	G-A3, I-2B, N-2, CP65	
377	1317-42-6	?	Cobalt (II) Sulfide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
378	3017-60-5	?	Cobalt (II) Thiocyanate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
379	1308-06-1	?	Cobalt (II, III) Oxide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
380	917-69-1	?	Cobalt (III) Acetate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
381	10026-18-3	?	Cobalt (III) Fluoride	I	0.02 mg/m^3 TLV	G-A3, I-2B	
382	1307-86-4	?	Cobalt (III) Hydroxide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
383	1308-04-9	?	Cobalt (III) Oxide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
384	12016-80-7	?	Cobalt (III) Oxide Monohydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
385	13782-01-9	?	Cobalt (III) Potassium Nitrite	I	0.02 mg/m^3 TLV	G-A3, I-2B	
386	10210-68-1	?	Cobalt Carbonyl, as Co	I	0.1 mg/m^3 TLV	I-2B	
387	11114-92-4	✓	Cobalt Chromium Alloy, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
388	16842-03-8	?	Cobalt Hydrocarbonyl, as Co	I	0.1 mg/m^3 TLV	I-2B	
389	1307-96-6	?	Cobalt Monoxide	I	0.02 mg/m^3 TLV	G-A3, I-2B, CP65	
390	10026-24-1	?	Cobalt Sulfate Heptahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B, CP65	
391	0-08-0	?	Coffee (urinary bladder only)	G	n.o.s.	I-2B	
392	0-61-0	✓	Coke Oven Emissions [1910.1029] {PAH}	IS	150 µg/m^3 PEL	O, I-1, N-1, CP65	
393	12002-03-8	✓	Copper (II) Acetoarsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
394	0-15-0	✓	Copper (II) Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
395	13548-42-0	✓	Copper Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
396	1308-09-4	✓	Copper Chromate Oxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
397	18906-50-8	✓	Copper Chromate Oxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
398	8001-58-9	✓	Creosotes	IS	n.o.s.	I-2A, N-1, CP65	
399	8021-39-4	✓	Creosotes (wood)	IS	n.o.s.	N-1, CP65	
400	120-71-8	?	*p*-Cresidine		n.o.s.	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
401	14464-46-1	✓	Cristobalite {Silica (respirable) - Crystalline}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
402	12001-28-4	✓	Crocidolite	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
403	135-20-6	?	Cupferron		n.o.s.	N-2, CP65	
404	12002-03-8	✓	Cupric Acetoarsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
405	10290-12-7	✓	Cupric Arsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
406	13548-42-0	✓	Cupric Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
407	14901-08-7	?	Cycasin		n.o.s.	I-2B, CP65	
408	27208-37-3	?	Cyclopenta[*cd*]pyrene {PAH}		0.2 mg/m^3 PEL	I-2A	
409	50-18-0	✓	Cyclophosphamide (hydrated)	GJ	n.o.s.	I-1, N-1, CP65	
410	6055-19-2	✓	Cyclophosphamide (hydrated)	GJ	n.o.s.	I-1, CP65	
411	79217-60-0	✓	Cyclosporin		n.o.s.	I-1, CP65	
412	59865-13-3	✓	Cyclosporin A		n.o.s.	I-1, N-1, CP65	
413	79217-60-0	✓	Cyclosporine		n.o.s.	I-1, CP65	
414	21739-91-3		Cytembena		n.o.s.	CP65	
415	94-75-7	?	2,4-D	S	10 mg/m^3 PEL	I-2B	
416	3468-63-1		D&C Orange No. 17		n.o.s.	CP65	
417	81-88-9		D&C Red No. 19		n.o.s.	CP65	
418	2092-56-0		D&C Red No. 8		n.o.s.	CP65	
419	5160-02-1		D&C Red No. 9		n.o.s.	CP65	
420	136-35-6	?	DAAB		n.o.s.	N-2, CP65	
421	4342-03-4	?	Dacarbazine		n.o.s.	I-2B, N-2, CP65	
422	1596-84-5		Daminozide		n.o.s.	CP65	
423	117-10-2	?	Dantron		n.o.s.	I-2B, N-2, CP65	
424	20830-81-3	?	Daunomycin		n.o.s.	I-2B, CP65	
425	96-12-8	✓	DBCP [1910.1044]	IS	1 ppb PEL	O, I-2B, N-2, CP65	
426	96-13-9	?	DBP		n.o.s.	I-2B, N-2, CP65	
427	72-54-8		DDD		n.o.s.	CP65	
428	72-55-9		DDE		n.o.s.	CP65	
429	50-29-3	?	DDT	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
430	50-29-3	?	*p,p'*-DDT	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
431	62-73-7	?	DDVP	S	0.1 mg/m^3 TLV {Sensitizer}	I-2B, CP65	
432	13654-09-6	?	Decabromobiphenyl {PBBs}		n.o.s.	N-2, CP65	
433	117-81-7	?	DEHP		5 mg/m^3 PEL	G-A3, N-2, CP65	
434	55-18-5	?	DEN		n.o.s.	I-2A, N-2, CP65	
435	56-53-1	✓	DES	G	n.o.s.	I-1, N-1, CP65	
436	101-90-6	?	DGRE		n.o.s.	I-2B, N-2, CP65	
437	613-35-4	?	N,N'-Diacetylbenzidine		n.o.s.	I-2B, CP65	
438	615-05-4	?	2,4-Diaminoanisole		n.o.s.	I-2B, CP65	
439	39156-41-7	?	2,4-Diaminoanisole Sulfate		n.o.s.	N-2, CP65	
440	101-80-4	?	4,4'-Diaminodiphenyl Ether		n.o.s.	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
441	0-16-0		Diaminotoluene (mixed)		n.o.s.	CP65	
442	95-80-7	?	2,4-Diaminotoluene		n.o.s.	I-2B, N-2, CP65	
443	119-90-4	?	*o*-Dianisidine Based Dyes		n.o.s.	I-2B, N-2, CP65	
444	20325-40-0	?	*o*-Dianisidine Dihydrochloride		n.o.s.	N-2, CP65	
445	136-35-6	?	Diazoaminobenzene		n.o.s.	N-2, CP65	
446	334-88-3	?	Diazomethane		0.2 ppm PEL {0.34 mg/m^3}	G-A2	
447	226-36-8	?	Dibenz[*a,h*]acridine {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
448	53-70-3	?	Dibenz[*a,h*]anthracene {PAH}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
449	224-42-0	?	Dibenz[*a,j*]acridine {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
450	192-65-4	?	Dibenzo[*a,e*]pyrene {PAH}	I	0.2 mg/m^3 PEL	N-2, CP65	
451	189-64-0	?	Dibenzo[*a,h*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
452	189-55-9	?	Dibenzo[*a,i*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
453	191-30-0	?	Dibenzo[*a,l*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
454	194-59-2	?	7H-Dibenzo[*c,g*]carbazole {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
455	96-13-9	?	2,3-Dibromo-1-propanol		n.o.s.	I-2B, N-2, CP65	
456	96-12-8	✓	1,2-Dibromo-3-chloropropane [1910.1044]	IS	1 ppb PEL	O, I-2B, N-2, CP65	
457	631-64-1		Dibromoacetic acid		n.o.s.	CP65	
458	106-93-4	?	1,2-Dibromoethane	IS	20 ppm PEL	G-A3, I-2A, N-2, CP65	
459	96-13-9	?	2,3-Dibromopropan-1-ol		n.o.s.	I-2B, N-2, CP65	
460	126-72-7	?	*tris*(2,3-Dibromopropyl) Phosphate		n.o.s.	I-2A, N-2, CP65	
461	764-41-0	?	1,4-Dichloro-2-butene	S	5 ppb TLV {25 µg/m^3}	G-A2, CP65	
462	28434-86-8	?	3,3'-Dichloro-4,4'-diaminodiphenyl Ether		n.o.s.	I-2B, CP65	
463	79-43-6	?	Dichloroacetic Acid	S	0.5 ppm TLV	G-A3, I-2B, CP65	
464	106-46-7	?	1,4-Dichlorobenzene	IA	10 ppm TLV {60 mg/m^3}	G-A3, I-2B, N-2, CP65	
465	106-46-7	?	*p*-Dichlorobenzene	IA	10 ppm TLV {60 mg/m^3}	G-A3, I-2B, N-2, CP65	
466	91-94-1	✓	3,3'-Dichlorobenzidine	IS	[1910.1003]	O, G-A3, I-2B, N-2, CP65	
467	612-83-9	?	3,3'-Dichlorobenzidine Dihydrochloride		n.o.s.	N-2, CP65	
468	505-60-2	✓	2,2'-Dichlorodiethylsulfide	IA	n.o.s.	I-1, N-1, CP65	
469	72-54-8		Dichlorodiphenyldichloroethane		n.o.s.	CP65	
470	72-55-9		Dichlorodiphenyldichloroethylene		n.o.s.	CP65	
471	50-29-3	?	Dichlorodiphenyltrichloroethane	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
472	75-34-3		1,1-Dichloroethane		100 ppm PEL {400 mg/m^3}	CP65	
473	107-06-2	?	1,2-Dichloroethane		10 ppm TLV {40.5 mg/m^3}	I-2B, N-2, CP65	
474	111-44-4		Dichloroethyl Ether	S	5 ppm TLV {29 mg/m^3}	CP65	
475	75-09-2	✓	Dichloromethane [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
476	1665-00-5	✓	Dichloromethane-d_2 {CD_2Cl_2} [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
477	94-75-7	?	(2,4-Dichlorophenoxy) Acetic Acid	S	10 mg/m^3 PEL	I-2B	
478	1836-75-5	?	2,4-Dichlorophenyl-*p*-nitrophenyl Ether		n.o.s.	I-2B, N-2, CP65	
479	78-87-5		1,2-Dichloropropane		10 ppm TLV {46 mg/m^3; Sensitizer}	CP65	
480	542-75-6	?	1,3-Dichloropropene (technical grade)	S	1 ppm TLV {4.5 mg/m^3}	G-A3, I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
481	62-73-7	?	Dichlorvos	S	0.1 mg/m^3 TLV {Sensitizer}	I-2B, CP65	
482	10210-68-1	?	Dicobalt Octacarbonyl, as Co	I	0.1 mg/m^3 TLV	I-2B	
483	60-57-1		Dieldrin	S	0.1 mg/m^3 TLV	G-A3, CP65	2009
484	84-17-3		Dienestrol		n.o.s.	CP65	
485	1464-53-5	?	Diepoxybutane		n.o.s.	I-2B, N-2, CP65	
486	0-50-0	?	Diesel Engine Exhaust	I	n.o.s.	I-2A, N-2, CP65	
487	68476-30-2	?	Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
488	68476-31-3	?	Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
489	77650-28-3	?	Diesel Fuel, Marine	IS	100 mg/m^3 TLV	G-A3, I-2B	
490	68476-34-6	?	Diesel Fuel #2	IS	100 mg/m^3 TLV	G-A3, I-2B	
491	68334-30-5	?	Diesel Fuel #4	IS	100 mg/m^3 TLV	G-A3, I-2B	
492	77650-28-3	?	Diesel Fuel #4	IS	100 mg/m^3 TLV	G-A3, I-2B	
493	95-06-7	?	N, N-Diethyldithiocarbamic Acid 2-Chloroallyl Ester		n.o.s.	I-2B, N-2, CP65	
494	1615-80-1	?	1,2-Diethylhydrazine		n.o.s.	I-2B, CP65	
495	55-18-5	?	Diethylnitrosamine		n.o.s.	I-2A, N-2, CP65	
496	56-53-1	✓	Diethylstilbestrol	G	n.o.s.	I-1, N-1, CP65	
497	64-67-5	?	Diethylsulfate		n.o.s.	I-2A, N-2, CP65	
498	101-90-6	?	Diglycidyl Resorcinol Ether		n.o.s.	I-2B, N-2, CP65	
499	94-58-6	?	Dihydrosafrole		n.o.s.	I-2B, CP65	
500	117-10-2	?	1,8-Dihydroxyanthraquinone		n.o.s.	I-2B, N-2, CP65	
501	2973-10-6	?	Diisopropylsulfate		n.o.s.	I-2B, CP65	
502	119-90-4	?	3,3'-Dimethoxybenzidine		n.o.s.	I-2B, N-2, CP65	
503	20325-40-0	?	3,3'-Dimethoxybenzidine Dihydrochloride		n.o.s.	N-2, CP65	
504	90-94-8	?	4,4'-(Dimethylamino) Benzophenone		n.o.s.	I-2B, N-2, CP65	
505	90-94-8	?	*bis*(Dimethylamino) Benzophenone		n.o.s.	I-2B, N-2, CP65	
506	25962-77-0	?	*trans*-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole		n.o.s.	I-2B	
507	55738-54-0		*trans*-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole		n.o.s.	CP65	
508	60-11-7	✓	4-Dimethylaminoazobenzene	S	[1910.1003]	O, I-2B, N-2, CP65	
509	60-11-7	✓	*p*-Dimethylaminoazobenzene	S	[1910.1003]	O, I-2B, N-2, CP65	
510	87-62-7	?	2,6-Dimethylaniline		0.5 ppm TLV	I-2B, CP65	
511	57-97-6		7,12-Dimethylbenz(*a*)anthracene		n.o.s.	CP65	
512	119-93-7	?	3,3'-Dimethylbenzidine	S	n.o.s.	G-A3, I-2B, N-2, CP65	
513	612-82-8		3,3'-Dimethylbenzidine Dihydrochloride		n.o.s.	CP65	
514	79-44-7	?	Dimethylcarbamoyl Chloride	IS	5 ppb TLV	G-A2, I-2A, N-2, CP65	
515	57-14-7	?	1,1-Dimethylhydrazine	IS	0.01 ppm TLV {0.025 mg/m^3}	G-A3, I-2B, N-2, CP65	
516	540-73-8	?	1,2-Dimethylhydrazine		n.o.s.	I-2A, CP65	
517	62-75-9	✓	N,N-Dimethylnitrosoamine	S	[1910.1003]	O, G-A3, I-2A, N-2, CP65	
518	77-78-1	?	Dimethylsulfate	S	0.1 ppm TLV {0.5 mg/m^3}	G-A3, I-2A, N-2, CP65	
519	513-37-1	?	Dimethylvinyl Chloride		n.o.s.	I-2B, N-2, CP65	
520	105735-71-5	?	3,7-Dinitrofluoranthene		n.o.s.	I-2B, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
521	22506-53-2	?	3,9-Dinitrofluoranthene		n.o.s.	I-2B, CP65	
522	42397-64-8	?	1,6-Dinitropyrene	I	n.o.s.	I-2B, N-2, CP65	
523	42397-65-9	?	1,8-Dinitropyrene	I	n.o.s.	I-2B, N-2, CP65	
524	121-14-2	?	2,4-Dinitrotoluene	S	27 ppb TLV {0.2 mg/m^3}	I-2B, CP65	
525	0-17-0		2,4-/2,6-Dinitrotoluene	S	27 ppb TLV {0.2 mg/m^3}	CP65	
526	606-20-2	?	2,6-Dinitrotoluene	S	27 ppb TLV {0.2 mg/m^3}	I-2B, CP65	
527	123-91-1	?	1,4-Dioxane	IS	20 ppm TLV {72 mg/m^3}	G-A3, I-2B, N-2, CP65	
528	17647-74-4	?	1,4-Dioxane-d_8	IS	20 ppm TLV {72 mg/m^3}	G-A3, I-2B, N-2	
529	57-41-0	?	Diphenylhydantoin		n.o.s.	I-2B, N-2, CP65	
530	630-93-3		Diphenylhydantoin		n.o.s.	CP65	
531	122-66-7	?	1,2-Diphenylhydrazine		n.o.s.	N-2, CP65	
532	1937-37-7	✓	Direct Black 38 (technical grade)		n.o.s.	I-2A, N-1, CP65	
533	1937-37-7	✓	Direct Black GX		n.o.s.	I-2A, N-1, CP65	
534	2602-46-2	✓	Direct Blue 6 (technical grade)		n.o.s.	I-2A, N-1, CP65	
535	16071-86-6	?	Direct Brown 95 (technical grade)		n.o.s.	I-2A, CP65	
536	7778-43-0	✓	Disodium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
537	10048-95-0	✓	Disodium Arsenate Heptahydrate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
538	10048-95-0	✓	Disodium Hydrogen Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
539	2475-45-8	?	Disperse Blue 1	I	n.o.s.	I-2B, N-2, CP65	
540	330-54-1		Diuron		10 mg/m^3 TLV	CP65	
541	62-75-9	✓	DMN	S	[1910.1003]	O, G-A3, I-2A, N-2, CP65	
542	8012-54-2	✓	Donovan's Solution, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
543	23214-92-8	?	Doxorubicin Hydrochloride		n.o.s.	I-2A, N-2, CP65	
544	25316-40-9	?	Doxorubicin Hydrochloride		n.o.s.	I-2A, N-2, CP65	
545	0-96-0	?	Dry Cleaning (occ. exposure in)		n.o.s.	I-2B	
546	119-90-4	?	Dyes that metabolize to 3,3'-Dimethylbenzidine		n.o.s.	N-2	
547	119-93-7	?	Dyes that metabolize to 3,3'-Dimethylbenzidine	S	n.o.s.	N-2	
548	0-30-0	✓	Dyes that metabolize to benzidine	IS	n.o.s.	I-1, N-1	
549	106-93-4	?	EDB	IS	20 ppm PEL	G-A3, I-2A, N-2, CP65	
550	0-51-0	?	Engine Exhaust, Gasoline (condensates/extracts)	I	n.o.s.	I-2B, CP65	
551	759-73-9	?	ENU		n.o.s.	I-2A, N-2, CP65	
552	106-89-8	?	Epichlorohydrin	IS	0.5 ppm TLV {1.9 mg/m^3}	G-A3, I-2A, N-2, CP65	
553	106-88-7	?	1,2-Epoxybutane		n.o.s.	I-2B	
554	75-56-9	?	1,2-Epoxypropane		2 ppm TLV {4.8 mg/m^3; Sensitizer}	G-A3, I-2B, N-2, CP65	
555	96-09-3	?	Epoxystyrene		n.o.s.	I-2A, N-2, CP65	
556	12510-42-8	✓	Erionite	I	n.o.s.	I-1, N-1, CP65	
557	66733-21-9	✓	Erionite	I	n.o.s.	I-1, N-1, CP65	
558	50-28-2	✓	Estradiol-17B	SG	n.o.s.	I-1, N-2, CP65	
559	140-67-0		Estragole		n.o.s.	CP65	
560	0-35-0	✓	Estrogen, Nonsteroidal	SG	n.o.s.	I-1	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
561	0-36-0	✓	Estrogen, Steroidal	SG	n.o.s.	I-1, N-1, CP65	
562	0-40-0	✓	Estrogen Therapy, Postmenopausal		n.o.s.	I-1	
563	0-39-0	✓	Estrogen-Progestogen Menopausal Therapy (combined)		n.o.s.	I-1	
564	0-41-0	✓	Estrogen-progestogen oral contraceptives (combined)	G	n.o.s.	I-1, CP65	
565	0-34-0		Estrogens, Conjugated (Indirect)	SG	n.o.s.	CP65	
566	53-16-7	✓	Estrone	SG	n.o.s.	I-1, N-2, CP65	
567	7280-37-7	✓	Estropipate		n.o.s.	N-1, CP65	
568	0-01-0	✓	Ethanol in alcoholic beverages	G	n.o.s.	I-1, N-1, CP65	
569	57-63-6	✓	Ethinylestradiol	SG	n.o.s.	I-1, N-2, CP65	
570	13194-48-4		Ethoprop		n.o.s.	CP65	
571	140-88-5	?	Ethyl Acrylate	IS	5 ppm TLV {20 mg/m^3}	I-2B, CP65	
572	0-01-0	✓	Ethyl Alcohol (in alcoholic beverages)	G	n.o.s.	I-1, N-1, CP65	
573	74-96-4		Ethyl Bromide	S	5 ppm TLV {23 mg/m^3}	G-A3, CP65	
574	51-79-6	?	Ethyl Carbamate		n.o.s.	I-2A, N-2, CP65	
575	75-00-3		Ethyl Chloride	S	100 ppm TLV {264 mg/m^3}	G-A3, CP65	
576	62-50-0	?	Ethyl Methanesulfonate		n.o.s.	I-2B, N-2, CP65	
577	510-15-6		Ethyl-4,4'-dichlorobenzilate		n.o.s.	CP65	
578	100-41-4	?	Ethylbenzene		50 ppm TLV {218 mg/m^3}	G-A3, I-2B, CP65	
579	106-93-4	?	Ethylene Dibromide	IS	20 ppm PEL	G-A3, I-2A, N-2, CP65	
580	107-06-2	?	Ethylene Dichloride		10 ppm TLV {40.5 mg/m^3}	I-2B, N-2, CP65	
581	75-21-8	✓	Ethylene Oxide [1910.1047]	I	1 ppm PEL {1.8 mg/m^3}	O, G-A2, I-1, N-1, CP65	
582	96-45-7	?	Ethylene Thiourea		n.o.s.	N-2, CP65	
583	151-56-4	✓	Ethyleneimine	IS	[1910.1003] {0.05 ppm TLV, 0.088 mg/m^3}	O, G-A3, I-2B, CP65	
584	117-81-7	?	*bis*(2-Ethylhexyl) Phthalate		5 mg/m^3 PEL	G-A3, N-2, CP65	
585	117-81-7	?	*di*(2-Ethylhexyl) Phthalate		5 mg/m^3 PEL	G-A3, N-2, CP65	
586	759-73-9	?	N-Ethyl-N-nitrosourea		n.o.s.	I-2A, N-2, CP65	
587	33419-42-0	✓	Etoposide		n.o.s.	I-1	
588	0-32-0	✓	Etoposide in combination with cisplatin and bleomycin		n.o.s.	I-1	
589	72490-01-8		Fenoxycarb		n.o.s.	CP65	
590	10294-52-7	✓	Ferric Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
591	0-97-0	?	Firefighter (occupational exposure as a)		n.o.s.	I-2B	
592	59536-65-1	?	Firemaster BP-6 {PBBs}		n.o.s.	I-2B, N-2, CP65	
593	67774-32-7	?	Firemaster FF-1 {PBBs}		n.o.s.	I-2B, N-2, CP65	
594	133-07-3		Folpet		n.o.s.	CP65	
595	50-00-0	✓	Formaldehyde [1910.1048]	IA	C 0.3 ppm TLV {C 0.37 mg/m^3; Sensitizer}	O, G-A2, I-1, N-2, CP65	
596	3570-75-0	?	2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole		n.o.s.	I-2B, CP65	
597	1327-53-3	✓	Fowler's Solution, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
598	68476-33-5	?	Fuel Oil, Residual (Heavy)	IS	n.o.s.	I-2B, CP65	
599	68476-30-2	?	Fuel Oil #2	IS	100 mg/m^3 TLV	G-A3, I-2B	
600	68476-31-3	?	Fuel Oil #4	IS	100 mg/m^3 TLV	G-A3, I-2B	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
601	116355-83-0	?	Fumonisin B1		n.o.s.	I-2B, CP65	
602	110-00-9	?	Furan		n.o.s.	I-2B, N-2, CP65	
603	531-82-8	?	Furathiazole		n.o.s.	I-2B, CP65	
604	67-45-8		Furazolidone		n.o.s.	CP65	
605	60568-05-0		Furmecyclox		n.o.s.	CP65	
606	0-98-0	✓	Furniture and Cabinet Making	I	n.o.s.	I-1	
607	3688-53-7	?	2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide		n.o.s.	I-2B, CP65	
608	79748-81-5		Fusarin C		n.o.s.	CP65	
609	1303-00-0	✓	Gallium Arsenide	IG	0.3 µg/m^3 TLV {Respirable}	O, G-A3, I-1, N-1, CP65	
610	0-76-0	✓	*Gamma* Radiation		n.o.s.	I-1, N-1	
611	82410-32-0		Ganciclovir Sodium		n.o.s.	CP65	
612	8006-61-9	?	Gasoline	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B	
613	86290-81-5	?	Gasoline	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B	
614	0-52-0	?	Gasoline, unleaded (wholly vaporized)	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B, CP65	
615	0-51-0	?	Gasoline Engine Exhaust (condensates/extracts)	I	n.o.s.	I-2B, CP65	
616	25812-30-0		Gemfibrozil		n.o.s.	CP65	
617	0-46-0	?	Glasswool (CP65: airborne particles of respirable size)	IS	1 f/cc TLV (respirable fibers)	G-A3, I-2B, N-2, CP65	
618	67730-11-4	?	Glu-P-1		n.o.s.	I-2B, CP65	
619	67730-10-3	?	Glu-P-2		n.o.s.	I-2B, CP65	
620	765-34-4	?	Glycidaldehyde		n.o.s.	I-2B, CP65	
621	556-52-5	?	Glycidol	ISG	2 ppm TLV {6.1 mg/m^3}	G-A3, I-2A, N-2, CP65	
622	126-07-8	?	Griseofulvin		n.o.s.	I-2B, CP65	
623	16568-02-8		Gyromitrin		n.o.s.	CP65	
624	0-99-0	?	Hairdresser or Barber (occ. exposure as a)		n.o.s.	I-2A	
625	2784-94-3	?	HC Blue No.1	I	n.o.s.	I-2B, CP65	
626	0-87-0	✓	Hematite Mining (underground) with exposure to radon		n.o.s.	I-1	
627	76-44-8	?	Heptachlor	S	0.05 mg/m^3 TLV	G-A3, I-2B, CP65	
628	1024-57-3	?	Heptachlor Epoxide	S	0.05 mg/m^3 TLV	G-A3, I-2B, CP65	
629	0-05-0		Herbal Remedies (containing plant species of the genus Aristolochia)		n.o.s.	CP65	
630	36355-01-8	?	Hexabromobiphenyl {PBBs}		n.o.s.	N-2	
631	67774-32-7	?	Hexabromobiphenyl {PBBs}		n.o.s.	I-2B, N-2, CP65	
632	118-74-1	?	Hexachlorobenzene	S	2 µg/m^3 TLV	G-A3, I-2B, N-2, CP65	
633	608-73-1	?	Hexachlorocyclohexane		n.o.s.	I-2B, N-2, CP65	
634	319-84-6	?	*alpha*-Hexachlorocyclohexane		n.o.s.	I-2B, N-2, CP65	
635	319-85-7	?	*beta*-Hexachlorocyclohexane		n.o.s.	I-2B, N-2, CP65	
636	58-89-9	?	*gamma*-Hexachlorocyclohexane	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
637	34465-46-8		Hexachlorodibenzodioxin		n.o.s.	CP65	
638	67-72-1	?	Hexachloroethane	SG	1 ppm PEL {9.7 mg/m^3}	G-A3, I-2B, N-2, CP65	
639	0-18-0		2,4-Hexadienal (89% trans, trans isomer, 11% cis, trans isomer)		n.o.s.	CP65	
640	680-31-9	?	Hexamethylphosphoramide	IS	n.o.s.	G-A3, I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
641	0-56-0	?	High-temperature frying, emissions from	I	n.o.s.	I-2A	
642	0-09-0	?	Hot Mate		n.o.s.	I-2A	
643	0-58-0	✓	Household combustion of coal, indoor emissions from	I	n.o.s.	I-1	
644	0-57-0	?	Household combution of biomass fuel (primarily wood), indoor emissions from	I	n.o.s.	I-2A	
645	302-01-2	?	Hydrazine	S	10 ppb TLV {13 µg/m^3}	G-A3, I-2B, N-2, CP65	
646	10034-93-2	?	Hydrazine Sulfate		n.o.s.	N-2, CP65	
647	122-66-7	?	Hydrazobenzene		n.o.s.	N-2, CP65	
648	129-43-1	?	1-Hydroxyanthraquinone		n.o.s.	I-2B, CP65	
649	193-39-5	?	Indeno[1,2,3-*cd*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
650	22398-80-7	?	Indium Phosphide		0.1 mg/m^3 TLV	I-2A, CP65	
651	7440-38-2	✓	Inorganic Arsenic [1910.1018] - [see specific compound]	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
652	0-12-0	✓	Involuntary Smoking (exposure to secondhand or 'environmental' tobacco smoke)	I	n.o.s.	I-1	
653	36734-19-7		Iprodione		n.o.s.	CP65	
654	140923-17-7		Iprovalicarb		n.o.s.	CP65	
655	140923-25-7		Iprovalicarb		n.o.s.	CP65	
656	76180-96-6	?	IQ		n.o.s.	I-2A, N-2, CP65	
657	10294-52-7	✓	Iron (III) Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
658	10294-53-8	✓	Iron (III) Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
659	0-88-0	✓	Iron and Steel Founding	I	n.o.s.	I-1	
660	9004-66-4	?	Iron Dextran Complex		n.o.s.	I-2B, N-2, CP65	
661	542-56-3		Isobutyl Nitrite		C 1 ppm TLV	G-A3, CP65	
662	78-79-5	?	Isopentadiene		n.o.s.	I-2B, N-2, CP65	
663	78-79-5	?	Isoprene		n.o.s.	I-2B, N-2, CP65	
664	0-69-0	✓	Isopropyl Alcohol Manufacture (strong-acid process)	IS	n.o.s.	I-1, N-1	
665	141112-29-0		Isoxaflutole		n.o.s.	CP65	
666	37317-41-2	?	Kanechlor® 500 {PCBs}		n.o.s.	N-2, CP65	
667	143-50-0	?	Kepone®		n.o.s.	I-2B, N-2, CP65	
668	77501-63-4		Lactofen		n.o.s.	CP65	
669	303-34-4	?	Lasiocarpine		n.o.s.	I-2B, CP65	
670	7439-92-1	?	Lead & Pb compounds, inorganic, as Pb - [see specific compound]	IG	50 µg/m^3 PEL	G-A3, I-2B, N-2, CP65	
671	301-04-2	?	Lead Acetate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
672	13510-89-9	?	Lead Antimonate (V)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
673	3687-31-8	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, I-1, N-1, CP65	
674	7645-25-2	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
675	7784-40-9	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
676	10102-48-4	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
677	10031-13-7	✓	Lead Arsenite, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
678	13424-46-9	?	Lead Azide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
679	10214-39-8	?	Lead Borate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
680	34018-28-5	?	Lead Bromate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
681	10031-22-8	?	Lead Bromide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
682	819-73-8	?	Lead Butyrate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
683	10294-47-0	?	Lead Chlorate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
684	7758-95-4	?	Lead Chloride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
685	7758-97-6	✓	Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A2, I-1, N-1, CP65	
686	8049-64-7	✓	Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
687	18454-12-1	✓	Lead Chromate Oxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
688	1309-60-0	?	Lead Dioxide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
689	7783-46-2	?	Lead Fluoride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
690	811-54-1	?	Lead Formate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
691	25808-74-6	?	Lead Hexafluorosilicate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
692	1311-11-1	?	Lead Hydroxide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
693	10294-58-3	?	Lead Hypophosphite	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
694	10101-63-0	?	Lead Iodide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
695	10190-55-3	?	Lead Molybdate (VI)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
696	1317-36-8	?	Lead Monoxide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
697	10099-74-8	?	Lead Nitrate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
698	7446-27-7	?	Lead Phosphate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
699	7446-15-3	?	Lead Selenate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
700	7488-51-9	?	Lead Selenite	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
701	1314-27-8	?	Lead Sesquioxide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
702	10101-94-7	?	Lead Sodium Thiosulfate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
703	1335-32-6	?	Lead Subacetate		n.o.s.	G-A3, I-2A, N-2, CP65	
704	7446-14-2	?	Lead Sulfate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
705	1314-87-0	?	Lead Sulfide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
706	1314-91-6	?	Lead Telluride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
707	7783-59-7	?	Lead Tetrafluoride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
708	1314-41-6	?	Lead Tetraoxide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
709	592-87-0	?	Lead Thiocyanate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
710	7759-01-5	?	Lead Tungstate (VI)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
711	10099-79-3	?	Lead Vanadate (V)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
712	1319-48-8	?	Leadhillite	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
713	58-89-9	?	Lindane	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
714	0-19-0	✓	Lithium Bichromate Dihydrate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
715	7789-01-7	✓	Lithium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
716	14307-35-8	✓	Lithium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
717	13843-81-7	✓	Lithium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
718	13010-47-4	?	Lomustine		n.o.s.	I-2A, N-2, CP65	
719	52-76-6		Lynestrenol		n.o.s.	CP65	
720	0-90-0	?	Magenta (mixtures of C.I. Basic Red, Methyl Fuchsin, Dimethyl Fuchsin or Trimethyl Fuchin) ..		n.o.s.	I-2B	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
721	0-89-0	✓	Magenta (production)	I	n.o.s.	I-1	
722	10103-50-1	✓	Magnesium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
723	13423-61-5	✓	Magnesium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
724	0-82-0	?	Magnetic Fields (extremely low frequency)		n.o.s.	I-2B	
725	8018-01-7		Mancozeb		n.o.s.	CP65	
726	12427-38-2		Maneb		n.o.s.	CP65	
727	0-10-0		Marijuana smoke		n.o.s.	CP65	
728	68334-30-5	?	Marine Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
729	77650-28-3	?	Marine Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
730	101-14-4	✓	MBOCA	S	0.01 ppm TLV {0.11 mg/m^3}	G-A2, I-1, N-2, CP65	
731	101-77-9	✓	MDA [1910.1050]	S	10 ppb PEL {0.081 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
732	68006-83-7	?	MeA-*alpha*-C		n.o.s.	I-2B, CP65	
733	13909-09-6	✓	MeCCNU		n.o.s.	I-1, N-1, CP65	
734	51-75-2	?	Mechlorethamine		n.o.s.	I-2A, N-2, CP65	
735	55-86-7	?	Mechlorethamine Hydrochloride		n.o.s.	N-2, CP65	
736	71-58-9	?	Medroxyprogesterone Acetate		n.o.s.	I-2B, CP65	
737	77094-11-2	?	MeIQ		n.o.s.	I-2B, N-2, CP65	
738	77500-04-0	?	MeIQx		n.o.s.	I-2B, N-2, CP65	
739	148-82-3	✓	Melphalan		n.o.s.	I-1, N-1, CP65	
740	110235-47-7		Mepanipyrim		n.o.s.	CP65	
741	13444-75-2	✓	Mercuric Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
742	7789-10-8	✓	Mercuric Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
743	13444-75-2	✓	Mercury (II) Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
744	7789-10-8	✓	Mercury (II) Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
745	531-76-0	?	Merphalan		n.o.s.	I-2B, CP65	
746	72-33-3	✓	Mestranol	SG	n.o.s.	I-1, N-2, CP65	
747	137-42-8		Metham Sodium		n.o.s.	CP65	
748	75-09-2	✓	Methane Dichloride [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
749	1665-00-5	✓	Methane-d_2 Dichloride {CD_2Cl_2} [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
750	298-81-7	✓	Methoxsalen	S	n.o.s.	I-1	
751	298-81-7	✓	Methoxsalen plus UV–A radiation	S	n.o.s.	I-1, N-1, CP65	
752	484-20-8	?	5-Methoxypsoralen		n.o.s.	I-2A	
753	484-20-8	?	5-Methoxypsoralen plus UV–A radiation		n.o.s.	I-2A, CP65	
754	298-81-7	✓	8-Methoxypsoralen plus UV–A radiation	S	n.o.s.	I-1, N-1, CP65	
755	598-55-0		Methyl Carbamate		n.o.s.	CP65	
756	74-88-4		Methyl Iodide	S	2 ppm TLV {11.6 mg/m^3}	CP65	
757	66-27-3	?	Methyl Methanesulfonate		n.o.s.	I-2A, N-2, CP65	
758	78-79-5	?	2-Methyl-1,3-butadiene		n.o.s.	I-2B, N-2, CP65	
759	129-15-7	?	2-Methyl-1-nitroanthraquinone		n.o.s.	I-2B, CP65	
760	75-55-8	?	2-Methylaziridine	S	0.2 ppm PEL {0.47 mg/m^3}	G-A3, I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
761	590-96-5		Methylazoxymethanol		n.o.s.	CP65	
762	592-62-1	?	Methylazoxymethanol Acetate		n.o.s.	I-2B, CP65	
763	51-75-2	?	N-Methyl-*bis*(2-chloroethyl) Amine		n.o.s.	I-2A, N-2, CP65	
764	13909-09-6	✓	Methyl-CCNU		n.o.s.	I-1, N-1, CP65	
765	107-30-2	✓	Methylchloro Methyl Ether	IS	[1910.1003]	O, G-A2, I-1, N-1, CP65	
766	56-49-5		3-Methylcholanthrene		n.o.s.	CP65	
767	3697-24-3	?	5-Methylchrysene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
768	101-14-4	✓	4,4'-Methylene *bis*(2-Chloroaniline)	S	0.01 ppm TLV {0.11 mg/m^3}	G-A2, I-1, N-2, CP65	
769	838-88-0	?	4,4'-Methylene *bis*(2-Methylaniline)		n.o.s.	I-2B, CP65	
770	101-61-1	?	4,4'-Methylene *bis*(N,N-dimethyl) Benzenamine		n.o.s.	I-2B, N-2, CP65	
771	75-09-2	✓	Methylene Chloride [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
772	1665-00-5	✓	Methylene-d_2 Chloride {CD2Cl2} [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
773	101-77-9	✓	4,4'-Methylenedianiline [1910.1050]	S	10 ppb PEL {0.081 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
774	13552-44-8	?	4,4'-Methylenedianiline Dihydrochloride		n.o.s.	N-2, CP65	
775	93-15-2	?	Methyleugenol		n.o.s.	N-2, CP65	
776	60-34-4		Methylhydrazine (and its salts)	S	0.01 ppm TLV {19 µg/m^3}	G-A3, CP65	
777	302-15-8		Methylhydrazine Sulfate		n.o.s.	CP65	
778	5118-34-3		Methylhydrazine Sulfate		n.o.s.	CP65	
779	115-09-3	?	Methylmercury Chloride		n.o.s.	I-2B, CP65	
780	0-20-0	?	Methylmercury compounds		0.01 mg/m^3 PEL	I-2B, CP65	
781	502-39-6	?	Methylmercury Dicyandiamide		n.o.s.	I-2B, CP65	
782	70-25-7	?	N-Methyl-N'-nitro-N-nitrosoguanidine		n.o.s.	I-2A, N-2, CP65	
783	684-93-5	?	N-Methyl-N-nitrosourea		n.o.s.	I-2A, N-2, CP65	
784	615-53-2	?	N-Methyl-N-nitrosourethane		n.o.s.	I-2B, CP65	
785	120-71-8	?	Methyl-*o*-anisidine		n.o.s.	I-2B, N-2, CP65	
786	924-42-5		N-Methylolacrylamide		n.o.s.	CP65	
787	56-04-2	?	Methylthiouracil		n.o.s.	I-2B, CP65	
788	9006-42-2		Metiram		n.o.s.	CP65	
789	443-48-1	?	Metronidazole		n.o.s.	I-2B, N-2, CP65	
790	136-45-8		MGK Repellant 326		n.o.s.	CP65	
791	101-61-1	?	Michler's Base		n.o.s.	I-2B, N-2, CP65	
792	90-94-8	?	Michler's Ketone		n.o.s.	I-2B, N-2, CP65	
793	101043-37-2	?	Microcystin-LR		n.o.s.	I-2B	
794	8002-05-9	✓	Mineral Oil (untreated/poorly and mildly refined/treated)	ISG	5 mg/m^3 TLV (inhalable particulate)	G-A2, I-1, N-1, CP65	2009
795	2385-85-5	?	Mirex		n.o.s.	I-2B, N-2, CP65	
796	50-07-7	?	Mitomycin C		n.o.s.	I-2B, CP65	
797	65271-80-9	?	Mitoxantrone		n.o.s.	I-2B	
798	70-25-7	?	MNNG		n.o.s.	I-2A, N-2, CP65	
799	101-14-4	✓	MOCA®	S	0.01 ppm TLV {0.11 mg/m^3}	G-A2, I-1, N-2, CP65	
800	8005-36-5	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
801	12213-61-5	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
802	12656-85-8	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
803	12709-98-7	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
804	64523-06-4	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
805	107-30-2	✓	Monochlorodimethyl Ether	IS	[1910.1003]	O, G-A2, I-1, N-1, CP65	
806	315-22-0	?	Monocrotaline		n.o.s.	I-2B, CP65	
807	0-31-0	✓	MOPP and other combined chemotherapy including alkylating agents		n.o.s.	I-1	
808	139-91-3		5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone		n.o.s.	CP65	
809	3795-88-8	?	5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone		n.o.s.	I-2B	
810	505-60-2	✓	Mustard Gas	IA	n.o.s.	I-1, N-1, CP65	
811	77439-76-0	?	MX		n.o.s.	I-2B, CP65	
812	55-98-1	✓	Myleran®	G	n.o.s.	I-1, N-1, CP65	
813	3771-19-5	?	Nafenopin		n.o.s.	I-2B, CP65	
814	389-08-2		Nalidixic Acid		n.o.s.	CP65	
815	91-20-3	?	Naphthalene	IS	10 ppm PEL {50 mg/m^3}	I-2B, N-2, CP65	
816	134-32-7	✓	1-Naphthylamine		[1910.1003]	O, CP65	
817	91-59-8	✓	2-Naphthylamine		[1910.1003]	O, G-A1, I-1, N-1, CP65	
818	134-32-7	✓	*alpha*-Naphthylamine		[1910.1003]	O, CP65	
819	91-59-8	✓	*beta*-Naphthylamine		[1910.1003]	O, G-A1, I-1, N-1, CP65	
820	55-18-5	?	NDEA		n.o.s.	I-2A, N-2, CP65	
821	16565-95-0	✓	Neodymium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
822	16569-87-2	✓	Neodymium Chromate Heptahydrate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
823	0-77-0	✓	Neutrons		n.o.s.	I-1, N-1	
824	7440-02-0	✓	Nickel metal powder & Ni alloys/compounds, as Ni - [see specific compound]	I	1 mg/m^3 PEL {inhalable fraction}	I-2B, N-1, CP65	
825	13478-00-7	✓	Nickel (II) Nitrate Hexahydrate, as Ni [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
826	373-02-4	✓	Nickel Acetate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
827	3264-82-2	✓	Nickel Acetylacetonate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
828	13462-88-9	✓	Nickel Bromide [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
829	3333-39-3	✓	Nickel Carbonate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
830	3333-67-3	✓	Nickel Carbonate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
831	12607-70-4	✓	Nickel Carbonate Hydroxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
832	13463-39-3	✓	Nickel Carbonyl	I	1 ppb PEL {7 µg/m^3}	I-1, N-1, CP65	
833	7718-54-9	✓	Nickel Chloride [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
834	557-19-7	✓	Nickel Cyanide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
835	13478-93-8	✓	Nickel Dimethylglyoxime	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
836	10028-18-9	✓	Nickel Fluoride [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
837	3349-06-2	✓	Nickel Formate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
838	11113-74-9	✓	Nickel Hydroxide	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
839	12054-48-7	✓	Nickel Hydroxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
840	12125-56-3	✓	Nickel Hydroxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
841	13462-90-3	✓	Nickel Iodide [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
842	1313-99-1	✓	Nickel Monoxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
843	13138-45-9	✓	Nickel Nitrate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
844	547-67-1	✓	Nickel Oxalate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
845	1313-99-1	✓	Nickel Oxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
846	13520-61-1	✓	Nickel Perchlorate Hexahydrate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
847	10381-36-9	✓	Nickel Phosphate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
848	0-91-0		Nickel Refinery Dust (from the pyrometallurgical process)		1.5 mg/m^3 TLV {inhalable fraction}	CP65	
849	1314-06-3	✓	Nickel Sesquioxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
850	12035-72-2	✓	Nickel Subsulfide	I	0.1 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
851	13770-89-3	✓	Nickel Sulfamate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
852	7786-81-4	✓	Nickel Sulfate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
853	37227-61-5	✓	Nickel-Beryllium Alloy, as Ni fume or dust [also see Be]	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
854	1271-28-9	✓	Nickelocene	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
855	61-57-4	?	Niridazole		n.o.s.	I-2B, CP65	
856	1929-82-4		Nitrapyrin		10 mg/m^3 TLV	CP65	
857	0-21-0	?	Nitrate or nitrite (ingested) under conditions that result in endogenous nitrosation	I	n.o.s.	I-2A	
858	139-13-9	?	Nitrilotriacetic Acid (and its salts)	I	n.o.s.	I-2B, N-2, CP65	
859	10042-84-9	?	Nitrilotriacetic Acid , Sodium Salt (unspecified)	I	n.o.s.	I-2B, N-2, CP65	
860	15467-20-6	?	Nitrilotriacetic Acid, Disodium Salt	I	n.o.s.	I-2B, N-2, CP65	
861	23255-03-0	?	Nitrilotriacetic Acid, Disodium Salt, Hydrate	I	n.o.s.	I-2B, N-2, CP65	
862	18994-66-6	?	Nitrilotriacetic Acid, Monosodium Salt	I	n.o.s.	I-2B, N-2, CP65	
863	5064-31-3	?	Nitrilotriacetic Acid, Trisodium Salt	I	n.o.s.	I-2B, N-2, CP65	
864	18662-53-8	?	Nitrilotriacetic Acid, Trisodium Salt, Hydrate	I	n.o.s.	I-2B, N-2, CP65	
865	531-82-8	?	N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide		n.o.s.	I-2B, CP65	
866	602-87-9	?	5-Nitroacenaphthene		n.o.s.	I-2B, CP65	
867	91-23-6	?	2-Nitroanisole		n.o.s.	I-2B, N-2, CP65	
868	91-23-6	?	*o*-Nitroanisole		n.o.s.	I-2B, N-2, CP65	
869	98-95-3	?	Nitrobenzene	S	1 ppm PEL {5 mg/m^3}	G-A3, I-2B, N-2, CP65	
870	92-93-3	✓	4-Nitrobiphenyl	S	[1910.1003]	O, G-A2, CP65	
871	100-00-5		*p*-Nitrochlorobenzene	S	1 mg/m^3 PEL {0.1 ppm TLV}	G-A3, CP65	
872	7496-02-8	?	6-Nitrochrysene	I	n.o.s.	I-2B, N-2, CP65	
873	92-93-3	✓	4-Nitrodiphenyl	S	[1910.1003]	O, G-A2, CP65	
874	1836-75-5	?	Nitrofen (technical grade)		n.o.s.	I-2B, N-2, CP65	
875	607-57-8	?	2-Nitrofluorene	I	n.o.s.	I-2B, CP65	
876	59-87-0		Nitrofurazone		n.o.s.	CP65	
877	555-84-0	?	1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone		n.o.s.	I-2B, CP65	
878	51-75-2	?	Nitrogen Mustard		n.o.s.	I-2A, N-2, CP65	
879	55-86-7	?	Nitrogen Mustard Hydrochloride		n.o.s.	N-2, CP65	
880	126-85-2	?	Nitrogen Mustard N-oxide		n.o.s.	I-2B, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
881	302-70-5	?	Nitrogen Mustard N-oxide Hydrochloride		n.o.s.	I-2B, CP65	
882	75-52-5	?	Nitromethane		20 ppm TLV {49.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
883	79-46-9	?	2-Nitropropane	I	10 ppm TLV {37 mg/m^3}	G-A3, I-2B, N-2, CP65	
884	5522-43-0	?	1-Nitropyrene	I	n.o.s.	I-2B, N-2, CP65	
885	57835-92-4	?	4-Nitropyrene	I	n.o.s.	I-2B, N-2, CP65	
886	1116-54-7	?	N-Nitrosodiethanolamine		n.o.s.	I-2B, N-2, CP65	
887	55-18-5	?	N-Nitrosodiethylamine		n.o.s.	I-2A, N-2, CP65	
888	62-75-9	✓	N-Nitrosodimethylamine	S	[1910.1003]	O, G-A3, I-2A, N-2, CP65	
889	924-16-3	?	N-Nitrosodi-*n*-butylamine		n.o.s.	I-2B, N-2, CP65	
890	621-64-7	?	N-Nitrosodi-*n*-propylamine		n.o.s.	I-2B, N-2, CP65	
891	86-30-6		N-Nitrosodiphenylamine		n.o.s.	CP65	
892	156-10-5		*p*-Nitrosodiphenylamine		n.o.s.	CP65	
893	64091-91-4	✓	4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone		n.o.s.	I-1, N-2, CP65	
894	60153-49-3	?	3-(N-Nitrosomethylamino)propionitrile		n.o.s.	I-2B, CP65	
895	10595-95-6	?	N-Nitrosomethylethylamine		n.o.s.	I-2B, CP65	
896	4549-40-0	?	N-Nitrosomethylvinylamine		n.o.s.	I-2B, N-2, CP65	
897	59-89-2	?	N-Nitrosomorpholine		n.o.s.	I-2B, N-2, CP65	
898	38252-74-3	?	N-Nitroso-*n*-butyl-N-(3-carboxypropyl)amine		n.o.s.	N-2	
899	3817-11-6	?	N-Nitroso-*n*-butyl-N-(4-hydroxybutyl)amine		n.o.s.	N-2	
900	759-73-9	?	N-Nitroso-N-ethylurea		n.o.s.	I-2A, N-2, CP65	
901	684-93-5	?	N-Nitroso-N-methylurea		n.o.s.	I-2A, N-2, CP65	
902	615-53-2	?	N-Nitroso-N-methylurethane		n.o.s.	I-2B, CP65	
903	16543-55-8	✓	N'-Nitrosonornicotine		n.o.s.	I-1, N-2, CP65	
904	100-75-4	?	N-Nitrosopiperidine		n.o.s.	I-2B, N-2, CP65	
905	930-55-2	?	N-Nitrosopyrrolidine		n.o.s.	I-2B, N-2, CP65	
906	13256-22-9	?	N-Nitrososarcosine		n.o.s.	I-2B, N-2, CP65	
907	88-72-2		*o*-Nitrotoluene	S	2 ppm TLV {11.2 mg/m^3}	CP65	
908	64091-91-4	✓	NNK		n.o.s.	I-1, N-2, CP65	
909	16543-55-8	✓	NNN		n.o.s.	I-1, N-2, CP65	
910	1-00-0	?	Non-Arsenical Insecticides (occ. exposures in spraying and application of)	I	n.o.s.	I-2A	
911	68-22-4	?	Norethindrone		n.o.s.	I-2B, N-2, CP65	
912	68-22-4	?	Norethisterone		n.o.s.	I-2B, N-2, CP65	
913	68-23-5		Norethynodrel		n.o.s.	CP65	
914	303-47-9	?	Ochratoxin A	G	n.o.s.	I-2B, N-2, CP65	
915	61288-13-9	?	Octabromobiphenyl {PBBs}		n.o.s.	N-2, CP65	
916	117-81-7	?	*di-sec*-Octylphthalate		5 mg/m^3 PEL	G-A3, N-2, CP65	
917	0-37-0	✓	Oestrogen (see Estrogen)	SG	n.o.s.	I-1	
918	2646-17-5	?	Oil Orange SS		n.o.s.	I-2B, CP65	
919	0-41-0	✓	Oral contraceptives, combined estrogen-progestogen	G	n.o.s.	I-1, CP65	
920	0-42-0	✓	Oral contraceptives, sequential		n.o.s.	I-1	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
921	19044-88-3		Oryzalin		n.o.s.	CP65	
922	19666-30-9		Oxadiazon		n.o.s.	CP65	
923	604-75-1	?	Oxazepam		n.o.s.	I-2B, CP65	
924	101-80-4	?	4,4'-Oxydianiline		n.o.s.	I-2B, N-2, CP65	
925	434-07-1	?	Oxymetholone		n.o.s.	N-2, CP65	
926	2439-01-2		Oxythioquinox		n.o.s.	CP65	
927	3697-24-3	?	PAH {5-Methylchrysene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
928	194-59-2	?	PAH {7H-Dibenzo[*c,g*]carbazole}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
929	56-55-3	?	PAH {Benz[*a*]anthracene}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
930	202-33-5	?	PAH {Benz[*j*]aceanthrylene}	I	0.2 mg/m^3 PEL	I-2B	
931	50-32-8	✓	PAH {Benzo[*a*]pyrene}		0.2 mg/m^3 PEL	G-A2, I-1, N-2, CP65	
932	205-99-2	?	PAH {Benzo[*b*]fluoranthene}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
933	195-19-7	?	PAH {Benzo[*c*]phenanthrene}	I	0.2 mg/m^3 PEL	I-2B	
934	205-82-3	?	PAH {Benzo[*j*]fluoranthene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
935	207-08-9	?	PAH {Benzo[*k*]fluoranthene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
936	27208-37-3	?	PAH {Cyclopenta[*cd*]pyrene}		0.2 mg/m^3 PEL	I-2A	
937	226-36-8	?	PAH {Dibenz[*a,h*]acridine}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
938	53-70-3	?	PAH {Dibenz[*a,h*]anthracene}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
939	224-42-0	?	PAH {Dibenz[*a,j*]acridine}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
940	192-65-4	?	PAH {Dibenzo[*a,e*]pyrene}	I	0.2 mg/m^3 PEL	N-2, CP65	
941	189-64-0	?	PAH {Dibenzo[*a,h*]pyrene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
942	189-55-9	?	PAH {Dibenzo[*a,i*]pyrene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
943	191-30-0	?	PAH {Dibenzo[*a,l*]pyrene}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
944	193-39-5	?	PAH {Indeno[1,2,3-*cd*]pyrene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
945	0-53-0	?	PAH {Polycyclic Aromatic Hydrocarbon(s); see 15 specific chemicals}	I	0.2 mg/m^3 PEL	N-2, CP65	
946	1-01-0	✓	Painter (occ. exposure as a)		n.o.s.	I-1	
947	12174-11-7	?	Palygorskite (long fibers, > 5 µm)	I	n.o.s.	I-2B, CP65	
948	794-93-4	?	Panfuran S (containing dihydroxymethylfuratrizine)		n.o.s.	I-2B, CP65	
949	30525-89-4	✓	Paraformaldehyde	IA	C 0.3 ppm TLV {C 0.37 mg/m^3}	O, G-A2, I-2A, N-2	
950	65996-93-2	✓	Particulate Polycyclic Aromatic Hydrocarbons [PPAH]	I	0.2 mg/m^3 PEL	G-A1, I-1, N-1	
951	1-02-0	✓	Paving and roofing with coal-tar pitch	IS	n.o.s.	I-1	
952	59536-65-1	?	PBBs {Polybrominated Biphenyls}		n.o.s.	I-2B, N-2, CP65	
953	67774-32-7	?	PBBs {Polybrominated Biphenyls}		n.o.s.	I-2B, N-2, CP65	
954	1336-36-3	?	PCBs {Polychorinated Biphenyls}		n.o.s.	I-2A, N-2, CP65	
955	87-86-5	?	Pentachlorophenol	S	0.5 mg/m^3 PEL	G-A3, I-2B, CP65	
956	127-18-4	?	Perchloroethylene		25 ppm TLV {170 mg/m^3}	G-A3, I-2A, N-2, CP65	
957	1-03-0	?	Petroleum Refining (occ. exposure in)		n.o.s.	I-2A	
958	122-60-1	?	PGE	S	0.1 ppm TLV {0.6 mg/m^3; Sensitizer}	G-A3, I-2B, CP65	
959	62-44-2	✓	Phenacetin		n.o.s.	I-1, N-2, CP65	
960	0-44-0	✓	Phenacetin, analgesic mixtures containing		n.o.s.	I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
961	94-78-0	?	Phenazopyridine		n.o.s.	N-2, CP65	
962	136-40-3	?	Phenazopyridine Hydrochloride		n.o.s.	I-2B, N-2, CP65	
963	3546-10-9		Phenesterin		n.o.s.	CP65	
964	50-06-6	?	Phenobarbital		n.o.s.	I-2B, CP65	
965	77-09-8	?	Phenolphthalein		n.o.s.	I-2B, N-2, CP65	
966	59-96-1		Phenoxybenzamine		n.o.s.	CP65	
967	63-92-3	?	Phenoxybenzamine Hydrochloride		n.o.s.	I-2B, N-2, CP65	
968	122-60-1	?	Phenyl Glycidyl Ether	S	0.1 ppm TLV {0.6 mg/m^3; Sensitizer}	G-A3, I-2B, CP65	
969	95-54-5		*o*-Phenylenediamine (and its salts)		0.1 mg/m^3 TLV	G-A3, CP65	
970	100-42-5	?	Phenylethylene	S	20 ppm TLV {85 mg/m^3}	I-2B	
971	100-63-0		Phenylhydrazine (and its salts)	S	0.1 ppm TLV {0.44 mg/m^3}	G-A3, CP65	
972	132-27-4	?	*o*-Phenylphenate, Sodium		n.o.s.	I-2B, CP65	
973	90-43-7		*o*-Phenylphenol		n.o.s.	CP65	
974	57-41-0	?	Phenytoin		n.o.s.	I-2B, N-2, CP65	
975	630-93-3		Phenytoin (sodium salt)		n.o.s.	CP65	
976	105650-23-5	?	PhIP		n.o.s.	I-2B, N-2, CP65	
977	7723-14-0	✓	Phosphorus (as ^{32}P, as phosphate)		n.o.s.	I-1	
978	7280-37-7	✓	Piperazine Estrone Sulfate		n.o.s.	N-1, CP65	
979	23103-98-2		Pirimicarb		n.o.s.	CP65	
980	0-04-0	✓	Plants containing Aristolochic Acid		n.o.s.	I-1	
981	7440-07-5	✓	Plutonium (as ^{239}Pu, and its decay products [may contain other isotopes], as aerosols)		n.o.s.	I-1	
982	59536-65-1	?	Polybrominated Biphenyls {PBBs}		n.o.s.	I-2B, N-2, CP65	
983	67774-32-7	?	Polybrominated Biphenyls {PBBs}		n.o.s.	I-2B, N-2, CP65	
984	1336-36-3		Polychlorinated Biphenyls (containing 60 or more percent chlorine by molecular weight) {PCBs}		n.o.s.	CP65	
985	1336-36-3	?	Polychlorinated Biphenyls {PCBs}		n.o.s.	I-2A, N-2, CP65	
986	8001-35-2	?	Polychlorinated Camphene	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
987	0-28-0		Polychlorinated Dibenzofurans		n.o.s.	CP65	
988	0-27-0		Polychlorinated Dibenzo-*p*-dioxins		n.o.s.	CP65	
989	0-26-0	?	Polychlorophenols (and their sodium salts) (mixed exposure)		n.o.s.	I-2B	
990	0-53-0	?	Polycyclic Aromatic Hydrocarbon(s) {PAH; see 15 specific chemicals}	I	0.2 mg/m^3 PEL	N-2, CP65	
991	53973-98-1		Polygeenan		n.o.s.	CP65	
992	3564-09-8	?	Ponceau 3R		n.o.s.	I-2B, CP65	
993	3761-53-3	?	Ponceau MX		n.o.s.	I-2B, CP65	
994	7784-41-0	✓	Potassium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
995	13464-35-2	✓	Potassium Arsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
996	7758-01-2	?	Potassium Bromate		n.o.s.	I-2B, CP65	
997	7789-00-6	✓	Potassium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
998	7778-50-9	✓	Potassium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
999	125-33-7		Primidone		n.o.s.	CP65	
1000	1-04-0	?	Printing Processes (occ. exposure in)		n.o.s.	I-2B	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1001	671-16-9	?	Procarbazine		n.o.s.	I-2A, N-2, CP65	
1002	366-70-1	?	Procarbazine Hydrochloride		n.o.s.	I-2A, N-2, CP65	
1003	32809-16-8		Procymidone		n.o.s.	CP65	
1004	57-83-0	?	Progesterone (Indirect)		n.o.s.	N-2, CP65	
1005	0-38-0	?	Progestins		n.o.s.	I-2B	
1006	0-43-0	?	Progestogen-only Contraceptives		n.o.s.	I-2B	
1007	23950-58-5		Pronamide		n.o.s.	CP65	
1008	1918-16-7		Propachlor		n.o.s.	CP65	
1009	1120-71-4	?	1,3-Propane Sultone		n.o.s.	G-A3, I-2B, N-2, CP65	
1010	0-69-0	✓	2-Propanol Manufacture (strong-acid process)		n.o.s.	I-1, N-1	
1011	2312-35-8		Propargite		n.o.s.	CP65	
1012	57-57-8	✓	*beta*-Propiolactone	S	[1910.1003] {0.5 ppm TLV, 1.5 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
1013	114-26-1		Propoxur		0.5 mg/m^3 TLV	G-A3, CP65	
1014	136-45-8		*di-n*-Propyl Isocinchomeronate		n.o.s.	CP65	
1015	78-87-5		Propylene Dichloride		10 ppm TLV {46 mg/m^3; Sensitizer}	CP65	
1016	57018-52-7		Propylene Glycol Mono-t-Butyl Ether		n.o.s.	CP65	
1017	75-56-9	?	Propylene Oxide		2 ppm TLV {4.8 mg/m^3; Sensitizer}	G-A3, I-2B, N-2, CP65	
1018	75-55-8	?	Propyleneimine	S	0.2 ppm PEL {0.47 mg/m^3}	G-A3, I-2B, N-2, CP65	
1019	51-52-5	?	Propylthiouracil		n.o.s.	I-2B, N-2, CP65	
1020	110-86-1		Pyridine		1 ppm TLV	G-A3, CP65	
1021	1317-95-9	?	*alpha*-Quartz {Silica (respirable) - Crystalline; a/k/a Tripoli}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-2A, CP65	
1022	14808-60-7	✓	*alpha*-Quartz {Silica (respirable) - Crystalline}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
1023	91-22-5		Quinoline (and its strong acid salts)		n.o.s.	CP65	
1024	0-78-0	✓	Radioiodines (short-lived isotopes including ^{131}I)		n.o.s.	I-1	
1025	0-79-0	✓	Radionuclides, *alpha*-particle-emitting (internally deposited)		n.o.s.	I-1, CP65	
1026	0-80-0	✓	Radionuclides, *beta*-particle-emitting (internally deposited)		n.o.s.	I-1, CP65	
1027	7440-14-4	✓	Radium (as ^{224}Ra, and its decay products)		n.o.s.	I-1	
1028	7440-14-4	✓	Radium (as ^{226}Ra, and its decay products)		n.o.s.	I-1	
1029	7440-14-4	✓	Radium (as ^{228}Ra, and its decay products)		n.o.s.	I-1	
1030	10043-92-2	✓	Radon (as ^{222}Rn, and its decay products)	IG	0.2–0.7 pCi/L EPA {indoor < outdoor}	I-1, N-1	
1031	409-21-2	?	Refractory Ceramic Fiber	I	0.2 f/cc TLV (respirable fibers)	G-A2, I-2B, N-2, CP65	
1032	50-55-5	?	Reserpine		n.o.s.	N-2, CP65	
1033	68476-33-5	?	Residual (Heavy) Fuel Oil	IS	n.o.s.	I-2B, CP65	
1034	10453-86-8		Resmethrin		n.o.s.	CP65	
1035	23246-96-0	?	Riddelliine		n.o.s.	I-2B, CP65	
1036	0-47-0	?	Rockwool	I	1 f/cc TLV (respirable fibers)	G-A3, I-2B	
1037	569-61-9	?	*p*-Rosaniline	IS	n.o.s.	I-2B, N-2, CP65	
1038	1-05-0	✓	Rubber Industry		n.o.s.	I-1	
1039	13446-72-5	✓	Rubidium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1040	13446-73-6	✓	Rubidium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1041	94-59-7	?	Safrole		n.o.s.	I-2B, N-2, CP65	
1042	599-79-1		Salicylazosulfapyridine		n.o.s.	CP65	
1043	16565-96-1	✓	Samarium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1044	58569-17-8	✓	Samarium Chromate Dihydrate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1045	58477-24-0	✓	Samarium Chromate Heptahydrate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1046	7446-34-6	?	Selenium Sulfide		n.o.s.	N-2, CP65	
1047	13909-09-6	✓	Semustine		n.o.s.	I-1, N-1, CP65	
1048	68308-34-9	✓	Shale Oils		n.o.s.	I-1, CP65	
1049	1-06-0	?	Shiftwork that involves circadian disruption		n.o.s.	I-2A	
1050	1317-95-9	?	Silica (respirable) - Crystalline {*alpha*-Quartz a/k/a Tripoli}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-2A, CP65	
1051	14808-60-7	✓	Silica (respirable) - Crystalline {*alpha*-Quartz}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
1052	14464-46-1	✓	Silica (respirable) - Crystalline {Cristobalite}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
1053	409-21-2	?	Silicon Carbide (fibrous forms, including whiskers)	I	0.2 f/cc TLV (respirable fibers)	G-A2, I-2B, N-2, CP65	
1054	7631-86-9	✓	Silicon Dioxide - [see specific crystalline silica form]	I	0.05 - 0.1 mg/m^3 PEL	I-2A, N-1, CP65	
1055	7784-01-2	✓	Silver Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1056	7784-02-3	✓	Silver Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1057	0-48-0	?	Slagwool	I	1 f/cc TLV (respirable fibers)	G-A3, I-2B	
1058	7631-89-2	✓	Sodium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1059	15120-17-9	✓	Sodium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1060	7784-46-5	✓	Sodium Arsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1061	7775-11-3	✓	Sodium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1062	10588-01-9	✓	Sodium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1063	12018-32-5	✓	Sodium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1064	16680-47-0	✓	Sodium Equilin Sulfate		n.o.s.	N-1	
1065	438-67-5	✓	Sodium Estrone Sulfate		n.o.s.	N-1	
1066	132-27-4	?	Sodium *o*-Phenylphenate		n.o.s.	I-2B, CP65	
1067	0-70-0	✓	Solar Radiation, as UV radiation	S	n.o.s.	I-1, N-1	
1068	0-55-0	✓	Soot extracts (containing PAHs)	ISG	n.o.s.	N-1, CP65	
1069	0-62-0	✓	Soots {PAH}	ISG	n.o.s.	I-1, N-1, CP65	
1070	0-49-0	?	Special-purpose fibers (such as E-glass and '475' glass fibers)		1 f/cc TLV	G-A3, I-2B	
1071	52-01-7		Spironolactone		n.o.s.	CP65	
1072	38455-77-5	✓	Stannic Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1073	10418-03-8		Stanozolol		n.o.s.	CP65	
1074	10048-13-2	?	Sterigmatocystin		n.o.s.	I-2B, CP65	
1075	18883-66-4	?	Streptozocin		n.o.s.	I-2B, N-2, CP65	
1076	18883-66-4	?	Streptozotocin		n.o.s.	I-2B, N-2, CP65	
1077	0-68-0	✓	Strong Inorganic Acid Mists Containing Sulfuric Acid (occ. exposure to)	IS	0.2 mg/m^3 TLV (thoracic fraction)	G-A2, I-1, N-1, CP65	
1078	7789-06-2	✓	Strontium Chromate, as Cr^{6+}	I	0.5 µg/m^3 TLV	O, G-A2, I-1, N-1, CP65	
1079	54322-60-0	✓	Strontium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1080	96-09-3	?	Styrene Epoxide		n.o.s.	I-2A, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1081	96-09-3	?	Styrene Oxide		n.o.s.	I-2A, N-2, CP65	
1082	100-42-5	?	Styrene, Monomer	S	20 ppm TLV {85 mg/m^3}	I-2B	
1083	96-09-3	?	Styrene-7,8-oxide		n.o.s.	I-2A, N-2, CP65	
1084	95-06-7	?	Sulfallate		n.o.s.	I-2B, N-2, CP65	
1085	505-60-2	✓	Sulfur Mustard	IA	n.o.s.	I-1, N-1, CP65	
1086	0-68-0	✓	Sulfuric Acid Mist (occ. exposure to strong inorganic acid mists)	IS	0.2 mg/m^3 TLV (thoracic fraction)	G-A2, I-1, N-1, CP65	
1087	0-75-0	✓	Sunlamps and sunbeds, use of [as UV radiation]	S	n.o.s.	I-2A, N-1	
1088	0-45-0	?	Synthetic Vitreous Fibers (see glasswool, rockwool, slagwool)	IS	1 f/cc TLV (respirable fibers)	G-A3, I-2B, N-2	
1089	93-76-5	?	2,4,5-T	S	10 mg/m^3 PEL	I-2B	
1090	0-22-0	✓	Talc (containing asbestiform fibers)	I	0.1 f/cc PEL	O, G-A1, I-1, N-1, CP65	
1091	0-23-0	?	Talc-based body powder (perineal use of)		n.o.s.	I-2B	
1092	10540-29-1	✓	Tamoxifen (and its salts)		n.o.s.	I-1, N-1, CP65	
1093	0-63-0	✓	Tars	I	n.o.s.	N-1, CP65	
1094	1746-01-6	✓	TCDD	S	n.o.s.	I-1, N-1, CP65	
1095	584-84-9	?	TDI	S	1 ppb TLV {7.2 µg/m^3; Sensitizer}	G-A3, I-2B, N-2	2006
1096	29767-20-2	?	Teniposide		n.o.s.	I-2A	
1097	2593-15-9		Terrazole		n.o.s.	CP65	
1098	58-22-0		Testosterone (and its esters)		n.o.s.	CP65	
1099	2475-45-8	?	1,4,5,8-Tetraamino-9,10-anthracenedione	I	n.o.s.	I-2B, N-2, CP65	
1100	1746-01-6	✓	2,3,7,8-Tetrachlorodibenzo-*p*-dioxin	S	n.o.s.	I-1, N-1, CP65	
1101	79-34-5		1,1,2,2-Tetrachloroethane	S	1 ppm TLV {6.9 mg/m^3}	G-A3, CP65	
1102	127-18-4	?	Tetrachloroethylene		25 ppm TLV {170 mg/m^3}	G-A3, I-2A, N-2, CP65	
1103	56-23-5	?	Tetrachloromethane	IS	5 ppm TLV {31.5 mg/m^3}	G-A2, I-2B, N-2, CP65	
1104	5216-25-1		*p-a,a,a*-Tetrachlorotoluene		n.o.s.	CP65	
1105	17786-31-1	?	Tetracobalt Dodecacarbonyl, as Co	I	0.02 mg/m^3 TLV	G-A3, I-2B	
1106	116-14-3	?	Tetrafluoroethylene		2 ppm TLV	G-A3, I-2B, N-2, CP65	
1107	509-14-8	?	Tetranitromethane	I	5 ppb TLV {0.04 mg/m^3}	G-A3, I-2B, N-2, CP65	
1108	1-07-0	?	Textile Manufacturing Industry (work in)		n.o.s.	I-2B	
1109	13473-75-1	✓	Thallium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1110	15190-21-3	✓	Thallium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1111	22534-09-4	✓	Thallium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1112	13453-35-5	✓	Thallium Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1113	62-55-5	?	Thioacetamide		n.o.s.	I-2B, N-2, CP65	
1114	139-65-1	?	4,4'-Thiodianiline		n.o.s.	I-2B, N-2, CP65	
1115	59669-26-0		Thiodicarb		n.o.s.	CP65	
1116	52-24-4	✓	Thiotepa		n.o.s.	I-1, N-1, CP65	
1117	141-90-2	?	Thiouracil		n.o.s.	I-2B, CP65	
1118	62-56-6	?	Thiourea		n.o.s.	N-2, CP65	
1119	7440-29-1	✓	Thorium (as ^{232}Th, and its decay products, administered intravenously)	J	n.o.s.	I-1	
1120	1314-20-1	✓	Thorium Dioxide - [see Thorium]	J	n.o.s.	N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1121	38455-77-5	✓	Tin (IV) Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1122	13463-67-7	?	Titanium Dioxide		10 mg/m^3 TLV	I-2B	
1123	0-11-0	✓	Tobacco Smoking and Tobacco Smoke	I	n.o.s.	I-1, N-1, CP65	
1124	0-13-0	✓	Tobacco, Smokeless (CP65: oral use of smokeless products)	S	n.o.s.	I-1, N-1, CP65	
1125	119-93-7	?	*o*-Tolidine	S	n.o.s.	G-A3, I-2B, N-2, CP65	
1126	26471-62-5	?	Toluene Diisocyanate		n.o.s. {Sensitizer}	I-2B, N-2, CP65	
1127	95-80-7	?	Toluene-2,4-diamine		n.o.s.	I-2B, N-2, CP65	
1128	584-84-9	?	Toluene-2,4-diisocyanate	S	1 ppb TLV {7.2 µg/m^3; Sensitizer}	G-A3, I-2B, N-2	2006
1129	91-08-7	?	Toluene-2,6-diisocyanate	S	1 ppb TLV {7.2 µg/m^3; Sensitizer}	G-A3, I-2B, N-2	2006
1130	95-53-4	✓	*o*-Toluidine	S	2 ppm TLV {8.8 mg/m^3}	G-A3, I-1, N-2, CP65	
1131	636-21-5	?	*o*-Toluidine Hydrochloride		n.o.s.	N-2, CP65	
1132	8001-35-2	?	Toxaphene	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
1133	14567-73-8	✓	Tremolite [asbestiform]	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
1134	299-75-2	✓	Treosulfan		n.o.s.	I-1, CP65	
1135	299-75-2	✓	Treosulphan		n.o.s.	I-1, CP65	
1136	817-09-4	?	Trichlormethine		n.o.s.	I-2B, CP65	
1137	50-29-3	?	1,1,1-Trichloro-2,2-*bis*(*p*-chlorophenyl)ethane	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
1138	79-00-5		1,1,2-Trichloroethane	S	10 ppm PEL {55 mg/m^3}	G-A3, CP65	
1139	79-01-6	?	Trichloroethylene		10 ppm TLV	G-A2, I-2A, N-2, CP65	
1140	67-66-3	?	Trichloromethane	IA	10 ppm TLV {48.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
1141	95-95-4	?	2,4,5-Trichlorophenol	S	n.o.s.	I-2B	
1142	88-06-2	?	2,4,6-Trichlorophenol	S	n.o.s.	I-2B, N-2, CP65	
1143	93-76-5	?	(2,4,5-Trichlorophenoxy) Acetic Acid	S	10 mg/m^3 PEL	I-2B	
1144	96-18-4	?	1,2,3-Trichlorpropane	S	10 ppm TLV {60.3 mg/m^3}	G-A3, I-2A, N-2, CP65	
1145	512-56-1		Trimethyl Phosphate		n.o.s.	CP65	
1146	137-17-7		2,4,5-Trimethylaniline (and its strong acid salts)		n.o.s.	CP65	
1147	21436-97-5		2,4,5-Trimethylaniline Hydrochloride		n.o.s.	CP65	
1148	817-09-4	?	Trimustine Hydrochloride		n.o.s.	I-2B, CP65	
1149	118-96-7		2,4,6-Trinitrotoluene	S	0.1 mg/m^3 TLV	CP65	
1150	76-87-9		Triphenyltin Hydroxide		n.o.s.	CP65	
1151	64070-83-3	✓	Trisodium Arsenate Heptahydrate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1152	62450-06-0	?	Trp-P-1		n.o.s.	I-2B, CP65	
1153	62450-07-1	?	Trp-P-2		n.o.s.	I-2B, CP65	
1154	72-57-1	?	Trypan Blue (commercial grade)		n.o.s.	I-2B, CP65	
1155	62450-06-0	?	Tryptophan-P-1		n.o.s.	I-2B, CP65	
1156	62450-07-1	?	Tryptophan-P-2		n.o.s.	I-2B, CP65	
1157	57-14-7	?	UDMH	IS	0.01 ppm TLV {0.025 mg/m^3}	G-A3, I-2B, N-2, CP65	
1158	0-71-0	✓	Ultraviolet Radiation – Broad Spectrum	S	n.o.s.	N-1	
1159	0-72-0	?	Ultraviolet–A Radiation {UV–A @ 315-400 nm}	S	n.o.s.	I-2A, N-2	
1160	0-73-0	?	Ultraviolet–B Radiation {UV–B @ 280-315 nm}	S	n.o.s.	I-2A, N-2	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1161	0-74-0	?	Ultraviolet–C Radiation {UV–C @ 100-280 nm}	S	n.o.s.	I-2A, N-2	
1162	0-52-0	?	Unleaded Gasoline (wholly vaporized)	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B, CP65	
1163	66-75-1	?	Uracil Mustard		n.o.s.	I-2B, CP65	
1164	7440-61-1	✓	Uranium, natural [soluble & insoluble compounds]	I	0.05 mg/m^3 PEL (sol.); 0.25 mg/m^3 PEL (insol.)	G-A1	
1165	51-79-6	?	Urethane		n.o.s.	I-2A, N-2, CP65	
1166	1314-62-1	?	Vanadium Pentoxide (CP65: orthorhombic crystalline form)	I	0.05 mg/m^3 TLV (inhalable fraction)	G-A3, I-2B, CP65	
1167	50471-44-8		Vinclozolin		n.o.s.	CP65	
1168	108-05-4	?	Vinyl Acetate		10 ppm TLV	G-A3, I-2B	
1169	100-42-5	?	Vinyl Benzene	S	20 ppm TLV {85 mg/m^3}	I-2B	
1170	593-60-2	?	Vinyl Bromide		0.5 ppm TLV {2.2 mg/m^3}	G-A2, I-2A, N-2, CP65	
1171	75-01-4	✓	Vinyl Chloride [1910.1017]		1 ppm PEL	O, G-A1, I-1, N-1, CP65	
1172	107-13-1	✓	Vinyl Cyanide [1910.1045]	IS	2 ppm PEL {4.3 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
1173	100-40-3	?	4-Vinyl Cyclohexene	S	0.1 ppm TLV {0.44 mg/m^3}	G-A3, I-2B, CP65	
1174	106-87-6	?	Vinyl Cyclohexene Dioxide	IS	0.1 ppm TLV {0.57 mg/m^3}	G-A3, I-2B, N-2, CP65	
1175	75-02-5	?	Vinyl Fluoride		1 ppm TLV	G-A2, I-2A, N-2, CP65	
1176	79-00-5		Vinyl Trichloride	S	10 ppm PEL {55 mg/m^3}	G-A3, CP65	
1177	106-87-6	?	4-Vinyl-1-cyclohexene Diepoxide	IS	0.1 ppm TLV {0.57 mg/m^3}	G-A3, I-2B, N-2, CP65	
1178	0-64-0	?	Welding Fumes	I	5 mg/m^3 TLV	I-2B	
1179	0-65-0	✓	Wood Dust	I	1.0 mg/m^3 TLV (inhalable fraction)	I-1, N-1	
1180	0-67-0	?	Wood Dust (birch, mahogany, teak, walnut)	I	1.0 mg/m^3 TLV (inhalable fraction)	G-A2	
1181	0-66-0	✓	Wood Dust (oak and beech)	I	1.0 mg/m^3 TLV (inhalable fraction)	G-A1	
1182	0-81-0	✓	X-Radiation		n.o.s.	I-1, N-1	
1183	87-62-7	?	2,6-Xylidine		0.5 ppm TLV	I-2B, CP65	
1184	7481-89-2	?	Zalcitabine		n.o.s.	I-2B	
1185	30516-87-1	?	Zidovudine		n.o.s.	I-2B	
1186	111406-87-2		Zileuton		n.o.s.	CP65	
1187	39413-47-3	✓	Zinc Beryllium Silicate, as Be	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1188	1308-13-0	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1189	1328-67-2	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1190	13530-65-9	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1191	14675-41-3	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1192	37300-23-5	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1193	57486-12-1	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1194	12206-12-1	✓	Zinc Chromate Hydroxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1195	15930-94-6	✓	Zinc Chromate Hydroxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1196	66516-58-3	✓	Zinc Chromate Hydroxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1197	11103-86-9	✓	Zinc Potassium Chromate (Hydroxide), as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1198	12527-08-1	✓	Zinc Potassium Chromate (Hydroxide), as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1199	37809-34-0	✓	Zinc Potassium Chromate (Hydroxide), as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1200	1308-13-0	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1201	1328-67-2	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1202	13530-65-9	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1203	14675-41-3	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1204	37300-23-5	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1205	57486-12-1	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

2009 CASRN-sorted List — KNOWN AND SUSPECTED HUMAN CARCINOGENS

Carcinogens Reference List

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1	0-01-0	✓	Alcoholic Beverages (CP65: assoc. w/alcohol abuse)	G	n.o.s.	I-1, N-1, CP65	
2	0-01-0	✓	Ethanol in alcoholic beverages	G	n.o.s.	I-1, N-1, CP65	
3	0-01-0	✓	Ethyl Alcohol (in alcoholic beverages)	G	n.o.s.	I-1, N-1, CP65	
4	0-02-0	✓	Areca Nut		n.o.s.	I-1, CP65	
5	0-03-0	✓	Aristolochic Acids (naturally occurring mixtures)		n.o.s.	I-1, CP65	
6	0-04-0	✓	Plants containing Aristolochic Acid		n.o.s.	I-1	
7	0-05-0		Herbal Remedies (containing plant species of the genus Aristolochia)		n.o.s.	CP65	
8	0-06-0	✓	Betel quid with or without tobacco		n.o.s.	I-1, CP65	
9	0-07-0	?	Bracken Fern		n.o.s.	I-2B, CP65	
10	0-08-0	?	Coffee (urinary bladder only)	G	n.o.s.	I-2B	
11	0-09-0	?	Hot Mate		n.o.s.	I-2A	
12	0-10-0		Marijuana smoke		n.o.s.	CP65	
13	0-11-0	✓	Tobacco Smoking and Tobacco Smoke	I	n.o.s.	I-1, N-1, CP65	
14	0-12-0	✓	Involuntary Smoking (exposure to secondhand or 'environmental' tobacco smoke)	I	n.o.s.	I-1	
15	0-13-0	✓	Tobacco, Smokeless (CP65: oral use of smokeless products)	S	n.o.s.	I-1, N-1, CP65	
16	0-14-0	?	Cobalt metal with tungsten carbide	I	0.02 mg/m^3 TLV	G-A3, I-2A	
17	0-15-0	✓	Copper (II) Dichromate, as Cr^{6+} [water soluble]	I	5 $\mu g/m^3$ PEL	O, G-A1, I-1, N-1, CP65	
18	0-16-0		Diaminotoluene (mixed)		n.o.s.	CP65	
19	0-17-0		2,4-/2,6-Dinitrotoluene	S	27 ppb TLV {0.2 mg/m^3}	CP65	
20	0-18-0		2,4-Hexadienal (89% trans, trans isomer, 11% cis, trans isomer)		n.o.s.	CP65	
21	0-19-0	✓	Lithium Bichromate Dihydrate, as Cr^{6+} [water soluble]	I	5 $\mu g/m^3$ PEL	O, G-A1, I-1, N-1, CP65	
22	0-20-0	?	Methylmercury compounds		0.01 mg/m^3 PEL	I-2B, CP65	
23	0-21-0	?	Nitrate or nitrite (ingested) under conditions that result in endogenous nitrosation	I	n.o.s.	I-2A	
24	0-22-0	✓	Talc (containing asbestiform fibers)	I	0.1 f/cc PEL	O, G-A1, I-1, N-1, CP65	
25	0-23-0	?	Talc-based body powder (perineal use of)		n.o.s.	I-2B	
26	0-24-0	?	*alpha*-Chlorinated Toluenes and Benzoyl Chloride (combined exposures)		n.o.s.	I-2A	
27	0-25-0	?	Chlorophenoxy Herbicides	S	10 mg/m^3 PEL	I-2B	
28	0-26-0	?	Polychlorophenols (and their sodium salts) (mixed exposure)		n.o.s.	I-2B	
29	0-27-0		Polychlorinated Dibenzo-*p*-dioxins		n.o.s.	CP65	
30	0-28-0		Polychlorinated Dibenzofurans		n.o.s.	CP65	
31	0-29-0	✓	Benzidine-based Dyes		n.o.s.	I-1, CP65	
32	0-30-0	✓	Dyes that metabolize to benzidine	IS	n.o.s.	I-1, N-1	
33	0-31-0	✓	MOPP and other combined chemotherapy including alkylating agents		n.o.s.	I-1	
34	0-32-0	✓	Etoposide in combination with cisplatin and bleomycin		n.o.s.	I-1	
35	0-33-0	?	Androgenic (anabolic) steroids		n.o.s.	I-2A	
36	0-34-0		Estrogens, Conjugated (Indirect)	SG	n.o.s.	CP65	
37	0-35-0	✓	Estrogen, Nonsteroidal	SG	n.o.s.	I-1	
38	0-36-0	✓	Estrogen, Steroidal	SG	n.o.s.	I-1, N-1, CP65	
39	0-37-0	✓	Oestrogen (see Estrogen)	SG	n.o.s.	I-1	
40	0-38-0	?	Progestins		n.o.s.	I-2B	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

Last Revision: 13 July 2009

Prepared by: Jeffrey Schinkel, LANL

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
41	0-39-0	✓	Estrogen-Progestogen Menopausal Therapy (combined)		n.o.s.	I-1	
42	0-40-0	✓	Estrogen Therapy, Postmenopausal		n.o.s.	I-1	
43	0-41-0	✓	Estrogen-progestogen oral contraceptives (combined)	G	n.o.s.	I-1, CP65	
44	0-41-0	✓	Oral contraceptives, combined estrogen-progestogen	G	n.o.s.	I-1, CP65	
45	0-42-0	✓	Oral contraceptives, sequential		n.o.s.	I-1	
46	0-43-0	?	Progestogen-only Contraceptives		n.o.s.	I-2B	
47	0-44-0	✓	Analgesic mixtures containing phenacetin		n.o.s.	I-1, N-1, CP65	
48	0-44-0	✓	Phenacetin, analgesic mixtures containing		n.o.s.	I-1, N-1, CP65	
49	0-45-0	?	Synthetic Vitreous Fibers (see glasswool, rockwool, slagwool)	IS	1 f/cc TLV (respirable fibers)	G-A3, I-2B, N-2	
50	0-46-0	?	Glasswool (CP65: airborne particles of respirable size)	IS	1 f/cc TLV (respirable fibers)	G-A3, I-2B, N-2, CP65	
51	0-47-0	?	Rockwool	I	1 f/cc TLV (respirable fibers)	G-A3, I-2B	
52	0-48-0	?	Slagwool	I	1 f/cc TLV (respirable fibers)	G-A3, I-2B	
53	0-49-0	?	Special-purpose fibers (such as E-glass and '475' glass fibers)		1 f/cc TLV	G-A3, I-2B	
54	0-50-0	?	Diesel Engine Exhaust	I	n.o.s.	I-2A, N-2, CP65	
55	0-51-0	?	Engine Exhaust, Gasoline (condensates/extracts)	I	n.o.s.	I-2B, CP65	
56	0-51-0	?	Gasoline Engine Exhaust (condensates/extracts)	I	n.o.s.	I-2B, CP65	
57	0-52-0	?	Gasoline, unleaded (wholly vaporized)	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B, CP65	
58	0-52-0	?	Unleaded Gasoline (wholly vaporized)	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B, CP65	
59	0-53-0	?	PAH {Polycyclic Aromatic Hydrocarbon(s); see 15 specific chemicals}	I	0.2 mg/m^3 PEL	N-2, CP65	
60	0-53-0	?	Polycyclic Aromatic Hydrocarbon(s) {PAH; see 15 specific chemicals}	I	0.2 mg/m^3 PEL	N-2, CP65	
61	0-54-0	?	Carbon Black extracts (benzene solvent) {PAH}		n.o.s.	I-2B, CP65	
62	0-55-0	✓	Soot extracts (containing PAHs)	ISG	n.o.s.	N-1, CP65	
63	0-56-0	?	High-temperature frying, emissions from	I	n.o.s.	I-2A	
64	0-57-0	?	Household combution of biomass fuel (primarily wood), indoor emissions from	I	n.o.s.	I-2A	
65	0-58-0	✓	Household combustion of coal, indoor emissions from	I	n.o.s.	I-1	
66	0-59-0	✓	Coal-tar Distillation	I	n.o.s.	I-1	
67	0-60-0	✓	Coal Gasification	I	n.o.s.	I-1	
68	0-61-0	✓	Coke Oven Emissions [1910.1029] {PAH}	IS	150 µg/m^3 PEL	O, I-1, N-1, CP65	
69	0-62-0	✓	Soots {PAH}	ISG	n.o.s.	I-1, N-1, CP65	
70	0-63-0	✓	Tars	I	n.o.s.	N-1, CP65	
71	0-64-0	?	Welding Fumes	I	5 mg/m^3 TLV	I-2B	
72	0-65-0	✓	Wood Dust	I	1.0 mg/m^3 TLV (inhalable fraction)	I-1, N-1	
73	0-66-0	✓	Wood Dust (oak and beech)	I	1.0 mg/m^3 TLV (inhalable fraction)	G-A1	
74	0-67-0	?	Wood Dust (birch, mahogany, teak, walnut)	I	1.0 mg/m^3 TLV (inhalable fraction)	G-A2	
75	0-68-0	✓	Strong Inorganic Acid Mists Containing Sulfuric Acid (occ. exposure to)	IS	0.2 mg/m^3 TLV (thoracic fraction)	G-A2, I-1, N-1, CP65	
76	0-68-0	✓	Sulfuric Acid Mist (occ. exposure to strong inorganic acid mists)	IS	0.2 mg/m^3 TLV (thoracic fraction)	G-A2, I-1, N-1, CP65	
77	0-69-0	✓	Isopropyl Alcohol Manufacture (strong-acid process)	IS	n.o.s.	I-1, N-1	
78	0-69-0	✓	2-Propanol Manufacture (strong-acid process)		n.o.s.	I-1, N-1	
79	0-70-0	✓	Solar Radiation, as UV radiation	S	n.o.s.	I-1, N-1	
80	0-71-0	✓	Broad Spectrum Ultraviolet Radiation	S	n.o.s.	N-1	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
81	0-71-0	✓	Ultraviolet Radiation – Broad Spectrum	S	n.o.s.	N-1	
82	0-72-0	?	Ultraviolet–A Radiation {UV–A @ 315-400 nm}	S	n.o.s.	I-2A, N-2	
83	0-73-0	?	Ultraviolet–B Radiation {UV–B @ 280-315 nm}	S	n.o.s.	I-2A, N-2	
84	0-74-0	?	Ultraviolet–C Radiation {UV–C @ 100-280 nm}	S	n.o.s.	I-2A, N-2	
85	0-75-0	✓	Sunlamps and sunbeds, use of [as UV radiation]	S	n.o.s.	I-2A, N-1	
86	0-76-0	✓	Gamma Radiation		n.o.s.	I-1, N-1	
87	0-77-0	✓	Neutrons		n.o.s.	I-1, N-1	
88	0-78-0	✓	Radioiodines (short-lived isotopes including ^{131}I)		n.o.s.	I-1	
89	0-79-0	✓	Radionuclides, *alpha*-particle-emitting (internally deposited)		n.o.s.	I-1, CP65	
90	0-80-0	✓	Radionuclides, *beta*-particle-emitting (internally deposited)		n.o.s.	I-1, CP65	
91	0-81-0	✓	X-Radiation		n.o.s.	I-1, N-1	
92	0-82-0	?	Magnetic Fields (extremely low frequency)		n.o.s.	I-2B	
93	0-83-0	✓	Aluminum (production)	I	n.o.s.	I-1	
94	0-84-0	✓	Auramine (production)		n.o.s.	I-1	
95	0-85-0	?	Carbon electrode manufacture	I	n.o.s.	I-2A	
96	0-86-0	✓	Chromite Ore Processing, as Cr^{6+}	I	5 µg/m^3 PEL	G-A1	
97	0-87-0	✓	Hematite Mining (underground) with exposure to radon		n.o.s.	I-1	
98	0-88-0	✓	Iron and Steel Founding	I	n.o.s.	I-1	
99	0-89-0	✓	Magenta (production)	I	n.o.s.	I-1	
100	0-90-0	?	Magenta (mixtures of C.I. Basic Red, Methyl Fuchsin, Dimethyl Fuchsin or Trimethyl Fuchin)		n.o.s.	I-2B	
101	0-91-0		Nickel Refinery Dust (from the pyrometallurgical process)		1.5 mg/m^3 TLV {inhalable fraction}	CP65	
102	0-92-0	?	Art Glass, Glass Containers, and Pressed Ware (manufacture of)	I	n.o.s.	I-2A	
103	0-93-0	✓	Boot and Shoe Manufacture and Repair		n.o.s.	I-1	
104	0-94-0	?	Carpentry and Joinery	I	n.o.s.	I-2B	
105	0-95-0	✓	Chimney Sweeping	IS	n.o.s.	I-1	
106	0-96-0	?	Dry Cleaning (occ. exposure in)		n.o.s.	I-2B	
107	0-97-0	?	Firefighter (occupational exposure as a)		n.o.s.	I-2B	
108	0-98-0	✓	Furniture and Cabinet Making	I	n.o.s.	I-1	
109	0-99-0	?	Hairdresser or Barber (occ. exposure as a)		n.o.s.	I-2A	
110	1-00-0	?	Non-Arsenical Insecticides (occ. exposures in spraying and application of)	I	n.o.s.	I-2A	
111	1-01-0	✓	Painter (occ. exposure as a)		n.o.s.	I-1	
112	1-02-0	✓	Paving and roofing with coal-tar pitch	IS	n.o.s.	I-1	
113	1-03-0	?	Petroleum Refining (occ. exposure in)		n.o.s.	I-2A	
114	1-04-0	?	Printing Processes (occ. exposure in)		n.o.s.	I-2B	
115	1-05-0	✓	Rubber Industry		n.o.s.	I-1	
116	1-06-0	?	Shiftwork that involves circadian disruption		n.o.s.	I-2A	
117	1-07-0	?	Textile Manufacturing Industry (work in)		n.o.s.	I-2B	
118	50-00-0	✓	Formaldehyde [1910.1048]	IA	C 0.3 ppm TLV {C 0.37 mg/m^3; Sensitizer}	O, G-A2, I-1, N-2, CP65	
119	50-06-6	?	Phenobarbital		n.o.s.	I-2B, CP65	
120	50-07-7	?	Mitomycin C		n.o.s.	I-2B, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
121	50-18-0	✓	Cyclophosphamide (hydrated)	GJ	n.o.s.	I-1, N-1, CP65	
122	50-28-2	✓	Estradiol-17B	SG	n.o.s.	I-1, N-2, CP65	
123	50-29-3	?	DDT	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
124	50-29-3	?	*p,p'*-DDT	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
125	50-29-3	?	Dichlorodiphenyltrichloroethane	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
126	50-29-3	?	1,1,1-Trichloro-2,2-*bis*(*p*-chlorophenyl)ethane	IS	1 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
127	50-32-8	✓	Benzo[*a*]pyrene {PAH}		0.2 mg/m^3 PEL	G-A2, I-1, N-2, CP65	
128	50-32-8	✓	PAH {Benzo[*a*]pyrene}		0.2 mg/m^3 PEL	G-A2, I-1, N-2, CP65	
129	50-55-5	?	Reserpine		n.o.s.	N-2, CP65	
130	50-76-0		Actinomycin D		n.o.s.	CP65	
131	51-52-5	?	Propylthiouracil		n.o.s.	I-2B, N-2, CP65	
132	51-75-2	?	Mechlorethamine		n.o.s.	I-2A, N-2, CP65	
133	51-75-2	?	N-Methyl-*bis*(2-chloroethyl) Amine		n.o.s.	I-2A, N-2, CP65	
134	51-75-2	?	Nitrogen Mustard		n.o.s.	I-2A, N-2, CP65	
135	51-79-6	?	Carbamic Acid, Ethyl Ester		n.o.s.	I-2A, N-2, CP65	
136	51-79-6	?	Ethyl Carbamate		n.o.s.	I-2A, N-2, CP65	
137	51-79-6	?	Urethane		n.o.s.	I-2A, N-2, CP65	
138	52-01-7		Spironolactone		n.o.s.	CP65	
139	52-24-4	✓	*tris*(1-Aziridinyl)phosphine Sulfide		n.o.s.	I-1, N-1, CP65	
140	52-24-4	✓	Thiotepa		n.o.s.	I-1, N-1, CP65	
141	52-76-6		Lynestrenol		n.o.s.	CP65	
142	53-16-7	✓	Estrone	SG	n.o.s.	I-1, N-2, CP65	
143	53-70-3	?	Dibenz[*a,h*]anthracene {PAH}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
144	53-70-3	?	PAH {Dibenz[*a,h*]anthracene}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
145	53-96-3	✓	2-Acetylaminofluorene	IS	[1910.1003]	O, N-2, CP65	
146	55-18-5	?	DEN		n.o.s.	I-2A, N-2, CP65	
147	55-18-5	?	Diethylnitrosamine		n.o.s.	I-2A, N-2, CP65	
148	55-18-5	?	NDEA		n.o.s.	I-2A, N-2, CP65	
149	55-18-5	?	N-Nitrosodiethylamine		n.o.s.	I-2A, N-2, CP65	
150	55-86-7	?	Mechlorethamine Hydrochloride		n.o.s.	N-2, CP65	
151	55-86-7	?	Nitrogen Mustard Hydrochloride		n.o.s.	N-2, CP65	
152	55-98-1	✓	Busulfan	G	n.o.s.	I-1, N-1, CP65	
153	55-98-1	✓	1,4-Butanediol Dimethylsulfonate	G	n.o.s.	I-1, N-1, CP65	
154	55-98-1	✓	Myleran®	G	n.o.s.	I-1, N-1, CP65	
155	56-04-2	?	Methylthiouracil		n.o.s.	I-2B, CP65	
156	56-23-5	?	Carbon Tetrachloride	IS	5 ppm TLV {31.5 mg/m^3}	G-A2, I-2B, N-2, CP65	
157	56-23-5	?	Tetrachloromethane	IS	5 ppm TLV {31.5 mg/m^3}	G-A2, I-2B, N-2, CP65	
158	56-49-5		3-Methylcholanthrene		n.o.s.	CP65	
159	56-53-1	✓	DES	G	n.o.s.	I-1, N-1, CP65	
160	56-53-1	✓	Diethylstilbestrol	G	n.o.s.	I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
161	56-55-3	?	Benz[*a*]anthracene {PAH}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
162	56-55-3	?	PAH {Benz[*a*]anthracene}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
163	56-75-7	?	Chloramphenicol		n.o.s.	I-2A, N-2, CP65	
164	57-14-7	?	1,1-Dimethylhydrazine	IS	0.01 ppm TLV {0.025 mg/m^3}	G-A3, I-2B, N-2, CP65	
165	57-14-7	?	UDMH	IS	0.01 ppm TLV {0.025 mg/m^3}	G-A3, I-2B, N-2, CP65	
166	57-41-0	?	Diphenylhydantoin		n.o.s.	I-2B, N-2, CP65	
167	57-41-0	?	Phenytoin		n.o.s.	I-2B, N-2, CP65	
168	57-57-8	✓	*beta*-Propiolactone	S	[1910.1003] {0.5 ppm TLV, 1.5 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
169	57-63-6	✓	Ethinylestradiol	SG	n.o.s.	I-1, N-2, CP65	
170	57-74-9	?	Chlordane	S	0.5 mg/m^3 PEL	G-A3, I-2B, CP65	
171	57-83-0	?	Progesterone (Indirect)		n.o.s.	N-2, CP65	
172	57-97-6		7,12-Dimethylbenz(*a*)anthracene		n.o.s.	CP65	
173	58-22-0		Testosterone (and its esters)		n.o.s.	CP65	
174	58-89-9	?	*gamma*-Hexachlorocyclohexane	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
175	58-89-9	?	Lindane	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
176	59-87-0		Nitrofurazone		n.o.s.	CP65	
177	59-89-2	?	N-Nitrosomorpholine		n.o.s.	I-2B, N-2, CP65	
178	59-96-1		Phenoxybenzamine		n.o.s.	CP65	
179	60-09-3	?	*p*-Aminoazobenzene		n.o.s.	I-2B, CP65	
180	60-11-7	✓	4-Dimethylaminoazobenzene	S	[1910.1003]	O, I-2B, N-2, CP65	
181	60-11-7	✓	*p*-Dimethylaminoazobenzene	S	[1910.1003]	O, I-2B, N-2, CP65	
182	60-34-4		Methylhydrazine (and its salts)	S	0.01 ppm TLV {19 µg/m^3}	G-A3, CP65	
183	60-35-5	?	Acetamide		n.o.s.	I-2B, CP65	
184	60-57-1		Dieldrin	S	0.1 mg/m^3 TLV	G-A3, CP65	2009
185	61-57-4	?	Niridazole		n.o.s.	I-2B, CP65	
186	61-82-5	?	3-Amino-1,2,4-triazole		0.2 mg/m^3 PEL	G-A3, N-2, CP65	
187	61-82-5	?	Amitrole		0.2 mg/m^3 PEL	G-A3, N-2, CP65	
188	62-44-2	✓	Phenacetin		n.o.s.	I-1, N-2, CP65	
189	62-50-0	?	Ethyl Methanesulfonate		n.o.s.	I-2B, N-2, CP65	
190	62-53-3		Aniline	S	2 ppm TLV {7.6 mg/m^3}	G-A3, CP65	
191	62-55-5	?	Thioacetamide		n.o.s.	I-2B, N-2, CP65	
192	62-56-6	?	Thiourea		n.o.s.	N-2, CP65	
193	62-73-7	?	DDVP	S	0.1 mg/m^3 TLV {Sensitizer}	I-2B, CP65	
194	62-73-7	?	Dichlorvos	S	0.1 mg/m^3 TLV {Sensitizer}	I-2B, CP65	
195	62-75-9	✓	N,N-Dimethylnitrosoamine	S	[1910.1003]	O, G-A3, I-2A, N-2, CP65	
196	62-75-9	✓	DMN	S	[1910.1003]	O, G-A3, I-2A, N-2, CP65	
197	62-75-9	✓	N-Nitrosodimethylamine	S	[1910.1003]	O, G-A3, I-2A, N-2, CP65	
198	63-92-3	?	Phenoxybenzamine Hydrochloride		n.o.s.	I-2B, N-2, CP65	
199	64-67-5	?	Diethylsulfate		n.o.s.	I-2A, N-2, CP65	
200	66-27-3	?	Methyl Methanesulfonate		n.o.s.	I-2A, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
201	66-75-1	?	Uracil Mustard		n.o.s.	I-2B, CP65	
202	67-45-8		Furazolidone		n.o.s.	CP65	
203	67-66-3	?	Chloroform	IA	10 ppm TLV {48.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
204	67-66-3	?	Trichloromethane	IA	10 ppm TLV {48.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
205	67-72-1	?	Hexachloroethane	SG	1 ppm PEL {9.7 mg/m^3}	G-A3, I-2B, N-2, CP65	
206	68-22-4	?	Norethindrone		n.o.s.	I-2B, N-2, CP65	
207	68-22-4	?	Norethisterone		n.o.s.	I-2B, N-2, CP65	
208	68-23-5		Norethynodrel		n.o.s.	CP65	
209	70-25-7	?	N-Methyl-N'-nitro-N-nitrosoguanidine		n.o.s.	I-2A, N-2, CP65	
210	70-25-7	?	MNNG		n.o.s.	I-2A, N-2, CP65	
211	71-43-2	✓	Benzene [1910.1028]	IS	0.5 ppm TLV {1.6 mg/m^3}	O, G-A1, I-1, N-1, CP65	
212	71-48-7	?	Cobalt (II) Acetate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
213	71-58-9	?	Medroxyprogesterone Acetate		n.o.s.	I-2B, CP65	
214	72-33-3	✓	Mestranol	SG	n.o.s.	I-1, N-2, CP65	
215	72-54-8		DDD		n.o.s.	CP65	
216	72-54-8		Dichlorodiphenyldichloroethane		n.o.s.	CP65	
217	72-55-9		DDE		n.o.s.	CP65	
218	72-55-9		Dichlorodiphenyldichloroethylene		n.o.s.	CP65	
219	72-57-1	?	C.I. Direct Blue 14	I	n.o.s.	I-2B, CP65	
220	72-57-1	?	Trypan Blue (commercial grade)		n.o.s.	I-2B, CP65	
221	74-88-4		Methyl Iodide	S	2 ppm TLV {11.6 mg/m^3}	CP65	
222	74-96-4		Bromoethane	S	5 ppm TLV {23 mg/m^3}	G-A3, CP65	
223	74-96-4		Ethyl Bromide	S	5 ppm TLV {23 mg/m^3}	G-A3, CP65	
224	75-00-3		Chloroethane	S	100 ppm TLV {264 mg/m^3}	G-A3, CP65	
225	75-00-3		Ethyl Chloride	S	100 ppm TLV {264 mg/m^3}	G-A3, CP65	
226	75-01-4	✓	Chloroethylene [1910.1017]		1 ppm PEL	O, G-A1, I-1, N-1, CP65	
227	75-01-4	✓	Vinyl Chloride [1910.1017]		1 ppm PEL	O, G-A1, I-1, N-1, CP65	
228	75-02-5	?	Vinyl Fluoride		1 ppm TLV	G-A2, I-2A, N-2, CP65	
229	75-07-0	?	Acetaldehyde		C 25 ppm TLV {C 45 mg/m^3}	G-A3, I-2B, N-2, CP65	
230	75-09-2	✓	Dichloromethane [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
231	75-09-2	✓	Methane Dichloride [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
232	75-09-2	✓	Methylene Chloride [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
233	75-21-8	✓	Ethylene Oxide [1910.1047]	I	1 ppm PEL {1.8 mg/m^3}	O, G-A2, I-1, N-1, CP65	
234	75-25-2		Bromoform	S	0.5 ppm PEL {5 mg/m^3}	G-A3, CP65	
235	75-27-4	?	Bromodichloromethane		n.o.s.	I-2B, N-2, CP65	
236	75-34-3		1,1-Dichloroethane		100 ppm PEL {400 mg/m^3}	CP65	
237	75-52-5	?	Nitromethane		20 ppm TLV {49.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
238	75-55-8	?	2-Methylaziridine	S	0.2 ppm PEL {0.47 mg/m^3}	G-A3, I-2B, N-2, CP65	
239	75-55-8	?	Propyleneimine	S	0.2 ppm PEL {0.47 mg/m^3}	G-A3, I-2B, N-2, CP65	
240	75-56-9	?	1,2-Epoxypropane		2 ppm TLV {4.8 mg/m^3; Sensitizer}	G-A3, I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
241	75-56-9	?	Propylene Oxide		2 ppm TLV {4.8 mg/m^3; Sensitizer}	G-A3, I-2B, N-2, CP65	
242	75-60-5		Cacodylic Acid		0.5 mg/m^3 PEL	CP65	
243	76-44-8	?	Heptachlor	S	0.05 mg/m^3 TLV	G-A3, I-2B, CP65	
244	76-87-9		Triphenyltin Hydroxide		n.o.s.	CP65	
245	77-09-8	?	Phenolphthalein		n.o.s.	I-2B, N-2, CP65	
246	77-78-1	?	Dimethylsulfate	S	0.1 ppm TLV {0.5 mg/m^3}	G-A3, I-2A, N-2, CP65	
247	78-79-5	?	Isopentadiene		n.o.s.	I-2B, N-2, CP65	
248	78-79-5	?	Isoprene		n.o.s.	I-2B, N-2, CP65	
249	78-79-5	?	2-Methyl-1,3-butadiene		n.o.s.	I-2B, N-2, CP65	
250	78-87-5		1,2-Dichloropropane		10 ppm TLV {46 mg/m^3; Sensitizer}	CP65	
251	78-87-5		Propylene Dichloride		10 ppm TLV {46 mg/m^3; Sensitizer}	CP65	
252	79-00-5		1,1,2-Trichloroethane	S	10 ppm PEL {55 mg/m^3}	G-A3, CP65	
253	79-00-5		Vinyl Trichloride	S	10 ppm PEL {55 mg/m^3}	G-A3, CP65	
254	79-01-6	?	Trichloroethylene		10 ppm TLV	G-A2, I-2A, N-2, CP65	
255	79-06-1	?	Acrylamide	IS	0.03 mg/m^3 TLV	G-A3, I-2A, N-2, CP65	
256	79-34-5		1,1,2,2-Tetrachloroethane	S	1 ppm TLV {6.9 mg/m^3}	G-A3, CP65	
257	79-43-6	?	Dichloroacetic Acid	S	0.5 ppm TLV	G-A3, I-2B, CP65	
258	79-44-7	?	Dimethylcarbamoyl Chloride	IS	5 ppb TLV	G-A2, I-2A, N-2, CP65	
259	79-46-9	?	2-Nitropropane	I	10 ppm TLV {37 mg/m^3}	G-A3, I-2B, N-2, CP65	
260	81-49-2	?	1-Amino-2,4-dibromoanthraquinone		n.o.s.	N-2, CP65	
261	81-88-9		D&C Red No. 19		n.o.s.	CP65	
262	82-28-0	?	1-Amino-2-methylanthraquinone	I	n.o.s.	N-2, CP65	
263	82-28-0	?	C.I. Disperse Orange 11	I	n.o.s.	N-2, CP65	
264	84-17-3		Dienestrol		n.o.s.	CP65	
265	84-65-1		Anthraquinone		n.o.s.	CP65	
266	86-30-6		N-Nitrosodiphenylamine		n.o.s.	CP65	
267	86-74-8		Carbazole		n.o.s.	CP65	
268	87-29-6		Cinnamyl Anthranilate		n.o.s.	CP65	
269	87-62-7	?	2,6-Dimethylaniline		0.5 ppm TLV	I-2B, CP65	
270	87-62-7	?	2,6-Xylidine		0.5 ppm TLV	I-2B, CP65	
271	87-86-5	?	Pentachlorophenol	S	0.5 mg/m^3 PEL	G-A3, I-2B, CP65	
272	88-06-2	?	2,4,6-Trichlorophenol	S	n.o.s.	I-2B, N-2, CP65	
273	88-72-2		*o*-Nitrotoluene	S	2 ppm TLV {11.2 mg/m^3}	CP65	
274	90-04-0	?	*o*-Anisidine	S	0.5 mg/m^3 PEL {0.1 ppm}	G-A3, I-2B, CP65	
275	90-43-7		*o*-Phenylphenol		n.o.s.	CP65	
276	90-94-8	?	4,4'-(Dimethylamino) Benzophenone		n.o.s.	I-2B, N-2, CP65	
277	90-94-8	?	*bis*(Dimethylamino) Benzophenone		n.o.s.	I-2B, N-2, CP65	
278	90-94-8	?	Michler's Ketone		n.o.s.	I-2B, N-2, CP65	
279	91-08-7	?	Toluene-2,6-diisocyanate	S	1 ppb TLV {7.2 µg/m^3; Sensitizer}	G-A3, I-2B, N-2	2006
280	91-20-3	?	Naphthalene	IS	10 ppm PEL {50 mg/m^3}	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
281	91-22-5		Quinoline (and its strong acid salts)		n.o.s.	CP65	
282	91-23-6	?	2-Nitroanisole		n.o.s.	I-2B, N-2, CP65	
283	91-23-6	?	*o*-Nitroanisole		n.o.s.	I-2B, N-2, CP65	
284	91-59-8	✓	2-Aminonaphthalene		[1910.1003]	O, G-A1, I-1, N-1, CP65	
285	91-59-8	✓	2-Naphthylamine		[1910.1003]	O, G-A1, I-1, N-1, CP65	
286	91-59-8	✓	*beta*-Naphthylamine		[1910.1003]	O, G-A1, I-1, N-1, CP65	
287	91-94-1	✓	3,3'-Dichlorobenzidine	IS	[1910.1003]	O, G-A3, I-2B, N-2, CP65	
288	92-67-1	✓	4-Aminobiphenyl	IS	[1910.1003]	O, G-A1, I-1, N-1, CP65	
289	92-67-1	✓	4-Aminodiphenyl	IS	[1910.1003]	O, G-A1, I-1, N-1, CP65	
290	92-87-5	✓	Benzidine	IS	[1910.1003]	O, G-A1, I-1, N-1, CP65	
291	92-93-3	✓	4-Nitrobiphenyl	S	[1910.1003]	O, G-A2, CP65	
292	92-93-3	✓	4-Nitrodiphenyl	S	[1910.1003]	O, G-A2, CP65	
293	93-15-2	?	Methyleugenol		n.o.s.	N-2, CP65	
294	93-76-5	?	2,4,5-T	S	10 mg/m^3 PEL	I-2B	
295	93-76-5	?	(2,4,5-Trichlorophenoxy) Acetic Acid	S	10 mg/m^3 PEL	I-2B	
296	94-58-6	?	Dihydrosafrole		n.o.s.	I-2B, CP65	
297	94-59-7	?	Safrole		n.o.s.	I-2B, N-2, CP65	
298	94-75-7	?	2,4-D	S	10 mg/m^3 PEL	I-2B	
299	94-75-7	?	(2,4-Dichlorophenoxy) Acetic Acid	S	10 mg/m^3 PEL	I-2B	
300	94-78-0	?	Phenazopyridine		n.o.s.	N-2, CP65	
301	95-06-7	?	N, N-Diethyldithiocarbamic Acid 2-Chloroallyl Ester		n.o.s.	I-2B, N-2, CP65	
302	95-06-7	?	Sulfallate		n.o.s.	I-2B, N-2, CP65	
303	95-53-4	✓	*o*-Toluidine	S	2 ppm TLV {8.8 mg/m^3}	G-A3, I-1, N-2, CP65	
304	95-54-5		*o*-Phenylenediamine (and its salts)		0.1 mg/m^3 TLV	G-A3, CP65	
305	95-57-8	?	2-Chlorophenol	S	n.o.s.	I-2B	
306	95-69-2	?	4-Chloro-2-methylbenzenamine (and its strong acid salts)		n.o.s.	I-2A, N-2, CP65	
307	95-69-2	?	4-Chloro-*o*-toluidine (and its strong acid salts)		n.o.s.	I-2A, N-2, CP65	
308	95-69-2	?	*p*-Chloro-*o*-toluidine (and its strong acid salts)		n.o.s.	I-2A, N-2, CP65	
309	95-79-4		5-Chloro-*o*-toluidine (and its strong acid salts)		n.o.s.	CP65	
310	95-80-7	?	2,4-Diaminotoluene		n.o.s.	I-2B, N-2, CP65	
311	95-80-7	?	Toluene-2,4-diamine		n.o.s.	I-2B, N-2, CP65	
312	95-83-0	?	4-Chloro-*o*-phenylenediamine		n.o.s.	I-2B, N-2, CP65	
313	95-95-4	?	2,4,5-Trichlorophenol	S	n.o.s.	I-2B	
314	96-09-3	?	Epoxystyrene		n.o.s.	I-2A, N-2, CP65	
315	96-09-3	?	Styrene Epoxide		n.o.s.	I-2A, N-2, CP65	
316	96-09-3	?	Styrene Oxide		n.o.s.	I-2A, N-2, CP65	
317	96-09-3	?	Styrene-7,8-oxide		n.o.s.	I-2A, N-2, CP65	
318	96-12-8	✓	DBCP [1910.1044]	IS	1 ppb PEL	O, I-2B, N-2, CP65	
319	96-12-8	✓	1,2-Dibromo-3-chloropropane [1910.1044]	IS	1 ppb PEL	O, I-2B, N-2, CP65	
320	96-13-9	?	DBP		n.o.s.	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
321	96-13-9	?	2,3-Dibromo-1-propanol		n.o.s.	I-2B, N-2, CP65	
322	96-13-9	?	2,3-Dibromopropan-1-ol		n.o.s.	I-2B, N-2, CP65	
323	96-18-4	?	1,2,3-Trichlorpropane	S	10 ppm TLV {60.3 mg/m^3}	G-A3, I-2A, N-2, CP65	
324	96-45-7	?	Ethylene Thiourea		n.o.s.	N-2, CP65	
325	97-56-3	?	*o*-Aminoazotoluene		n.o.s.	I-2B, N-2, CP65	
326	98-07-7	?	Benzotrichloride	S	C 0.1 ppm TLV {C 0.8 mg/m^3}	G-A2, I-2A, N-2, CP65	
327	98-87-3	?	Benzal Chloride (and Benzoyl Chloride [combined exposure])		n.o.s.	I-2A	
328	98-88-4	?	Benzoyl Chloride (and *alpha*-Chlorinated Toluenes [combined exposure])		C 0.5 ppm TLV	I-2A	
329	98-95-3	?	Nitrobenzene	S	1 ppm PEL {5 mg/m^3}	G-A3, I-2B, N-2, CP65	
330	100-00-5		1-Chloro-4-nitrobenzene	S	1 mg/m^3 PEL {0.1 ppm TLV}	G-A3, CP65	
331	100-00-5		*p*-Nitrochlorobenzene	S	1 mg/m^3 PEL {0.1 ppm TLV}	G-A3, CP65	
332	100-40-3	?	4-Vinyl Cyclohexene	S	0.1 ppm TLV {0.44 mg/m^3}	G-A3, I-2B, CP65	
333	100-41-4	?	Ethylbenzene		50 ppm TLV {218 mg/m^3}	G-A3, I-2B, CP65	
334	100-42-5	?	Phenylethylene	S	20 ppm TLV {85 mg/m^3}	I-2B	
335	100-42-5	?	Styrene, Monomer	S	20 ppm TLV {85 mg/m^3}	I-2B	
336	100-42-5	?	Vinyl Benzene	S	20 ppm TLV {85 mg/m^3}	I-2B	
337	100-44-7	?	Benzyl Chloride		1 ppm PEL {5 mg/m^3}	G-A3, I-2A, CP65	
338	100-63-0		Phenylhydrazine (and its salts)	S	0.1 ppm TLV {0.44 mg/m^3}	G-A3, CP65	
339	100-75-4	?	N-Nitrosopiperidine		n.o.s.	I-2B, N-2, CP65	
340	101-14-4	✓	MBOCA	S	0.01 ppm TLV {0.11 mg/m^3}	G-A2, I-1, N-2, CP65	
341	101-14-4	✓	4,4'-Methylene *bis*(2-Chloroaniline)	S	0.01 ppm TLV {0.11 mg/m^3}	G-A2, I-1, N-2, CP65	
342	101-14-4	✓	MOCA®	S	0.01 ppm TLV {0.11 mg/m^3}	G-A2, I-1, N-2, CP65	
343	101-61-1	?	4,4'-Methylene *bis*(N,N-dimethyl) Benzenamine		n.o.s.	I-2B, N-2, CP65	
344	101-61-1	?	Michler's Base		n.o.s.	I-2B, N-2, CP65	
345	101-77-9	✓	MDA [1910.1050]	S	10 ppb PEL {0.081 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
346	101-77-9	✓	4,4'-Methylenedianiline [1910.1050]	S	10 ppb PEL {0.081 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
347	101-80-4	?	4,4'-Diaminodiphenyl Ether		n.o.s.	I-2B, N-2, CP65	
348	101-80-4	?	4,4'-Oxydianiline		n.o.s.	I-2B, N-2, CP65	
349	101-90-6	?	DGRE		n.o.s.	I-2B, N-2, CP65	
350	101-90-6	?	Diglycidyl Resorcinol Ether		n.o.s.	I-2B, N-2, CP65	
351	103-33-3		Azobenzene		n.o.s.	CP65	
352	106-46-7	?	1,4-Dichlorobenzene	IA	10 ppm TLV {60 mg/m^3}	G-A3, I-2B, N-2, CP65	
353	106-46-7	?	*p*-Dichlorobenzene	IA	10 ppm TLV {60 mg/m^3}	G-A3, I-2B, N-2, CP65	
354	106-47-8	?	4-Chloroaniline		n.o.s.	I-2B, CP65	
355	106-47-8	?	*p*-Chloroaniline		n.o.s.	I-2B, CP65	
356	106-48-9	?	4-Chlorophenol	S	n.o.s.	I-2B	
357	106-87-6	?	Vinyl Cyclohexene Dioxide	IS	0.1 ppm TLV {0.57 mg/m^3}	G-A3, I-2B, N-2, CP65	
358	106-87-6	?	4-Vinyl-1-cyclohexene Diepoxide	IS	0.1 ppm TLV {0.57 mg/m^3}	G-A3, I-2B, N-2, CP65	
359	106-88-7	?	1,2-Epoxybutane		n.o.s.	I-2B	
360	106-89-8	?	1-Chloro-2,3-epoxy-propane	IS	0.5 ppm TLV {1.9 mg/m^3}	G-A3, I-2A, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
361	106-89-8	?	Epichlorohydrin	IS	0.5 ppm TLV {1.9 mg/m^3}	G-A3, I-2A, N-2, CP65	
362	106-93-4	?	1,2-Dibromoethane	IS	20 ppm PEL	G-A3, I-2A, N-2, CP65	
363	106-93-4	?	EDB	IS	20 ppm PEL	G-A3, I-2A, N-2, CP65	
364	106-93-4	?	Ethylene Dibromide	IS	20 ppm PEL	G-A3, I-2A, N-2, CP65	
365	106-99-0	✓	1,3-Butadiene [1910.1051]	I	1 ppm PEL {2.2 mg/m^3}	O, G-A2, I-1, N-1, CP65	
366	107-06-2	?	1,2-Dichloroethane		10 ppm TLV {40.5 mg/m^3}	I-2B, N-2, CP65	
367	107-06-2	?	Ethylene Dichloride		10 ppm TLV {40.5 mg/m^3}	I-2B, N-2, CP65	
368	107-13-1	✓	Acrylonitrile [1910.1045]	IS	2 ppm PEL {4.3 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
369	107-13-1	✓	Vinyl Cyanide [1910.1045]	IS	2 ppm PEL {4.3 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
370	107-30-2	✓	Chloromethyl Methyl Ether	IS	[1910.1003]	O, G-A2, I-1, N-1, CP65	
371	107-30-2	✓	Methylchloro Methyl Ether	IS	[1910.1003]	O, G-A2, I-1, N-1, CP65	
372	107-30-2	✓	Monochlorodimethyl Ether	IS	[1910.1003]	O, G-A2, I-1, N-1, CP65	
373	108-05-4	?	Vinyl Acetate		10 ppm TLV	G-A3, I-2B	
374	108-43-0	?	3-Chlorophenol	S	n.o.s.	I-2B	
375	108-60-1		*bis*(2-Chloro-1-methylethyl) Ether (technical grade)		n.o.s.	CP65	
376	110-00-9	?	Furan		n.o.s.	I-2B, N-2, CP65	
377	110-86-1		Pyridine		1 ppm TLV	G-A3, CP65	
378	111-44-4		*bis*(2-Chloroethyl) Ether	S	5 ppm TLV {29 mg/m^3}	CP65	
379	111-44-4		Dichloroethyl Ether	S	5 ppm TLV {29 mg/m^3}	CP65	
380	114-26-1		Propoxur		0.5 mg/m^3 TLV	G-A3, CP65	
381	115-02-6	?	Azaserine		n.o.s.	I-2B, CP65	
382	115-09-3	?	Methylmercury Chloride		n.o.s.	I-2B, CP65	
383	115-28-6	?	Chlorendic Acid		n.o.s.	I-2B, N-2, CP65	
384	115-96-8		*tris*(2-Chloroethyl) Phosphate		n.o.s.	CP65	
385	116-14-3	?	Tetrafluoroethylene		2 ppm TLV	G-A3, I-2B, N-2, CP65	
386	117-10-2	?	Chrysazin		n.o.s.	I-2B, N-2, CP65	
387	117-10-2	?	Dantron		n.o.s.	I-2B, N-2, CP65	
388	117-10-2	?	1,8-Dihydroxyanthraquinone		n.o.s.	I-2B, N-2, CP65	
389	117-79-3	?	2-Aminoanthraquinone		n.o.s.	N-2, CP65	
390	117-81-7	?	DEHP		5 mg/m^3 PEL	G-A3, N-2, CP65	
391	117-81-7	?	*bis*(2-Ethylhexyl) Phthalate		5 mg/m^3 PEL	G-A3, N-2, CP65	
392	117-81-7	?	*di*(2-Ethylhexyl) Phthalate		5 mg/m^3 PEL	G-A3, N-2, CP65	
393	117-81-7	?	*di-sec*-Octylphthalate		5 mg/m^3 PEL	G-A3, N-2, CP65	
394	118-74-1	?	Hexachlorobenzene	S	2 µg/m^3 TLV	G-A3, I-2B, N-2, CP65	
395	118-96-7		2,4,6-Trinitrotoluene	S	0.1 mg/m^3 TLV	CP65	
396	119-34-6		4-Amino-2-nitrophenol		n.o.s.	CP65	
397	119-90-4	?	*o*-Dianisidine Based Dyes		n.o.s.	I-2B, N-2, CP65	
398	119-90-4	?	3,3'-Dimethoxybenzidine		n.o.s.	I-2B, N-2, CP65	
399	119-90-4	?	Dyes that metabolize to 3,3'-Dimethylbenzidine		n.o.s.	N-2	
400	119-93-7	?	3,3'-Dimethylbenzidine	S	n.o.s.	G-A3, I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
401	119-93-7	?	Dyes that metabolize to 3,3'-Dimethylbenzidine	S	n.o.s.	N-2	
402	119-93-7	?	*o*-Tolidine	S	n.o.s.	G-A3, I-2B, N-2, CP65	
403	120-71-8	?	*p*-Cresidine		n.o.s.	I-2B, N-2, CP65	
404	120-71-8	?	Methyl-*o*-anisidine		n.o.s.	I-2B, N-2, CP65	
405	120-80-9	?	Catechol	S	5 ppm TLV	G-A3, I-2B, CP65	
406	121-14-2	?	2,4-Dinitrotoluene	S	27 ppb TLV {0.2 mg/m^3}	I-2B, CP65	
407	122-60-1	?	PGE	S	0.1 ppm TLV {0.6 mg/m^3; Sensitizer}	G-A3, I-2B, CP65	
408	122-60-1	?	Phenyl Glycidyl Ether	S	0.1 ppm TLV {0.6 mg/m^3; Sensitizer}	G-A3, I-2B, CP65	
409	122-66-7	?	1,2-Diphenylhydrazine		n.o.s.	N-2, CP65	
410	122-66-7	?	Hydrazobenzene		n.o.s.	N-2, CP65	
411	123-91-1	?	1,4-Dioxane	IS	20 ppm TLV {72 mg/m^3}	G-A3, I-2B, N-2, CP65	
412	125-33-7		Primidone		n.o.s.	CP65	
413	126-07-8	?	Griseofulvin		n.o.s.	I-2B, CP65	
414	126-72-7	?	*tris*(2,3-Dibromopropyl) Phosphate		n.o.s.	I-2A, N-2, CP65	
415	126-85-2	?	Nitrogen Mustard N-oxide		n.o.s.	I-2B, CP65	
416	126-99-8	?	*beta*-Chloroprene	S	10 ppm TLV	I-2B, N-2, CP65	
417	127-18-4	?	Perchloroethylene		25 ppm TLV {170 mg/m^3}	G-A3, I-2A, N-2, CP65	
418	127-18-4	?	Tetrachloroethylene		25 ppm TLV {170 mg/m^3}	G-A3, I-2A, N-2, CP65	
419	129-15-7	?	2-Methyl-1-nitroanthraquinone		n.o.s.	I-2B, CP65	
420	129-43-1	?	1-Hydroxyanthraquinone		n.o.s.	I-2B, CP65	
421	132-27-4	?	*o*-Phenylphenate, Sodium		n.o.s.	I-2B, CP65	
422	132-27-4	?	Sodium *o*-Phenylphenate		n.o.s.	I-2B, CP65	
423	133-06-2		Captan		5 mg/m^3 TLV {Sensitizer}	G-A3, CP65	
424	133-07-3		Folpet		n.o.s.	CP65	
425	134-29-2	?	*o*-Anisidine Hydrochloride		n.o.s.	N-2, CP65	
426	134-32-7	✓	1-Naphthylamine		[1910.1003]	O, CP65	
427	134-32-7	✓	*alpha*-Naphthylamine		[1910.1003]	O, CP65	
428	135-20-6	?	Cupferron		n.o.s.	N-2, CP65	
429	136-35-6	?	DAAB		n.o.s.	N-2, CP65	
430	136-35-6	?	Diazoaminobenzene		n.o.s.	N-2, CP65	
431	136-40-3	?	Phenazopyridine Hydrochloride		n.o.s.	I-2B, N-2, CP65	
432	136-45-8		MGK Repellant 326		n.o.s.	CP65	
433	136-45-8		*di-n*-Propyl Isocinchomeronate		n.o.s.	CP65	
434	137-17-7		2,4,5-Trimethylaniline (and its strong acid salts)		n.o.s.	CP65	
435	137-42-8		Metham Sodium		n.o.s.	CP65	
436	139-13-9	?	Nitrilotriacetic Acid (and its salts)	I	n.o.s.	I-2B, N-2, CP65	
437	139-65-1	?	4,4'-Thiodianiline		n.o.s.	I-2B, N-2, CP65	
438	139-91-3		5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone		n.o.s.	CP65	
439	140-57-8	?	Aramite®		n.o.s.	I-2B, CP65	
440	140-57-8	?	Butylphenoxyisopropyl Chloroethyl Sulfite		n.o.s.	I-2B, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
441	140-67-0		Estragole		n.o.s.	CP65	
442	140-88-5	?	Ethyl Acrylate	IS	5 ppm TLV {20 mg/m^3}	I-2B, CP65	
443	141-90-2	?	Thiouracil		n.o.s.	I-2B, CP65	
444	142-04-1		Aniline Hydrochloride		n.o.s.	CP65	
445	143-50-0	?	Chlordecone		n.o.s.	I-2B, N-2, CP65	
446	143-50-0	?	Kepone®		n.o.s.	I-2B, N-2, CP65	
447	148-82-3	✓	Melphalan		n.o.s.	I-1, N-1, CP65	
448	151-56-4	✓	Aziridine	IS	[1910.1003] {0.05 ppm TLV, 0.088 mg/m^3}	O, G-A3, I-2B, CP65	
449	151-56-4	✓	Ethyleneimine	IS	[1910.1003] {0.05 ppm TLV, 0.088 mg/m^3}	O, G-A3, I-2B, CP65	
450	153-78-6		2-Aminofluorene		n.o.s.	CP65	
451	154-93-8	?	BCNU		n.o.s.	I-2A, N-2, CP65	
452	154-93-8	?	Carmustine		n.o.s.	I-2A, N-2, CP65	
453	154-93-8	?	*bis*(Chloroethyl) Nitrosourea		n.o.s.	I-2A, N-2, CP65	
454	156-10-5		*p*-Nitrosodiphenylamine		n.o.s.	CP65	
455	189-55-9	?	Dibenzo[*a*,*i*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
456	189-55-9	?	PAH {Dibenzo[*a*,*i*]pyrene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
457	189-64-0	?	Dibenzo[*a*,*h*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
458	189-64-0	?	PAH {Dibenzo[*a*,*h*]pyrene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
459	191-30-0	?	Dibenzo[*a*,*l*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
460	191-30-0	?	PAH {Dibenzo[*a*,*l*]pyrene}	I	0.2 mg/m^3 PEL	I-2A, N-2, CP65	
461	192-65-4	?	Dibenzo[*a*,*e*]pyrene {PAH}	I	0.2 mg/m^3 PEL	N-2, CP65	
462	192-65-4	?	PAH {Dibenzo[*a*,*e*]pyrene}	I	0.2 mg/m^3 PEL	N-2, CP65	
463	193-39-5	?	Indeno[1,2,3-*cd*]pyrene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
464	193-39-5	?	PAH {Indeno[1,2,3-*cd*]pyrene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
465	194-59-2	?	7H-Dibenzo[*c*,*g*]carbazole {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
466	194-59-2	?	PAH {7H-Dibenzo[*c*,*g*]carbazole}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
467	195-19-7	?	Benzo[*c*]phenanthrene {PAH}	I	0.2 mg/m^3 PEL	I-2B	
468	195-19-7	?	PAH {Benzo[*c*]phenanthrene}	I	0.2 mg/m^3 PEL	I-2B	
469	202-33-5	?	Benz[*j*]aceanthrylene {PAH}	I	0.2 mg/m^3 PEL	I-2B	
470	202-33-5	?	PAH {Benz[*j*]aceanthrylene}	I	0.2 mg/m^3 PEL	I-2B	
471	205-82-3	?	Benzo[*j*]fluoranthene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
472	205-82-3	?	PAH {Benzo[*j*]fluoranthene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
473	205-99-2	?	Benzo[*b*]fluoranthene {PAH}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
474	205-99-2	?	PAH {Benzo[*b*]fluoranthene}	I	0.2 mg/m^3 PEL	G-A2, I-2B, N-2, CP65	
475	207-08-9	?	Benzo[*k*]fluoranthene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
476	207-08-9	?	PAH {Benzo[*k*]fluoranthene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
477	218-01-9	?	Chrysene	S	0.2 mg/m^3 PEL	G-A3, I-2B, CP65	
478	224-42-0	?	Dibenz[*a*,*j*]acridine {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
479	224-42-0	?	PAH {Dibenz[*a*,*j*]acridine}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
480	226-36-8	?	Dibenz[*a*,*h*]acridine {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
481	226-36-8	?	PAH {Dibenz[*a*,*h*]acridine}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
482	271-89-6	?	Benzofuran		n.o.s.	I-2B, CP65	
483	298-81-7	✓	Methoxsalen	S	n.o.s.	I-1	
484	298-81-7	✓	Methoxsalen plus UV–A radiation	S	n.o.s.	I-1, N-1, CP65	
485	298-81-7	✓	8-Methoxypsoralen plus UV–A radiation	S	n.o.s.	I-1, N-1, CP65	
486	299-75-2	✓	Treosulfan		n.o.s.	I-1, CP65	
487	299-75-2	✓	Treosulphan		n.o.s.	I-1, CP65	
488	301-04-2	?	Lead Acetate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
489	302-01-2	?	Hydrazine	S	10 ppb TLV {13 µg/m^3}	G-A3, I-2B, N-2, CP65	
490	302-15-8		Methylhydrazine Sulfate		n.o.s.	CP65	
491	302-70-5	?	Nitrogen Mustard N-oxide Hydrochloride		n.o.s.	I-2B, CP65	
492	303-34-4	?	Lasiocarpine		n.o.s.	I-2B, CP65	
493	303-47-9	?	Ochratoxin A	G	n.o.s.	I-2B, N-2, CP65	
494	305-03-3	✓	Chlorambucil	G	n.o.s.	I-1, N-1, CP65	
495	309-00-2		Aldrin	S	0.05 mg/m^3 TLV	G-A3, CP65	
496	315-22-0	?	Monocrotaline		n.o.s.	I-2B, CP65	
497	319-84-6	?	*alpha*-Hexachlorocyclohexane		n.o.s.	I-2B, N-2, CP65	
498	319-85-7	?	*beta*-Hexachlorocyclohexane		n.o.s.	I-2B, N-2, CP65	
499	320-67-2	?	5-AzaC		n.o.s.	I-2A, N-2, CP65	
500	320-67-2	?	Azacitidine		n.o.s.	I-2A, N-2, CP65	
501	320-67-2	?	5-Azacytidine®		n.o.s.	I-2A, N-2, CP65	
502	330-54-1		Diuron		10 mg/m^3 TLV	CP65	
503	331-39-5	?	Caffeic Acid		n.o.s.	I-2B, CP65	
504	334-88-3	?	Diazomethane		0.2 ppm PEL {0.34 mg/m^3}	G-A2	
505	366-70-1	?	Procarbazine Hydrochloride		n.o.s.	I-2A, N-2, CP65	
506	373-02-4	✓	Nickel Acetate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
507	389-08-2		Nalidixic Acid		n.o.s.	CP65	
508	409-21-2	?	Ceramic Fiber (CP65: airborne particles of respirable size)	I	0.2 f/cc TLV (respirable fibers)	G-A2, I-2B, N-2, CP65	
509	409-21-2	?	Refractory Ceramic Fiber	I	0.2 f/cc TLV (respirable fibers)	G-A2, I-2B, N-2, CP65	
510	409-21-2	?	Silicon Carbide (fibrous forms, including whiskers)	I	0.2 f/cc TLV (respirable fibers)	G-A2, I-2B, N-2, CP65	
511	434-07-1	?	Oxymetholone		n.o.s.	N-2, CP65	
512	438-67-5	✓	Sodium Estrone Sulfate		n.o.s.	N-1	
513	443-48-1	?	Metronidazole		n.o.s.	I-2B, N-2, CP65	
514	446-86-6	✓	Azathioprine	J	n.o.s.	I-1, N-1, CP65	
515	484-20-8	?	5-Methoxypsoralen		n.o.s.	I-2A	
516	484-20-8	?	5-Methoxypsoralen plus UV–A radiation		n.o.s.	I-2A, CP65	
517	492-80-8	?	Auramine (technical grade)		n.o.s.	I-2B, CP65	
518	494-03-1	✓	Chlornaphazine		n.o.s.	I-1, CP65	
519	494-03-1	✓	N,N-*bis*(2-Chloroethyl)-2-naphthylamine		n.o.s.	I-1, CP65	
520	502-39-6	?	Methylmercury Dicyandiamide		n.o.s.	I-2B, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
521	505-60-2	✓	2,2'-Dichlorodiethylsulfide	IA	n.o.s.	I-1, N-1, CP65	
522	505-60-2	✓	Mustard Gas	IA	n.o.s.	I-1, N-1, CP65	
523	505-60-2	✓	Sulfur Mustard	IA	n.o.s.	I-1, N-1, CP65	
524	506-66-1	✓	Beryllium Carbide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
525	509-14-8	?	Tetranitromethane	I	5 ppb TLV {0.04 mg/m^3}	G-A3, I-2B, N-2, CP65	
526	510-15-6		Ethyl-4,4'-dichlorobenzilate		n.o.s.	CP65	
527	512-56-1		Trimethyl Phosphate		n.o.s.	CP65	
528	513-37-1	?	1-Chloro-2-methylpropene		n.o.s.	I-2B, N-2, CP65	
529	513-37-1	?	Dimethylvinyl Chloride		n.o.s.	I-2B, N-2, CP65	
530	513-78-0	✓	Cadmium Carbonate	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
531	513-79-1	?	Cobalt (II) Carbonate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
532	531-76-0	?	Merphalan		n.o.s.	I-2B, CP65	
533	531-82-8	?	Furathiazole		n.o.s.	I-2B, CP65	
534	531-82-8	?	N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide		n.o.s.	I-2B, CP65	
535	540-73-8	?	1,2-Dimethylhydrazine		n.o.s.	I-2A, CP65	
536	542-56-3		Isobutyl Nitrite		C 1 ppm TLV	G-A3, CP65	
537	542-75-6	?	1,3-Dichloropropene (technical grade)	S	1 ppm TLV {4.5 mg/m^3}	G-A3, I-2B, N-2, CP65	
538	542-83-6	✓	Cadmium Cyanide	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
539	542-84-7	?	Cobalt (II) Cyanide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
540	542-88-1	✓	*bis*(Chloromethyl) Ether	I	[1910.1003] {1 ppb TLV, 4.7 µg/m^3}	O, G-A1, I-1, N-1, CP65	
541	543-81-7	✓	Beryllium Acetate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
542	543-90-8	✓	Cadmium Acetate	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
543	544-18-3	?	Cobalt (II) Formate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
544	547-67-1	✓	Nickel Oxalate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
545	555-84-0	?	1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone		n.o.s.	I-2B, CP65	
546	556-52-5	?	Glycidol	ISG	2 ppm TLV {6.1 mg/m^3}	G-A3, I-2A, N-2, CP65	
547	557-19-7	✓	Nickel Cyanide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
548	563-47-3	?	3-Chloro-2-methylpropene		n.o.s.	N-2, CP65	
549	569-57-3		Chlorotrianisene		n.o.s.	CP65	
550	569-61-9	?	C.I. Basic Red 9 Monohydrochloride	IS	n.o.s.	I-2B, N-2, CP65	
551	569-61-9	?	*p*-Rosaniline	IS	n.o.s.	I-2B, N-2, CP65	
552	584-84-9	?	TDI	S	1 ppb TLV {7.2 µg/m^3; Sensitizer}	G-A3, I-2B, N-2	2006
553	584-84-9	?	Toluene-2,4-diisocyanate	S	1 ppb TLV {7.2 µg/m^3; Sensitizer}	G-A3, I-2B, N-2	2006
554	590-96-5		Methylazoxymethanol		n.o.s.	CP65	
555	592-62-1	?	Methylazoxymethanol Acetate		n.o.s.	I-2B, CP65	
556	592-87-0	?	Lead Thiocyanate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
557	593-60-2	?	Vinyl Bromide		0.5 ppm TLV {2.2 mg/m^3}	G-A2, I-2A, N-2, CP65	
558	598-55-0		Methyl Carbamate		n.o.s.	CP65	
559	599-79-1		Salicylazosulfapyridine		n.o.s.	CP65	
560	602-87-9	?	5-Nitroacenaphthene		n.o.s.	I-2B, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
561	604-75-1	?	Oxazepam		n.o.s.	I-2B, CP65	
562	606-20-2	?	2,6-Dinitrotoluene	S	27 ppb TLV {0.2 mg/m^3}	I-2B, CP65	
563	607-57-8	?	2-Nitrofluorene	I	n.o.s.	I-2B, CP65	
564	608-73-1	?	Hexachlorocyclohexane		n.o.s.	I-2B, N-2, CP65	
565	612-82-8		3,3'-Dimethylbenzidine Dihydrochloride		n.o.s.	CP65	
566	612-83-9	?	3,3'-Dichlorobenzidine Dihydrochloride		n.o.s.	N-2, CP65	
567	613-35-4	?	N,N'-Diacetylbenzidine		n.o.s.	I-2B, CP65	
568	615-05-4	?	2,4-Diaminoanisole		n.o.s.	I-2B, CP65	
569	615-53-2	?	N-Methyl-N-nitrosourethane		n.o.s.	I-2B, CP65	
570	615-53-2	?	N-Nitroso-N-methylurethane		n.o.s.	I-2B, CP65	
571	621-64-7	?	N-Nitrosodi-*n*-propylamine		n.o.s.	I-2B, N-2, CP65	
572	630-93-3		Diphenylhydantoin		n.o.s.	CP65	
573	630-93-3		Phenytoin (sodium salt)		n.o.s.	CP65	
574	631-64-1		Dibromoacetic acid		n.o.s.	CP65	
575	636-21-5	?	*o*-Toluidine Hydrochloride		n.o.s.	N-2, CP65	
576	637-07-0		Clofibrate		n.o.s.	CP65	
577	671-16-9	?	Procarbazine		n.o.s.	I-2A, N-2, CP65	
578	680-31-9	?	Hexamethylphosphoramide	IS	n.o.s.	G-A3, I-2B, N-2, CP65	
579	684-93-5	?	N-Methyl-N-nitrosourea		n.o.s.	I-2A, N-2, CP65	
580	684-93-5	?	N-Nitroso-N-methylurea		n.o.s.	I-2A, N-2, CP65	
581	712-68-5	?	2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole		n.o.s.	I-2B, CP65	
582	759-73-9	?	ENU		n.o.s.	I-2A, N-2, CP65	
583	759-73-9	?	N-Ethyl-N-nitrosourea		n.o.s.	I-2A, N-2, CP65	
584	759-73-9	?	N-Nitroso-N-ethylurea		n.o.s.	I-2A, N-2, CP65	
585	764-41-0	?	1,4-Dichloro-2-butene	S	5 ppb TLV {25 µg/m^3}	G-A2, CP65	
586	765-34-4	?	Glycidaldehyde		n.o.s.	I-2B, CP65	
587	794-93-4	?	Panfuran S (containing dihydroxymethylfuratrizine)		n.o.s.	I-2B, CP65	
588	811-54-1	?	Lead Formate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
589	814-89-1	?	Cobalt (II) Oxalate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
590	817-09-4	?	Trichlormethine		n.o.s.	I-2B, CP65	
591	817-09-4	?	Trimustine Hydrochloride		n.o.s.	I-2B, CP65	
592	819-73-8	?	Lead Butyrate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
593	838-88-0	?	4,4'-Methylene *bis*(2-Methylaniline)		n.o.s.	I-2B, CP65	
594	842-07-9		C.I. Solvent Yellow 14		n.o.s.	CP65	
595	865-49-6	?	Chloroform-d {$CDCl_3$}	IA	10 ppm TLV {48.9 mg/m^3}	G-A3, I-2B, N-2, CP65	
596	917-69-1	?	Cobalt (III) Acetate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
597	924-16-3	?	N-Nitrosodi-*n*-butylamine		n.o.s.	I-2B, N-2, CP65	
598	924-42-5		N-Methylolacrylamide		n.o.s.	CP65	
599	930-55-2	?	N-Nitrosopyrrolidine		n.o.s.	I-2B, N-2, CP65	
600	1024-57-3	?	Heptachlor Epoxide	S	0.05 mg/m^3 TLV	G-A3, I-2B, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
601	1066-30-4	✓	Chromic Acetate, as Cr^{6+} [water-soluble]		5 µg/m³ PEL	O, N-1, CP65	
602	1076-43-3	✓	Benzene-d_6 {C_6D_6}	IS	0.5 ppm TLV {1.6 mg/m³}	O, G-A1, I-1, N-1, CP65	
603	1111-71-3	✓	Beryllium Formate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
604	1116-54-7	?	N-Nitrosodiethanolamine		n.o.s.	I-2B, N-2, CP65	
605	1120-71-4	?	1,3-Propane Sultone		n.o.s.	G-A3, I-2B, N-2, CP65	
606	1120-89-4	✓	Benzene-d {$C_6H_5D_1$}	IS	0.5 ppm TLV {1.6 mg/m³}	O, G-A1, I-1, N-1, CP65	
607	1189-85-1	✓	*tert*-Butyl Chromate, as Cr^{6+}	S	5 µg/m³ PEL	O, I-1, N-1, CP65	
608	1271-28-9	✓	Nickelocene	I	0.2 mg/m³ TLV	G-A1, I-1, N-1, CP65	
609	1302-52-9	✓	Beryl Ore	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
610	1302-52-9	✓	Beryllium Aluminum Silicate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
611	1303-00-0	✓	Gallium Arsenide	IG	0.3 µg/m³ TLV {Respirable}	O, G-A3, I-1, N-1, CP65	
612	1303-28-2	✓	Arsenic Pentoxide	IG	10 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
613	1303-32-8	✓	Arsenic Disulfide	IG	10 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
614	1303-33-9	✓	Arsenic Trisulfide	IG	10 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
615	1303-36-2	✓	Arsenic Triselenide	IG	10 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
616	1304-54-7	✓	Beryllium Nitride	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
617	1304-56-9	✓	Beryllium Oxide	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
618	1306-19-0	✓	Cadmium Oxide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
619	1306-23-6	✓	Cadmium Sulfide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
620	1306-24-7	✓	Cadmium Selenide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
621	1306-25-8	✓	Cadmium Telluride	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
622	1307-86-4	?	Cobalt (III) Hydroxide	I	0.02 mg/m³ TLV	G-A3, I-2B	
623	1307-96-6	?	C.I. Pigment Black 13	I	0.02 mg/m³ TLV	G-A3, I-2B, CP65	
624	1307-96-6	?	Cobalt (II) Oxide	I	0.02 mg/m³ TLV	G-A3, I-2B, CP65	
625	1307-96-6	?	Cobalt Monoxide	I	0.02 mg/m³ TLV	G-A3, I-2B, CP65	
626	1308-04-9	?	Cobalt (III) Oxide	I	0.02 mg/m³ TLV	G-A3, I-2B	
627	1308-06-1	?	Cobalt (II, III) Oxide	I	0.02 mg/m³ TLV	G-A3, I-2B	
628	1308-09-4	✓	Basic Copper (II) Chromate, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
629	1308-09-4	✓	Copper Chromate Oxide, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
630	1308-13-0	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
631	1308-13-0	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
632	1308-13-0	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
633	1309-60-0	?	Lead Dioxide	IG	50 µg/m³ PEL	G-A3, I-2A, N-2, CP65	
634	1309-64-4	?	Antimony Trioxide (ACGIH®: production)	I	0.5 mg/m³ PEL	G-A2, I-2B, CP65	
635	1311-11-1	?	Lead Hydroxide	IG	50 µg/m³ PEL	G-A3, I-2A, N-2, CP65	
636	1313-99-1	✓	Nickel Monoxide	I	0.2 mg/m³ TLV	G-A1, I-1, N-1, CP65	
637	1313-99-1	✓	Nickel Oxide	I	0.2 mg/m³ TLV	G-A1, I-1, N-1, CP65	
638	1314-06-3	✓	Nickel Sesquioxide	I	0.2 mg/m³ TLV	G-A1, I-1, N-1, CP65	
639	1314-20-1	✓	Thorium Dioxide - [see Thorium]	J	n.o.s.	N-1, CP65	
640	1314-27-8	?	Lead Sesquioxide	IG	50 µg/m³ PEL	G-A3, I-2A, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
641	1314-41-6	?	Lead Tetraoxide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
642	1314-62-1	?	Vanadium Pentoxide (CP65: orthorhombic crystalline form)	I	0.05 mg/m^3 TLV (inhalable fraction)	G-A3, I-2B, CP65	
643	1314-87-0	?	Lead Sulfide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
644	1314-91-6	?	Lead Telluride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
645	1317-36-8	?	Lead Monoxide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
646	1317-42-6	?	Cobalt (II) Sulfide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
647	1317-95-9	?	*alpha*-Quartz {Silica (respirable) - Crystalline; a/k/a Tripoli}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-2A, CP65	
648	1317-95-9	?	Silica (respirable) - Crystalline {*alpha*-Quartz a/k/a Tripoli}	I	0.025 mg/m^3 TLV (respirable fraction)	G-A2, I-2A, CP65	
649	1319-43-3	✓	Beryllium Carbonate Basic	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
650	1319-48-8	?	Basic Lead Carbonate Sulfate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
651	1319-48-8	?	Leadhillite	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
652	1327-53-3	✓	Arsenic Trioxide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
653	1327-53-3	✓	Fowler's Solution, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
654	1328-67-2	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
655	1328-67-2	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
656	1328-67-2	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
657	1332-21-4	✓	Asbestos	I	0.1 f/cc PEL	O, G-A1, I-1, N-1, CP65	
658	1332-52-1	✓	Beryllium Acetate, Basic	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
659	1333-82-0	✓	Chromic Acid, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
660	1333-82-0	✓	Chromium Oxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
661	1333-82-0	✓	Chromium Trioxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
662	1333-86-4	?	Carbon Black (CP65: airborne, unbound particles of respirable size)	I	3.5 mg/m^3 PEL	I-2B, CP65	
663	1335-32-6	?	Lead Subacetate		n.o.s.	G-A3, I-2A, N-2, CP65	
664	1336-36-3	?	PCBs {Polychorinated Biphenyls}		n.o.s.	I-2A, N-2, CP65	
665	1336-36-3		Polychlorinated Biphenyls (containing 60 or more percent chlorine by molecular weight) {PCBs}		n.o.s.	CP65	
666	1336-36-3	?	Polychlorinated Biphenyls {PCBs}		n.o.s.	I-2A, N-2, CP65	
667	1344-38-3	✓	Basic Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
668	1344-38-3	✓	C.I. Pigment Orange 21, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
669	1402-68-2	✓	Aflatoxins	IG	n.o.s.	I-1, N-1, CP65	
670	1464-53-5	?	Diepoxybutane		n.o.s.	I-2B, N-2, CP65	
671	1596-84-5		Daminozide		n.o.s.	CP65	
672	1615-80-1	?	1,2-Diethylhydrazine		n.o.s.	I-2B, CP65	
673	1665-00-5	✓	Dichloromethane-d_2 {CD_2Cl_2} [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
674	1665-00-5	✓	Methane-d_2 Dichloride {CD_2Cl_2} [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
675	1665-00-5	✓	Methylene-d_2 Chloride {CD_2Cl_2} [1910.1052]	IS	25 ppm PEL {87 mg/m^3}	O, G-A3, I-2B, N-2, CP65	
676	1684-47-5	✓	Benzene-1,3,5-d_3 {$C_6H_3D_3$}	IS	0.5 ppm TLV {1.6 mg/m^3}	O, G-A1, I-1, N-1, CP65	
677	1694-09-3	?	Benzyl Violet 4B		n.o.s.	I-2B, CP65	
678	1746-01-6	✓	TCDD	S	n.o.s.	I-1, N-1, CP65	
679	1746-01-6	✓	2,3,7,8-Tetrachlorodibenzo-*p*-dioxin	S	n.o.s.	I-1, N-1, CP65	
680	1836-75-5	?	2,4-Dichlorophenyl-*p*-nitrophenyl Ether		n.o.s.	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
681	1836-75-5	?	Nitrofen (technical grade)		n.o.s.	I-2B, N-2, CP65	
682	1897-45-6	?	Chlorothalonil		n.o.s.	I-2B, CP65	
683	1918-16-7		Propachlor		n.o.s.	CP65	
684	1929-82-4		Nitrapyrin		10 mg/m^3 TLV	CP65	
685	1937-37-7	✓	Direct Black 38 (technical grade)		n.o.s.	I-2A, N-1, CP65	
686	1937-37-7	✓	Direct Black GX		n.o.s.	I-2A, N-1, CP65	
687	2092-56-0		D&C Red No. 8		n.o.s.	CP65	
688	2223-93-0	✓	Cadmium Stearate	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
689	2312-35-8		Propargite		n.o.s.	CP65	
690	2385-85-5	?	Mirex		n.o.s.	I-2B, N-2, CP65	
691	2425-06-1	?	Captafol	S	0.1 mg/m^3 PEL	I-2A, CP65	
692	2429-74-5	?	C.I. Direct Blue 15	I	n.o.s.	I-2B, CP65	
693	2439-01-2		Oxythioquinox		n.o.s.	CP65	
694	2475-45-8	?	Disperse Blue 1	I	n.o.s.	I-2B, N-2, CP65	
695	2475-45-8	?	1,4,5,8-Tetraamino-9,10-anthracenedione	I	n.o.s.	I-2B, N-2, CP65	
696	2593-15-9		Terrazole		n.o.s.	CP65	
697	2602-46-2	✓	Direct Blue 6 (technical grade)		n.o.s.	I-2A, N-1, CP65	
698	2646-17-5	?	C.I. Solvent Orange 2		n.o.s.	I-2B, CP65	
699	2646-17-5	?	Oil Orange SS		n.o.s.	I-2B, CP65	
700	2784-94-3	?	HC Blue No.1	I	n.o.s.	I-2B, CP65	
701	2973-10-6	?	Diisopropylsulfate		n.o.s.	I-2B, CP65	
702	3017-60-5	?	Cobalt (II) Thiocyanate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
703	3068-88-0	?	*beta*-Butyrolactone		n.o.s.	I-2B, CP65	
704	3165-93-3	?	4-Chloro-2-methylbenzenamine Hydrochloride		n.o.s.	I-2A, N-2, CP65	
705	3165-93-3	?	*p*-Chloro-*o*-toluidine Hydrochloride		n.o.s.	I-2A, N-2, CP65	
706	3264-82-2	✓	Nickel Acetylacetonate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
707	3296-90-0	?	BBMP		n.o.s.	I-2B, N-2, CP65	
708	3296-90-0	?	2,2-*bis*(Bromomethyl)-1,3-propandiol		n.o.s.	I-2B, N-2, CP65	
709	3296-90-0	?	2,2-*bis*(Bromomethyl)propane-1,3-diol		n.o.s.	I-2B, N-2, CP65	
710	3333-39-3	✓	Nickel Carbonate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
711	3333-67-3	✓	Nickel Carbonate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
712	3349-06-2	✓	Nickel Formate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
713	3468-63-1		D&C Orange No. 17		n.o.s.	CP65	
714	3546-10-9		Phenesterin		n.o.s.	CP65	
715	3564-09-8	?	Ponceau 3R		n.o.s.	I-2B, CP65	
716	3570-75-0	?	2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole		n.o.s.	I-2B, CP65	
717	3687-31-8	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, I-1, N-1, CP65	
718	3688-53-7	?	AF-2		n.o.s.	I-2B, CP65	
719	3688-53-7	?	2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide		n.o.s.	I-2B, CP65	
720	3697-24-3	?	5-Methylchrysene {PAH}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
721	3697-24-3	?	PAH {5-Methylchrysene}	I	0.2 mg/m^3 PEL	I-2B, N-2, CP65	
722	3761-53-3	?	Ponceau MX		n.o.s.	I-2B, CP65	
723	3771-19-5	?	Nafenopin		n.o.s.	I-2B, CP65	
724	3795-88-8	?	5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone		n.o.s.	I-2B	
725	3817-11-6	?	N-Nitroso-*n*-butyl-N-(4-hydroxybutyl)amine		n.o.s.	N-2	
726	4342-03-4	?	Dacarbazine		n.o.s.	I-2B, N-2, CP65	
727	4549-40-0	?	N-Nitrosomethylvinylamine		n.o.s.	I-2B, N-2, CP65	
728	5064-31-3	?	Nitrilotriacetic Acid, Trisodium Salt	I	n.o.s.	I-2B, N-2, CP65	
729	5118-34-3		Methylhydrazine Sulfate		n.o.s.	CP65	
730	5160-02-1		D&C Red No. 9		n.o.s.	CP65	
731	5216-25-1		*p-a,a,a*-Tetrachlorotoluene		n.o.s.	CP65	
732	5522-43-0	?	1-Nitropyrene	I	n.o.s.	I-2B, N-2, CP65	
733	6055-19-2	✓	Cyclophosphamide (hydrated)	GJ	n.o.s.	I-1, CP65	
734	6109-97-3		3-Amino-9-ethylcarbazole Hydrochloride		n.o.s.	CP65	
735	6147-53-1	?	Cobalt (II) Acetate Tetrahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
736	6164-98-3		Chlordimeform		n.o.s.	CP65	
737	6358-53-8	?	Citrus Red No.2		n.o.s.	I-2B, CP65	
738	6459-94-5	?	C.I. Acid Red 114	I	n.o.s.	I-2B, CP65	
739	6795-23-9	?	Aflatoxin M1		n.o.s.	I-2B, CP65	
740	7280-37-7	✓	Estropipate		n.o.s.	N-1, CP65	
741	7280-37-7	✓	Piperazine Estrone Sulfate		n.o.s.	N-1, CP65	
742	7439-92-1	?	Lead & Pb compounds, inorganic, as Pb - [see specific compound]	IG	50 µg/m^3 PEL	G-A3, I-2B, N-2, CP65	
743	7440-02-0	✓	Nickel metal powder & Ni alloys/compounds, as Ni - [see specific compound]	I	1 mg/m^3 PEL {inhalable fraction}	I-2B, N-1, CP65	
744	7440-07-5	✓	Plutonium (as ^{239}Pu, and its decay products [may contain other isotopes], as aerosols)		n.o.s.	I-1	
745	7440-14-4	✓	Radium (as ^{224}Ra, and its decay products)		n.o.s.	I-1	
746	7440-14-4	✓	Radium (as ^{226}Ra, and its decay products)		n.o.s.	I-1	
747	7440-14-4	✓	Radium (as ^{228}Ra, and its decay products)		n.o.s.	I-1	
748	7440-29-1	✓	Thorium (as ^{232}Th, and its decay products, administered intravenously)	J	n.o.s.	I-1	
749	7440-38-2	✓	Arsenic in Drinking Water	IG	n.o.s.	I-1	
750	7440-38-2	✓	Arsenic, Inorganic [1910.1018] - [see specific compound]	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
751	7440-38-2	✓	Inorganic Arsenic [1910.1018] - [see specific compound]	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
752	7440-41-7	✓	Beryllium & compounds, as Be - [see specific compound]	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
753	7440-43-9	✓	Cadmium & Cd compounds, as Cd [1910.1027] - [see specific compound]	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
754	7440-48-4		Cobalt metal powder	I	0.02 mg/m^3 TLV	G-A3, CP65	
755	7440-61-1	✓	Uranium, natural [soluble & insoluble compounds]	I	0.05 mg/m^3 PEL (sol.); 0.25 mg/m^3 PEL (insol.)	G-A1	
756	7446-14-2	?	Lead Sulfate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
757	7446-15-3	?	Lead Selenate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
758	7446-27-7	?	Lead Phosphate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
759	7446-34-6	?	Selenium Sulfide		n.o.s.	N-2, CP65	
760	7481-89-2	?	Zalcitabine		n.o.s.	I-2B	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
761	7488-51-9	?	Lead Selenite	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
762	7496-02-8	?	6-Nitrochrysene	I	n.o.s.	I-2B, N-2, CP65	
763	7631-86-9	✓	Silicon Dioxide - [see specific crystalline silica form]	I	0.05 - 0.1 mg/m^3 PEL	I-2A, N-1, CP65	
764	7631-89-2	✓	Sodium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
765	7645-25-2	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
766	7646-79-9	?	Cobalt (II) Chloride	I	0.02 mg/m^3 TLV	G-A3, I-2B	
767	7718-54-9	✓	Nickel Chloride [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
768	7723-14-0	✓	Phosphorus (as ^{32}P, as phosphate)		n.o.s.	I-1	
769	7758-01-2	?	Potassium Bromate		n.o.s.	I-2B, CP65	
770	7758-95-4	?	Lead Chloride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
771	7758-97-6	✓	C.I. Pigment Yellow 34, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A2, I-1, N-1, CP65	
772	7758-97-6	✓	Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A2, I-1, N-1, CP65	
773	7759-01-5	?	Lead Tungstate (VI)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
774	7774-41-6	✓	Arsenic Acid Hemihydrate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
775	7775-11-3	✓	Sodium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
776	7778-39-4	✓	*o*-Arsenic Acid	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
777	7778-43-0	✓	Disodium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
778	7778-44-1	✓	Calcium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
779	7778-50-9	✓	Potassium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
780	7783-46-2	?	Lead Fluoride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
781	7783-59-7	?	Lead Tetrafluoride	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
782	7784-01-2	✓	Silver Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
783	7784-02-3	✓	Silver Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
784	7784-33-0	✓	Arsenic Tribromide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
785	7784-34-1	✓	Arsenic Trichloride	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
786	7784-35-2	✓	Arsenic Trifluoride	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
787	7784-40-9	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
788	7784-41-0	✓	Potassium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
789	7784-45-4	✓	Arsenic Triiodide	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
790	7784-46-5	✓	Sodium Arsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
791	7785-24-2	✓	Cobalt (II) Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
792	7786-81-4	✓	Nickel Sulfate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
793	7787-46-4	✓	Beryllium Bromide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
794	7787-47-5	✓	Beryllium Chloride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
795	7787-49-7	✓	Beryllium Fluoride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
796	7787-50-0	✓	Beryllium Potassium Fluoride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
797	7787-52-2	✓	Beryllium Hydride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
798	7787-53-3	✓	Beryllium Iodide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
799	7787-55-5	✓	Beryllium Nitrate Trihydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
800	7787-56-6	✓	Beryllium Sulfate Tetrahydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
801	7788-98-9	✓	Ammonium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
802	7789-00-6	✓	Potassium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
803	7789-01-7	✓	Lithium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
804	7789-04-0	✓	Chromium Phosphate, as Cr^{6+} [water-soluble]		5 µg/m^3 PEL	O, N-1, CP65	
805	7789-06-2	✓	Strontium Chromate, as Cr^{6+}	I	0.5 µg/m^3 TLV	O, G-A2, I-1, N-1, CP65	
806	7789-09-5	✓	Ammonium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
807	7789-10-8	✓	Mercuric Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
808	7789-10-8	✓	Mercury (II) Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
809	7789-42-6	✓	Cadmium Bromide	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
810	7789-43-7	?	Cobalt (II) Bromide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
811	7790-79-6	✓	Cadmium Fluoride	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
812	7790-80-9	✓	Cadmium Iodide	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
813	7790-85-4	✓	Cadmium Tungstate (VI)	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
814	7791-13-1	?	Cobalt (II) Chloride Hexahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
815	8001-35-2	?	Chlorinated Camphene	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
816	8001-35-2	?	Polychlorinated Camphene	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
817	8001-35-2	?	Toxaphene	S	0.5 mg/m^3 PEL	G-A3, I-2B, N-2, CP65	
818	8001-58-9	✓	Creosotes	IS	n.o.s.	I-2A, N-1, CP65	
819	8002-05-9	✓	Mineral Oil (untreated/poorly and mildly refined/treated)	ISG	5 mg/m^3 TLV (inhalable particulate)	G-A2, I-1, N-1, CP65	2009
820	8005-36-5	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
821	8005-36-5	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
822	8006-61-9	?	Gasoline	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B	
823	8007-45-2	✓	Coal Tars	I	n.o.s.	I-1, N-1	
824	8012-54-2	✓	Donovan's Solution, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
825	8018-01-7		Mancozeb		n.o.s.	CP65	
826	8021-39-4	✓	Creosotes (wood)	IS	n.o.s.	N-1, CP65	
827	8024-75-9	✓	Arsenical Dip	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
828	8049-64-7	✓	Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
829	8052-42-4	?	Asphalt (Petroleum) Fumes	I	0.5 mg/m^3 TLV	I-2B, CP65	
830	8052-42-4	?	Bitumen (extracts of steam-refined and air-refined)	I	0.5 mg/m^3 TLV	I-2B, CP65	
831	9000-07-1	?	Carrageenan, degraded		n.o.s.	I-2B	
832	9004-66-4	?	Iron Dextran Complex		n.o.s.	I-2B, N-2, CP65	
833	9006-42-2		Metiram		n.o.s.	CP65	
834	10026-17-2	?	Cobalt (II) Fluoride	I	0.02 mg/m^3 TLV	G-A3, I-2B	
835	10026-18-3	?	Cobalt (III) Fluoride	I	0.02 mg/m^3 TLV	G-A3, I-2B	
836	10026-22-9	?	Cobalt (II) Nitrate Hexahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
837	10026-24-1	?	Cobalt Sulfate Heptahydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B, CP65	
838	10028-18-9	✓	Nickel Fluoride [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
839	10031-13-7	✓	Lead Arsenite, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
840	10031-22-8	?	Lead Bromide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
841	10034-93-2	?	Hydrazine Sulfate		n.o.s.	N-2, CP65	
842	10039-31-3	✓	Beryllium Selenate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
843	10042-84-9	?	Nitrilotriacetic Acid , Sodium Salt (unspecified)	I	n.o.s.	I-2B, N-2, CP65	
844	10043-92-2	✓	Radon (as ^{222}Rn, and its decay products)	IG	0.2–0.7 pCi/L EPA {indoor < outdoor}	I-1, N-1	
845	10048-13-2	?	Sterigmatocystin		n.o.s.	I-2B, CP65	
846	10048-95-0	✓	Disodium Arsenate Heptahydrate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
847	10048-95-0	✓	Disodium Hydrogen Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
848	10099-74-8	?	Lead Nitrate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
849	10099-79-3	?	Lead Vanadate (V)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
850	10101-63-0	?	Lead Iodide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
851	10101-94-7	?	Lead Sodium Thiosulfate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
852	10102-48-4	✓	Lead Arsenate, as As^{3+}	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
853	10102-53-1	✓	*m*-Arsenic Acid	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
854	10103-50-1	✓	Magnesium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
855	10103-62-5	✓	Calcium Arsenate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
856	10108-64-2	✓	Cadmium Chloride	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
857	10124-36-4	✓	Cadmium Sulfate	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
858	10124-43-3	?	Cobalt (II) Sulfate	I	0.02 mg/m^3 TLV	G-A3, I-2B, N-2, CP65	
859	10141-05-6	?	Cobalt (II) Nitrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
860	10190-55-3	?	Lead Molybdate (VI)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
861	10210-64-7	✓	Beryllium Acetylacetonate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
862	10210-68-1	?	Cobalt Carbonyl, as Co	I	0.1 mg/m^3 TLV	I-2B	
863	10210-68-1	?	Dicobalt Octacarbonyl, as Co	I	0.1 mg/m^3 TLV	I-2B	
864	10214-39-8	?	Lead Borate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
865	10290-12-7	✓	Cupric Arsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
866	10294-40-3	✓	Barium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
867	10294-47-0	?	Lead Chlorate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
868	10294-52-7	✓	C.I. Pigment Yellow 45, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
869	10294-52-7	✓	Ferric Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
870	10294-52-7	✓	Iron (III) Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
871	10294-53-8	✓	Iron (III) Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
872	10294-58-3	?	Lead Hypophosphite	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
873	10325-94-7	✓	Cadmium Nitrate	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
874	10381-36-9	✓	Nickel Phosphate	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
875	10418-03-8		Stanozolol		n.o.s.	CP65	
876	10453-86-8		Resmethrin		n.o.s.	CP65	
877	10540-29-1	✓	Tamoxifen (and its salts)		n.o.s.	I-1, N-1, CP65	
878	10588-01-9	✓	Sodium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
879	10595-95-6	?	N-Nitrosomethylethylamine		n.o.s.	I-2B, CP65	
880	11056-06-7	?	Bleomycins		n.o.s.	I-2B	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
881	11096-82-5	?	Aroclor® 1260 {PCBs}	S	n.o.s.	N-2, CP65	
882	11097-69-1	?	Aroclor® 1254 {PCBs}	S	0.5 mg/m^3 PEL	G-A3, I-2A, N-2, CP65	
883	11097-69-1	?	Chlorodiphenyl (54% chlorine) {PCBs}	S	0.5 mg/m^3 PEL	G-A3, I-2A, N-2, CP65	
884	11103-86-9	✓	Zinc Potassium Chromate (Hydroxide), as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
885	11113-74-9	✓	Nickel Hydroxide	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
886	11114-92-4	✓	Cobalt Chromium Alloy, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
887	11133-98-5	✓	Beryllium-Copper Alloy, as Be fume or dust	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
888	12000-34-9	✓	Barium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
889	12001-28-4	✓	Crocidolite	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
890	12001-29-5	✓	Chrysotile	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
891	12002-03-8	✓	Copper (II) Acetoarsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
892	12002-03-8	✓	Cupric Acetoarsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
893	12016-80-7	?	Cobalt (III) Oxide Monohydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
894	12018-32-5	✓	Sodium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
895	12035-72-2	✓	Nickel Subsulfide	I	0.1 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
896	12054-48-7	✓	Nickel Hydroxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
897	12069-68-0	?	Cobalt (II) Carbonate Hydroxide (1:1)	I	0.02 mg/m^3 TLV	G-A3, I-2B	
898	12125-56-3	✓	Nickel Hydroxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
899	12161-82-9	✓	Bertrandite	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
900	12161-82-9	✓	Beryllium Silicate Hydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
901	12172-73-5	✓	Amosite	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
902	12174-11-7	?	Attapulgite (long fibers, > 5 µm)	I	n.o.s.	I-2B, CP65	
903	12174-11-7	?	Palygorskite (long fibers, > 5 µm)	I	n.o.s.	I-2B, CP65	
904	12206-12-1	✓	Zinc Chromate Hydroxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
905	12213-61-5	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
906	12213-61-5	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
907	12231-18-4	✓	Barium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
908	12324-05-9	✓	Chromic Acid, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
909	12324-05-9	✓	Chromium Oxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
910	12324-05-9	✓	Chromium Trioxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
911	12324-08-2	✓	Chromic Acid, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
912	12324-08-2	✓	Chromium Oxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
913	12324-08-2	✓	Chromium Trioxide, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
914	12427-38-2		Maneb		n.o.s.	CP65	
915	12510-42-8	✓	Erionite	I	n.o.s.	I-1, N-1, CP65	
916	12527-08-1	✓	Zinc Potassium Chromate (Hydroxide), as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
917	12602-23-2	?	Cobalt (II) Carbonate Hydroxide (2:3)	I	0.02 mg/m^3 TLV	G-A3, I-2B	
918	12607-70-4	✓	Nickel Carbonate Hydroxide	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
919	12656-85-8	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
920	12656-85-8	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
921	12685-29-9	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
922	12709-98-7	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
923	12709-98-7	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
924	12770-50-2	✓	Beryllium-Aluminum Alloy, as Be fume or dust	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
925	12789-03-6	?	Chlordane (technical grade)	S	0.5 mg/m^3 TLV	G-A3, I-2B	
926	13007-92-6	✓	Chromium Carbonyl, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
927	13010-47-4	?	CCNU		n.o.s.	I-2A, N-2, CP65	
928	13010-47-4	?	1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea		n.o.s.	I-2A, N-2, CP65	
929	13010-47-4	?	Lomustine		n.o.s.	I-2A, N-2, CP65	
930	13106-47-3	✓	Beryllium Carbonate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
931	13138-45-9	✓	Nickel Nitrate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
932	13194-48-4		Ethoprop		n.o.s.	CP65	
933	13256-22-9	?	N-Nitrososarcosine		n.o.s.	I-2B, N-2, CP65	
934	13327-32-7	✓	Beryllium Hydroxide	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
935	13423-61-5	✓	Magnesium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
936	13424-46-9	?	Lead Azide	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
937	13444-75-2	✓	Mercuric Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
938	13444-75-2	✓	Mercury (II) Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
939	13446-72-5	✓	Rubidium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
940	13446-73-6	✓	Rubidium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
941	13453-35-5	✓	Thallium Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
942	13454-78-9	✓	Cesium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
943	13455-25-9	?	Cobalt (II) Chromate (III)	I	0.02 mg/m^3 TLV	G-A3, I-2B	
944	13455-36-2	?	Cobalt (II) Phosphate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
945	13462-88-9	✓	Nickel Bromide [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
946	13462-90-3	✓	Nickel Iodide [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
947	13463-39-3	✓	Nickel Carbonyl	I	1 ppb PEL {7 µg/m^3}	I-1, N-1, CP65	
948	13463-67-7	?	Titanium Dioxide		10 mg/m^3 TLV	I-2B	
949	13464-35-2	✓	Potassium Arsenite	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
950	13473-75-1	✓	Thallium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
951	13478-00-7	✓	Nickel (II) Nitrate Hexahydrate, as Ni [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
952	13478-93-8	✓	Nickel Dimethylglyoxime	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
953	13510-48-0	✓	Beryllium Nitrate Tetrahydrate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
954	13510-49-1	✓	Beryllium Sulfate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
955	13510-89-9	?	Lead Antimonate (V)	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
956	13520-61-1	✓	Nickel Perchlorate Hexahydrate [water soluble]	I	0.1 mg/m^3 TLV	I-1, N-1, CP65	
957	13530-65-9	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
958	13530-65-9	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
959	13530-65-9	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
960	13548-42-0	✓	Copper Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
961	13548-42-0	✓	Cupric Chromate, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
962	13552-44-8	?	4,4'-Methylenedianiline Dihydrochloride		n.o.s.	N-2, CP65	
963	13596-22-0	?	Cobalt (II) Potassium Sulfate	I	0.02 mg/m³ TLV	G-A3, I-2B	
964	13597-95-0	✓	Beryllium Perchlorate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
965	13597-99-4	✓	Beryllium Nitrate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
966	13598-00-0	✓	Beryllium Silicate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
967	13598-15-7	✓	Beryllium Phosphate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
968	13598-26-0	✓	Beryllium Phosphate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
969	13654-09-6	?	Decabromobiphenyl {PBBs}		n.o.s.	N-2, CP65	
970	13762-14-6	?	Cobalt (II) Molybdenum (VI) Oxide	I	0.02 mg/m³ TLV	G-A3, I-2B	
971	13765-19-0	✓	Calcium Chromate, as Cr^{6+}	I	5 µg/m³ PEL {1 µg/m³ TLV}	O, G-A2, I-1, N-1, CP65	
972	13770-89-3	✓	Nickel Sulfamate	I	0.2 mg/m³ TLV	G-A1, I-1, N-1, CP65	
973	13782-01-9	?	Cobalt (III) Potassium Nitrite	I	0.02 mg/m³ TLV	G-A3, I-2B	
974	13814-62-5	✓	Cadmium Selenate	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
975	13843-81-7	✓	Lithium Dichromate, as Cr^{6+} [water soluble]	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
976	13871-27-7	✓	Beryllium Sodium Fluoride	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
977	13909-09-6	✓	1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea		n.o.s.	I-1, N-1, CP65	
978	13909-09-6	✓	MeCCNU		n.o.s.	I-1, N-1, CP65	
979	13909-09-6	✓	Methyl-CCNU		n.o.s.	I-1, N-1, CP65	
980	13909-09-6	✓	Semustine		n.o.s.	I-1, N-1, CP65	
981	13930-94-4	✓	Chromium Carbonyl, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
982	14060-38-9	✓	Arsenious Acid	IG	10 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
983	14307-35-8	✓	Lithium Chromate, as Cr^{6+} [water soluble]	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
984	14402-75-6	✓	Cadmium Potassium Cyanide	I	5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
985	14464-46-1	✓	Cristobalite {Silica (respirable) - Crystalline}	I	0.025 mg/m³ TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
986	14464-46-1	✓	Silica (respirable) - Crystalline {Cristobalite}	I	0.025 mg/m³ TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
987	14486-19-2	✓	Cadmium Fluoborate		5 µg/m³ PEL {2 µg/m³ respirable TLV}	O, G-A2, I-1, N-1, CP65	
988	14567-73-8	✓	Tremolite [asbestiform]	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
989	14675-41-3	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
990	14675-41-3	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
991	14675-41-3	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
992	14808-60-7	✓	*alpha*-Quartz {Silica (respirable) - Crystalline}	I	0.025 mg/m³ TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
993	14808-60-7	✓	Silica (respirable) - Crystalline {*alpha*-Quartz}	I	0.025 mg/m³ TLV (respirable fraction)	G-A2, I-1, N-1, CP65	
994	14901-08-7	?	Cycasin		n.o.s.	I-2B, CP65	
995	14977-61-8	✓	Chromyl Chloride, as Cr^{6+} [water soluble]	I	5 µg/m³ PEL	O, I-1, N-1, CP65	
996	14986-48-2	✓	Chromium [VI] Chloride	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
997	14986-48-2	✓	Chromium Hexachloride, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
998	15120-17-9	✓	Sodium Arsenate	IG	10 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
999	15190-21-3	✓	Thallium Chromate, as Cr^{6+}	I	5 µg/m³ PEL	O, G-A1, I-1, N-1, CP65	
1000	15191-85-2	✓	Beryllium Silicate	IS	0.05 µg/m³ TLV {Sensitizer}	G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1001	15194-98-6	✓	Calcium Arsenite, 2:1	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1002	15238-00-3	?	Cobalt (II) Iodide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
1003	15467-20-6	?	Nitrilotriacetic Acid, Disodium Salt	I	n.o.s.	I-2B, N-2, CP65	
1004	15541-45-4		Bromate		n.o.s.	CP65	
1005	15663-27-1	?	Cisplatin		n.o.s.	I-2A, N-2, CP65	
1006	15930-94-6	✓	Zinc Chromate Hydroxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1007	15972-60-8		Alachlor		1 mg/m^3 TLV {Sensitizer}	G-A3, CP65	
1008	16071-86-6	?	Direct Brown 95 (technical grade)		n.o.s.	I-2A, CP65	
1009	16543-55-8	✓	N'-Nitrosonornicotine		n.o.s.	I-1, N-2, CP65	
1010	16543-55-8	✓	NNN		n.o.s.	I-1, N-2, CP65	
1011	16565-95-0	✓	Neodymium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1012	16565-96-1	✓	Samarium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1013	16568-02-8		Acetaldehyde Methylformylhydrazone		n.o.s.	CP65	
1014	16568-02-8		Gyromitrin		n.o.s.	CP65	
1015	16569-87-2	✓	Neodymium Chromate Heptahydrate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1016	16680-47-0	✓	Sodium Equilin Sulfate		n.o.s.	N-1	
1017	16842-03-8	?	Cobalt Hydrocarbonyl, as Co	I	0.1 mg/m^3 TLV	I-2B	
1018	17440-85-6	✓	Beryllium Borohydride	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1019	17647-74-4	?	1,4-Dioxane-d_8	IS	20 ppm TLV {72 mg/m^3}	G-A3, I-2B, N-2	
1020	17786-31-1	?	Tetracobalt Dodecacarbonyl, as Co	I	0.02 mg/m^3 TLV	G-A3, I-2B	
1021	18454-12-1	✓	Basic Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1022	18454-12-1	✓	Chrome Red, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1023	18454-12-1	✓	Lead Chromate Oxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1024	18540-29-9	✓	Chromium (VI) & inorganic Cr^{6+} compounds - [see specific compound]	I	5 µg/m^3 PEL	O, I-1, N-1, CP65	
1025	18662-53-8	?	Nitrilotriacetic Acid, Trisodium Salt, Hydrate	I	n.o.s.	I-2B, N-2, CP65	
1026	18883-66-4	?	Streptozocin		n.o.s.	I-2B, N-2, CP65	
1027	18883-66-4	?	Streptozotocin		n.o.s.	I-2B, N-2, CP65	
1028	18906-50-8	✓	Copper Chromate Oxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1029	18994-66-6	?	Nitrilotriacetic Acid, Monosodium Salt	I	n.o.s.	I-2B, N-2, CP65	
1030	19044-88-3		Oryzalin		n.o.s.	CP65	
1031	19049-40-2	✓	Beryllium Acetate, Basic	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1032	19666-30-9		Oxadiazon		n.o.s.	CP65	
1033	20265-96-7		*p*-Chloroaniline Hydrochloride		n.o.s.	CP65	
1034	20325-40-0	?	*o*-Dianisidine Dihydrochloride		n.o.s.	N-2, CP65	
1035	20325-40-0	?	3,3'-Dimethoxybenzidine Dihydrochloride		n.o.s.	N-2, CP65	
1036	20830-81-3	?	Daunomycin		n.o.s.	I-2B, CP65	
1037	21041-93-0	?	Cobalt (II) Hydroxide	I	0.02 mg/m^3 TLV	G-A3, I-2B	
1038	21041-95-2	✓	Cadmium Hydroxide	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
1039	21436-97-5		2,4,5-Trimethylaniline Hydrochloride		n.o.s.	CP65	
1040	21739-91-3		Cytembena		n.o.s.	CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1041	22398-80-7	?	Indium Phosphide		0.1 mg/m^3 TLV	I-2A, CP65	
1042	22506-53-2	?	3,9-Dinitrofluoranthene		n.o.s.	I-2B, CP65	
1043	22534-09-4	✓	Thallium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1044	23103-98-2		Pirimicarb		n.o.s.	CP65	
1045	23214-92-8	?	Adriamycin®		n.o.s.	I-2A, N-2, CP65	
1046	23214-92-8	?	Doxorubicin Hydrochloride		n.o.s.	I-2A, N-2, CP65	
1047	23246-96-0	?	Riddelliine		n.o.s.	I-2B, CP65	
1048	23255-03-0	?	Nitrilotriacetic Acid, Disodium Salt, Hydrate	I	n.o.s.	I-2B, N-2, CP65	
1049	23950-58-5		Pronamide		n.o.s.	CP65	
1050	24613-89-6	✓	Chromic Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1051	25013-16-5	?	BHA		n.o.s.	I-2B, N-2, CP65	
1052	25013-16-5	?	Butylated Hydroxyanisole		n.o.s.	I-2B, N-2, CP65	
1053	25316-40-9	?	Adriamycin®		n.o.s.	I-2A, N-2, CP65	
1054	25316-40-9	?	Doxorubicin Hydrochloride		n.o.s.	I-2A, N-2, CP65	
1055	25808-74-6	?	Lead Hexafluorosilicate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
1056	25812-30-0		Gemfibrozil		n.o.s.	CP65	
1057	25962-77-0	?	*trans*-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole		n.o.s.	I-2B	
1058	26148-68-5	?	A-*alpha*-C		n.o.s.	I-2B, CP65	
1059	26148-68-5	?	2-Amino-9H-pyrido[2,3-*b*]indole		n.o.s.	I-2B, CP65	
1060	26471-62-5	?	Toluene Diisocyanate		n.o.s. {Sensitizer}	I-2B, N-2, CP65	
1061	27152-57-4	✓	Calcium Arsenite, 2:3	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1062	27208-37-3	?	Cyclopenta[*cd*]pyrene {PAH}		0.2 mg/m^3 PEL	I-2A	
1063	27208-37-3	?	PAH {Cyclopenta[*cd*]pyrene}		0.2 mg/m^3 PEL	I-2A	
1064	28407-37-6		C.I. Direct Blue 218		n.o.s.	CP65	
1065	28434-86-8	?	3,3'-Dichloro-4,4'-diaminodiphenyl Ether		n.o.s.	I-2B, CP65	
1066	29191-52-4	?	*o*-Anisidine	S	0.5 mg/m^3 PEL {0.1 ppm}	G-A3, I-2B	
1067	29689-14-3	✓	Chromium Carbonate, as Cr^{6+} [water-soluble]		5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1068	29767-20-2	?	Teniposide		n.o.s.	I-2A	
1069	30516-87-1	?	AZT		n.o.s.	I-2B	
1070	30516-87-1	?	Zidovudine		n.o.s.	I-2B	
1071	30525-89-4	✓	Paraformaldehyde	IA	C 0.3 ppm TLV {C 0.37 mg/m^3}	O, G-A2, I-2A, N-2	
1072	32809-16-8		Procymidone		n.o.s.	CP65	
1073	33419-42-0	✓	Etoposide		n.o.s.	I-1	
1074	34018-28-5	?	Lead Bromate	IG	50 µg/m^3 PEL	G-A3, I-2A, N-2, CP65	
1075	34256-82-1		Acetochlor		n.o.s.	CP65	
1076	34465-46-8		Hexachlorodibenzodioxin		n.o.s.	CP65	
1077	35089-00-0	✓	Beryllium Phosphate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1078	36355-01-8	?	Hexabromobiphenyl {PBBs}		n.o.s.	N-2	
1079	36734-19-7		Iprodione		n.o.s.	CP65	
1080	37227-61-5	✓	Beryllium-Nickel Alloy, as Be fume or dust [also see Ni]	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1081	37227-61-5	✓	Nickel-Beryllium Alloy, as Ni fume or dust [also see Be]	I	0.2 mg/m^3 TLV	G-A1, I-1, N-1, CP65	
1082	37235-82-8	✓	Basic Bismuth Dichromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1083	37300-23-5	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1084	37300-23-5	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1085	37300-23-5	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1086	37317-41-2	?	Kanechlor® 500 {PCBs}		n.o.s.	N-2, CP65	
1087	37364-06-0	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
1088	37809-34-0	✓	Zinc Potassium Chromate (Hydroxide), as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1089	38252-74-3	?	N-Nitroso-*n*-butyl-N-(3-carboxypropyl)amine		n.o.s.	N-2	
1090	38455-77-5	✓	Stannic Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1091	38455-77-5	✓	Tin (IV) Chromate, as Cr^{6+} [water soluble]	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1092	39156-41-7	?	2,4-Diaminoanisole Sulfate		n.o.s.	N-2, CP65	
1093	39413-47-3	✓	Beryllium Zinc Silicate, as Be	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1094	39413-47-3	✓	Zinc Beryllium Silicate, as Be	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1095	42397-64-8	?	1,6-Dinitropyrene	I	n.o.s.	I-2B, N-2, CP65	
1096	42397-65-9	?	1,8-Dinitropyrene	I	n.o.s.	I-2B, N-2, CP65	
1097	50471-44-8		Vinclozolin		n.o.s.	CP65	
1098	51264-14-3	?	Amsacrine		n.o.s.	I-2B	
1099	51839-24-8	?	Cobalt (II) Carbonate Hydroxide (2:3) Monohydrate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
1100	52740-16-6	✓	Calcium Arsenite, 1:1	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1101	53469-21-9	?	Chlorodiphenyl (42% chlorine) {PCBs}	S	1 mg/m^3 PEL	I-2A, CP65	
1102	53684-48-3	✓	Beryllium Potassium Sulfate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1103	53973-98-1		Polygeenan		n.o.s.	CP65	
1104	54322-60-0	✓	Strontium Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1105	54692-53-4	✓	Basic Lead Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1106	54692-53-4	✓	C.I. Pigment Orange 21, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1107	54749-90-5	?	Chlorozotocin		n.o.s.	I-2A, N-2, CP65	
1108	55158-44-6	✓	Beryllium-Copper-Cobalt Alloy, as Be fume or dust	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1109	55738-54-0		*trans*-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)vinyl]-1,3,4-oxadiazole		n.o.s.	CP65	
1110	57018-52-7		Propylene Glycol Mono-t-Butyl Ether		n.o.s.	CP65	
1111	57486-12-1	✓	C.I. Pigment Yellow 36, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1112	57486-12-1	✓	Zinc Chromate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1113	57486-12-1	✓	Zinc Yellow, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1114	57835-92-4	?	4-Nitropyrene	I	n.o.s.	I-2B, N-2, CP65	
1115	58477-24-0	✓	Samarium Chromate Heptahydrate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1116	58500-38-2	✓	Beryllium Silicate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1117	58569-17-8	✓	Samarium Chromate Dihydrate, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1118	59536-65-1	?	Firemaster BP-6 {PBBs}		n.o.s.	I-2B, N-2, CP65	
1119	59536-65-1	?	PBBs {Polybrominated Biphenyls}		n.o.s.	I-2B, N-2, CP65	
1120	59536-65-1	?	Polybrominated Biphenyls {PBBs}		n.o.s.	I-2B, N-2, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1121	59669-26-0		Thiodicarb		n.o.s.	CP65	
1122	59865-13-3	✓	Ciclosporin		n.o.s.	N-1, CP65	
1123	59865-13-3	✓	Ciclosporine		n.o.s.	I-1, N-1, CP65	
1124	59865-13-3	✓	Cyclosporin A		n.o.s.	I-1, N-1, CP65	
1125	60153-49-3	?	3-(N-Nitrosomethylamino)propionitrile		n.o.s.	I-2B, CP65	
1126	60391-92-6		N-Carboxymethyl-N-nitrosourea		n.o.s.	CP65	
1127	60568-05-0		Furmecyclox		n.o.s.	CP65	
1128	61288-13-9	?	Octabromobiphenyl {PBBs}		n.o.s.	N-2, CP65	
1129	61789-51-3	?	Cobalt (II) Naphthenate	I	0.02 mg/m^3 TLV	G-A3, I-2B	
1130	62450-06-0	?	3-Amino-1,4-dimethyl-5H-pyrido[4,3-*b*]indole		n.o.s.	I-2B, CP65	
1131	62450-06-0	?	Trp-P-1		n.o.s.	I-2B, CP65	
1132	62450-06-0	?	Tryptophan-P-1		n.o.s.	I-2B, CP65	
1133	62450-07-1	?	3-Amino-1-methyl-5H-pyrido[4,3-*b*]indole		n.o.s.	I-2B, CP65	
1134	62450-07-1	?	Trp-P-2		n.o.s.	I-2B, CP65	
1135	62450-07-1	?	Tryptophan-P-2		n.o.s.	I-2B, CP65	
1136	62476-59-9		Acifluorfen		n.o.s.	CP65	
1137	63449-39-8	?	Chlorinated Paraffins (avg. C_{12}, 60% Chlorine)		n.o.s.	I-2B, N-2	
1138	64070-83-3	✓	Trisodium Arsenate Heptahydrate	IG	10 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1139	64091-91-4	✓	4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone		n.o.s.	I-1, N-2, CP65	
1140	64091-91-4	✓	NNK		n.o.s.	I-1, N-2, CP65	
1141	64523-06-4	✓	C.I. Pigment Red 104, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1142	64523-06-4	✓	Molybdenum Orange, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1143	65271-80-9	?	Mitoxantrone		n.o.s.	I-2B	
1144	65996-89-6	✓	Coal Tars & Extracts, and high-temp. coal tars	I	n.o.s.	I-1, N-1	
1145	65996-93-2	✓	Coal Tar Pitch Volatiles (as benzene solubles)	I	0.2 mg/m^3 PEL	G-A1, I-1, N-1	
1146	65996-93-2	✓	Particulate Polycyclic Aromatic Hydrocarbons [PPAH]	I	0.2 mg/m^3 PEL	G-A1, I-1, N-1	
1147	66104-24-3	✓	Beryllium Carbonate	IS	0.05 µg/m^3 TLV {Sensitizer}	G-A1, I-1, N-1, CP65	
1148	66516-58-3	✓	Zinc Chromate Hydroxide, as Cr^{6+}	I	5 µg/m^3 PEL	O, G-A1, I-1, N-1, CP65	
1149	66733-21-9	✓	Erionite	I	n.o.s.	I-1, N-1, CP65	
1150	67730-10-3	?	2-Aminodipyrido[1,2-*a*:3',2'-*d*]imidazole		n.o.s.	I-2B, CP65	
1151	67730-10-3	?	Glu-P-2		n.o.s.	I-2B, CP65	
1152	67730-11-4	?	2-Amino-6-methyldipyrido[1,2-*a*:3',2'-*d*]imidazole		n.o.s.	I-2B, CP65	
1153	67730-11-4	?	Glu-P-1		n.o.s.	I-2B, CP65	
1154	67774-32-7	?	Firemaster FF-1 {PBBs}		n.o.s.	I-2B, N-2, CP65	
1155	67774-32-7	?	Hexabromobiphenyl {PBBs}		n.o.s.	I-2B, N-2, CP65	
1156	67774-32-7	?	PBBs {Polybrominated Biphenyls}		n.o.s.	I-2B, N-2, CP65	
1157	67774-32-7	?	Polybrominated Biphenyls {PBBs}		n.o.s.	I-2B, N-2, CP65	
1158	68006-83-7	?	2-Amino-3-methyl-9H-pyrido[2,3-*b*]indole		n.o.s.	I-2B, CP65	
1159	68006-83-7	?	MeA-*alpha*-C		n.o.s.	I-2B, CP65	
1160	68308-34-9	✓	Shale Oils		n.o.s.	I-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1161	68334-30-5	?	Diesel Fuel #4	IS	100 mg/m^3 TLV	G-A3, I-2B	
1162	68334-30-5	?	Marine Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
1163	68476-30-2	?	Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
1164	68476-30-2	?	Fuel Oil #2	IS	100 mg/m^3 TLV	G-A3, I-2B	
1165	68476-31-3	?	Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
1166	68476-31-3	?	Fuel Oil #4	IS	100 mg/m^3 TLV	G-A3, I-2B	
1167	68476-33-5	?	Fuel Oil, Residual (Heavy)	IS	n.o.s.	I-2B, CP65	
1168	68476-33-5	?	Residual (Heavy) Fuel Oil	IS	n.o.s.	I-2B, CP65	
1169	68476-34-6	?	Diesel Fuel #2	IS	100 mg/m^3 TLV	G-A3, I-2B	
1170	72490-01-8		Fenoxycarb		n.o.s.	CP65	
1171	76180-96-6	?	2-Amino-3-methylimidazo[4,5-*f*]quinoline		n.o.s.	I-2A, N-2, CP65	
1172	76180-96-6	?	IQ		n.o.s.	I-2A, N-2, CP65	
1173	77094-11-2	?	2-Amino-3,4-dimethylimidazo[4,5-*f*]quinoline		n.o.s.	I-2B, N-2, CP65	
1174	77094-11-2	?	MeIQ		n.o.s.	I-2B, N-2, CP65	
1175	77439-76-0	?	3-Chloro-4-dichloromethyl-5-hydroxy-2(5H)-furanone		n.o.s.	I-2B, CP65	
1176	77439-76-0	?	MX		n.o.s.	I-2B, CP65	
1177	77500-04-0	?	2-Amino-3,8-dimethylimidazo[4,5-*f*]quinoxaline		n.o.s.	I-2B, N-2, CP65	
1178	77500-04-0	?	MeIQx		n.o.s.	I-2B, N-2, CP65	
1179	77501-63-4		Lactofen		n.o.s.	CP65	
1180	77536-66-4	✓	Actinolite [asbestiform]	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
1181	77536-67-5	✓	Anthophyllite [asbestiform]	I	0.1 f/cc PEL	O, G-A1, I-1, N-1	
1182	77650-28-3	?	Diesel Fuel, Marine	IS	100 mg/m^3 TLV	G-A3, I-2B	
1183	77650-28-3	?	Diesel Fuel #4	IS	100 mg/m^3 TLV	G-A3, I-2B	
1184	77650-28-3	?	Marine Diesel Fuel	IS	100 mg/m^3 TLV	G-A3, I-2B	
1185	79217-60-0		Ciclosporin		n.o.s.	CP65	
1186	79217-60-0	✓	Cyclosporin		n.o.s.	I-1, CP65	
1187	79217-60-0	✓	Cyclosporine		n.o.s.	I-1, CP65	
1188	79748-81-5		Fusarin C		n.o.s.	CP65	
1189	82410-32-0		Ganciclovir Sodium		n.o.s.	CP65	
1190	86290-81-5	?	Gasoline	I	300 ppm TLV {890 mg/m^3}	G-A3, I-2B	
1191	101043-37-2	?	Microcystin-LR		n.o.s.	I-2B	
1192	105650-23-5	?	2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine		n.o.s.	I-2B, N-2, CP65	
1193	105650-23-5	?	PhIP		n.o.s.	I-2B, N-2, CP65	
1194	105735-71-5	?	3,7-Dinitrofluoranthene		n.o.s.	I-2B, CP65	
1195	108171-26-2	?	Chlorinated Paraffins (avg. C_{12}, 60% Chlorine)		n.o.s.	I-2B, N-2, CP65	
1196	110235-47-7		Mepanipyrim		n.o.s.	CP65	
1197	111406-87-2		Zileuton		n.o.s.	CP65	
1198	113852-37-2		Cidofovir		n.o.s.	CP65	
1199	116355-83-0	?	Fumonisin B1		n.o.s.	I-2B, CP65	
1200	132295-56-8	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.

	CASRN	CHP†	Carcinogen Name	R/E[A]	PEL/TLV (8 hr. TWA)	Source Agency[B]	NIC[C]
1201	132295-57-9	✓	Cadmium-Copper Alloy, cadmium nonbase	I	5 µg/m^3 PEL {2 µg/m^3 respirable TLV}	O, G-A2, I-1, N-1, CP65	
1202	140923-17-7		Iprovalicarb		n.o.s.	CP65	
1203	140923-25-7		Iprovalicarb		n.o.s.	CP65	
1204	141112-29-0		Isoxaflutole		n.o.s.	CP65	
1205	177406-68-7		Benthiavalicarb-isopropyl		n.o.s.	CP65	

A R/E (Routes of Exposure): I = Inhalation, S = Skin (A = Absorption), G = Ingestion, J = Injection.

B Source Agency: O = OSHA, G = ACGIH®, I = IARC, N = NTP, CP65 = California Prop. 65. Categories: 1 = Known, 2 = Suspected, 3 = Animal/Experimental.
Source publications/dates: OSHA – most recent CFR; ACGIH® – 2009 TLVs®, IARC – 2 April 2009 update; NTP – 11th Report on Carcinogens; CP65 – 19 June 2009 list.

C ACGIH Notice of Intended Changes (NIC) – year of addition or revision.

† CHP: ✓ indicates a Chemical Hygiene Plan (CHP) is required. ? indicates a possible select carcinogen and an evaluation of usage is required; a CHP may be required.